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ABSTRACT 
 
Interest in cancer immunotherapy has grown in recent years due to its potential 
for significant and durable therapeutic responses. Immune checkpoint blockade has 
emerged as an immunotherapy as a single agent but has even greater appeal when it is 
used in combination with other immunostimulatory approaches. However, the dosing of 
checkpoint blockade and its combinatorial use with other immunotherapies has been 
limited by systemic immune-related adverse side effects. One way to overcome these 
adverse effects is to deliver the therapeutic agents specifically to the tumor 
microenvironment. Salmonella enterica Typhimurium (S. Typhimurium) has been studied 
for cancer therapy due to its genetic manipulability and tumor-targeting propensity, and 
in this thesis, the potential of S. Typhimurium as a tumor-targeting immunotherapy 
vector was investigated. Functional antagonistic single chain antibodies (scFvs) against 
the immune checkpoints CTLA-4 and PD-L1 were isolated from an immunized chicken 
library and engineered for secretion from S. Typhimurium. The inherent anti-tumor 
properties and tumor-targeting capability of S. Typhimurium were then tested in 
transplanted primary and metastatic tumor models as well as a genetically engineered 
autochthonous BALB-neuT breast cancer model. In each of these models, S. 
Typhimurium demonstrated native anti-tumor efficacy; however the bacteria did not 
adequately colonize the autochthonous tumors of the BALB-neuT model. Disruption of 
tumor vasculature by treating BALB-neuT mice with a vasculature disrupting agent 
(VDA) improved the colonization of autochthonous tumors over 1000-fold to levels 
similar to those observed for transplanted tumors. Subsequent comparison of the tumor 
targeting capability and efficacy of S. Typhimurium engineered to secrete the 
antagonistic αPD-L1 (scFv) versus a control strain showed that secretion of the scFv 
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may further improve the colonization of autochthonous tumors, leading to a greater 
reduction in tumor burden of treated mice. These findings provide a proof of principle for 
the expression and delivery of functional immunotherapeutic single chain antibodies 
using S. Typhimurium, demonstrate S. Typhimurium’s native tumoricidal activity 
independent of tumor-targeting, illustrate the importance of clinically representative 
tumor models when studying bacterial cancer therapy, and demonstrate the potential of 
VDA treatment to improve bacterial tumor-targeting. Collectively, this work illustrates S. 
Typhimurium’s promise as a tumor-targeting immunotherapy vector.
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CHAPTER 1 
GENERAL INTRODUCTION 
 
The National Cancer Institute Surveillance, Epidemiology, and End Results 
Program estimates that one in two men and one in three women will develop cancer in 
their lifetime. In the United States alone nearly every minute of every day a person dies 
due to cancer, resulting in approximately 500,000 cancer deaths each year. This is in 
spite of over 40 years of fighting a declared “war on cancer” (1). While exciting progress 
has been made in the treatment of some forms of cancer, it is often incremental, and 
fatalities due to the more deadly forms of cancer have remained largely unchanged in 
recent history. Victory in the war on cancer will depend on substantial advances in the 
diagnosis and treatment of the disease. One area that has demonstrated exciting 
potential in cancer treatment is immunotherapy, which is the utilization of the immune 
system to treat cancer.  
 
TUMOR IMMUNOLOGY 
Immunosurveillance  
The theory of immunosurveillance claims that nascent tumors emerge 
sporadically throughout life, but are recognized and destroyed by the immune system 
before becoming clinically apparent (2), much like the immune system responding to and 
destroying a pathogen before the symptoms of infection appear. Historically, the theory 
of immunosurveillance of tumors was not widely accepted. After the notion was first 
proposed in 1909 by Paul Ehrlich (3), it was formally introduced by Marcfarlane Burnet 
and Lewis Thomas 50 years later (4, 5). However when tested experimentally, studies at 
the time demonstrated no difference in methylcholanthrene (MCA) carcinogen-induced 
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or spontaneous tumor incidence in athymic nude CBA/H mice when compared to wild 
type controls. In response to these experiments, the idea of immunosurveillance was 
widely unaccepted into the 1970’s (2). The caveats of these studies, unknown at the 
time, included 1) the use of nude mice as a model of immunodeficiency, which are now 
understood to harbor both a fully-functional innate immune system, including functional 
natural killer (NK) cells, and even some degree of an adaptive immune system 
containing detectable numbers of αβ T-cells and 2) CBA/H mice that were used in the 
studies are particularly sensitive to the transforming effects of MCA due to their 
expression of a highly active enzyme isoform required to metabolize MCA into its 
carcinogenic form. Therefore, it may be that MCA-induced carcinogenesis in these mice 
was so effective that any protective immunity to tumor formation was insufficient to show 
a significant effect (2). Resurgence in the theory of immunosurveillance began in the 
1990’s, in light of a more detailed understanding of the components of the 
immunosurveillance network. Several reports in the subsequent decades demonstrated 
a greater tumor incidence and/or aggression in mice that are deficient in certain 
components of the immune system such as T, B and NKT cells; interferon gamma 
(IFNγ) production or sensitivity; monocytes; macrophages; perforin; TNF-related 
apoptosis inducing ligand (TRAIL); interleukin 12 (IL-12); and more (reviewed in (2)). In 
light of these studies and additional clinical observations, such as an increased 
incidence of several tumor types in patients with acquired immune deficiencies (6), 
immunosurveillance theory holds widespread acceptance in the scientific community 
today.  
 
Immunoediting of tumors 
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Clinically apparent tumors by definition have avoided the surveillance of the 
immune system through a process termed “immunoediting.” This is thought to occur in 
three stages or “E’s” of immunoediting: elimination, equilibrium and escape (2). 
Elimination phase: Immunosurveillance is represented during the elimination 
phase of immunoediting, in which nascent tumors are recognized by the immune system 
and effectively eradicated before they cause disease. Elucidating the components of an 
effective anti-tumor immune response is an ongoing area of investigation, and current 
understanding involves both the innate and adaptive arms of the immune system. 
Initially, the innate immune system may be alerted to a developing tumor by the damage 
it causes to local tissues (7, 8). This recruits cells of the innate immune system such as 
NK cells, NKT cells, γδ T-cells, and macrophages (2). Tumor cells may be recognized at 
this point by NKG2D receptors on NK cells and/or NKT cells recognizing NKG2D ligands 
expressed on the transforming cells. NKT cells have also been shown to respond to 
glycolipid complexes expressed on tumor cells during transformation (9). Ultimately, an 
important outcome of this initial recognition is the production of IFNγ. IFNγ signaling has 
several effects that drive the anti-tumor immune response at this stage, such as inducing 
the production of chemokines that in turn recruit additional immune cells to the tumor 
environment (2), inducing tumor-infiltrating macrophages to secrete low levels of IL-12, 
and stimulating NK cells to secrete additional IFNγ. IL-12 induces NK cell production of 
IFNγ, which in turn induces macrophage secretion of IL-12 in a positive feedback loop 
(10). This additional boost in IFNγ not only increases the cytotoxicity of NK cells but also 
results in anti-proliferative (11), pro-apoptotic (12), and anti-angiogenic (13, 14) effects in 
the tumor that cause tumor cell death. Additionally, IFNγ-activated macrophages can kill 
cells indirectly via the production of reactive oxygen species (ROS) or TNF-related 
apoptosis-inducing ligand (TRAIL) (15, 16). Ultimately, these activities result in the 
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availability of tumor antigens (TA) from dead tumor cells that allow the enlistment of the 
adaptive immune system to target tumor cells. Immature dendritic cells (DCs) recruited 
to the tumor environment in response to chemokine signals become activated in the 
presence of the NK cells and the cytokine milieu generated from the innate immune 
system (17). Activated DCs then pick up TA directly by phagocytizing tumor cell debris 
or indirectly by the transfer of heat shock protein/TA complexes to the DCs (18, 19). 
Activated, TA-loaded DCs then migrate to the tumor-draining lymph node (20, 21), 
where they present antigen to naïve CD4 T-cells in the presence of IL-12, inducing CD4 
T-cell differentiation into activated T-helper 1 (Th1) cells, which in turn help the activation 
and proliferation of tumor-specific CD8 cytotoxic T-lymphocytes (CTL) by assisting DC-
mediated cross presentation of TA (22, 23). The T-cell-mediated adaptive immune 
response then allows for the complete elimination of the developing tumor. Tumor-
specific CD4 and CD8 T-cells accumulate in the tumor microenvironment, and CD4 T-
cells produce interleukins 2 and 15 (IL2, IL15), which sustain the function and viability of 
tumor-specific CTL. CD8 T-cells kill tumor cells both directly, via the recognition of TA 
peptide on the surface of tumor cells in the context of major histocompatibility complex 
class 1 (MHC I), and indirectly via the production of high amounts of IFNγ, which (as 
described above) may cause pleotropic tumoricidal effects on cell cycle, apoptosis, 
angiogenesis, and macrophage activation. As this Th1-driven, CTL-mediated tumor 
elimination phase is TA-specific, it must be repeated for each new antigenically variant 
population of tumor cells that may appear. 
 
Equilibrium phase: If a particularly prolific, genetically unstable tumor cell 
population is generated, it may avoid elimination and enter an equilibrium phase with the 
host immune system, wherein an IFNγ-driven cellular immune response kills tumor cells 
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at a rate that is enough to contain, but not fully abolish a tumor bed harboring genetically 
unstable cancer cells. This phase will often last several years in humans and is a crucial 
stage in cancer development. During this time, the host immune system exerts a 
relentless selection pressure on the developing tumor, which through a micro Darwinian-
like selection will become edited for immunosuppressive characteristics that allow it to 
ultimately escape equilibrium and grow in the final escape phase as clinically apparent 
cancer (2).  
Escape phase: Through the process of immunoediting, tumors develop immune 
hallmarks that are required for growth and progression in an immunocompetent host, 
such as the ability to evade immune recognition and the ability to suppress immune 
reactivity (24). Tumors are marked by an increasing genetic instability during 
development (25), and mutations in tumor antigens themselves or antigen presentation 
machinery that reduce the recognizability of the tumor cells by the adaptive system 
(termed “immunogenicity”) are selected for during immunoediting, resulting in less 
immunogenic tumor cells. Additionally, tumor cells have been reported to alter or lose 
MHC I surface expression, hampering antigenic peptide presentation to tumor specific T-
cells and allowing them to evade recognition by the adaptive immune response (26, 27). 
 
Immunosuppressive mechanisms of tumor cells 
While immunoevasive strategies are problematic, they are not enough alone to 
prevent the generation an anti-tumor immune response. This is evidenced by most, if not 
all, tumors also acquiring additional mechanisms to suppress the host immune system to 
avoid destruction. Tumor cells will often directly release immunoinhibitory agents, such 
as cytokines including transforming growth factor beta (TGFβ) or interleukin 10 (IL-10), 
or factors such as the tryptophan catabolizing enzyme indolamine 2,3-dioxygenase 
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(IDO), which depletes available tryptophan that is essential for T-cell effector function 
(24). Additionally tumors recruit or induce the differentiation of immunosuppressive cell 
populations causing their accumulation in the tumor microenvironment (TME) and 
attenuating the effects of the immune system. 
 
Regulatory T-cells 
Regulatory T-cells (T-regs) are an immunosuppressive subset of CD4 T-cells that 
are often found in high concentrations in tumor tissues (28). The mechanisms of T-reg-
mediated T-cell inhibition continues to be an area of active investigation, though 
evidence has been proposed for multiple mechanisms that may vary depending on 
tumor type or stage of development (reviewed in (29)) including the secretion of soluble 
or membrane-bound immunosuppressive molecules such as IL-10, TGFβ, and IL-35; the 
direct cytolysis of T-cells and possibly antigen-presenting DCs; disruption of T-cell 
metabolism by “starving” T cells of cytokine signals such as IL-2 or catalyzing the 
conversion of ATP to adenosine, which suppresses T-cell effector function; and by 
suppressing DC function by preventing maturation and expression of co-stimulatory 
molecules and inducing DC expression of IDO.  
T-regs are important cell populations in peripheral tolerance that prevent the 
activation of high affinity self-reactive T-cells that have escaped negative selection in the 
thymus. As tumor-associated antigens are often not foreign in the way pathogenic 
antigens are, the enrichment of T-regs in the tumor microenvironment might be expected 
as the immune system attempts to prevent a cytotoxic response against what may 
largely be recognized as “self.” In addition to the presence of these “natural” T-regs in 
the TME, tumors may also cause the accumulation of “induced” T-regs. In this case, 
tumor cells themselves or tumor associated cells will express factors such as TGFβ that 
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that can induce naïve CD4 cells to act like or differentiate into T-regs; these induced T-
regs express the canonical FoxP3 transcription factor that characterizes natural T-regs 
and will suppress T-cell mediated immunity similarly to natural T-regs (29). 
 
Tumor-associated macrophages 
In addition to regulatory T-cells, tumors will often harbor large populations of 
immunosuppressive myeloid cells such as tumor-associated macrophages (TAMs). 
Typically, macrophages are described phenotypically as either classically activated (M1) 
or alternatively activated (M2). M1 macrophages are required for tumor 
immunosurveillance and protection against pathogens, while M2 macrophages are 
important in inflammation, angiogenesis, and wound healing. Current understanding 
suggests that M1 and M2 polarization is too simplistic to adequately characterize the 
diverse spectrum of phenotypes that are actually encountered in vivo (30); however for 
simplicity, this nomenclature will be used here while acknowledging its potential to over-
simplify macrophage characterization. Instead of the M1-like macrophages desired for 
tumor elimination, tumors that have escaped immunosurveillance will be enriched with 
M2-like TAMs. Rather than expressing IL-12, activating NK and Th1 CD4 cells, and 
stimulating anti-tumor immunity, TAMs will actually be commandeered by the tumor to 
support tumor growth and inhibit anti-tumor immune responses. TAMs will display 
several M2-like characteristics that drive tumor progression including the promotion of 
angiogenesis (31) and the assistance in tumor cell intravasation and epithelial to 
mesenchymal transition, which drives tumor metastasis (32, 33). Additionally, TAMs 
have been implicated for many M2-like mechanisms of immunosuppression including but 
not limited to: the expression of surface-bound and secreted inhibitory factors such as 
HLA-G, an MHC molecule that may inhibit IFNγ-mediated CD4 T-cell activation (30), IL-
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10, and TGFβ (34); the constitutive expression of the immunoinhibitory checkpoint 
ligands such as PD-L1 and B7-H4 and their up-regulation in hypoxic areas (35); the 
recruitment of T-regs via the expression of the CCL22 (36) and the induction of T-regs 
and direct suppression of T-cells via IL-10 and TGFβ (37-40); and by the expression and 
secretion of Arginase I (ArgI), which metabolizes L-arginine, an essential amino acid for 
maintaining the ζ-chain expression important for T-cell receptor (TCR) signaling (41). 
 
Myeloid-derived suppressor cells 
 In addition to TAMs, populations of less mature myeloid cells are emerging as 
important immunomodulators in tumor immune escape. In a tumor-bearing host, a large 
collection of immature myeloid cells will accumulate in the tumor and spleen and 
suppress host anti-tumor immunity. These cells, termed myeloid-derived suppressor 
cells (MDCSs), are normally generated as myeloid cell precursors in the bone marrow of 
a healthy host and when transferred into a non-tumor bearing host will develop into 
mature macrophages and DCs; however if adoptively transferred into a tumor bearing 
host or cultured in the presence of tumor-derived soluble factors, these cells will remain 
MDSCs or differentiate into immunosuppressive TAMs (42). MDSCs, initially identified 
as Gr-1+ and CD11b+, have since been subdivided into Ly6G+ granulocytic (G-MDSC) 
and Ly6C+ monocytic (M-MDSC) subsets (the “Gr-1” antibody recognizes an epitope 
expressed on both Ly6C and Ly6G). G-MDSCs are usually the more numerous of the 
two populations in cancer and suppress CD8 T-cells primarily through the production of 
reactive oxygen species (ROS) (42). M-MDSCs, although less prevalent, are more 
immunosuppressive on a per-cell basis (43-45). M-MDSCs suppress T-cells primarily 
through ArgI expression and may subsequently develop into TAMs (42). While a 
relatively new area of ongoing study, MDCSs are thought to suppress the immune 
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system through multiple mechanisms, including: the depletion of L-arginine and L-
cysteine by expression of metabolizing enzymes such as ArgI (46, 47); the generation of 
oxidative stress via the production of ROS and reactive nitrogen species (42), which 
effects T-cell ζ-chain expression (48), IL-2 receptor signaling (49), and TCR sensitivity 
(50); the inhibition of effector T-cell trafficking to the tumor by decreasing T-cell L-
selectin expression (51); and the activation and expansion of T-regs possibly through 
cell-to-cell contact (52) or by the production of IL10, TGFβ, and/or retinoic acid (53-55). 
 
Immunoinhibitory checkpoints 
In addition to secretion of immunoinhibitory molecules and the recruitment of 
immunosuppressive cells, tumors will avoid elimination by taking advantage of 
immunoinhibitory checkpoints such as CTLA-4 and PD-1. These receptors are naturally 
important in peripheral tolerance and are up-regulated on T-cells shortly after activation. 
Their expression primes the T-cells for subsequent self-regulation by rendering the cells 
susceptible to homeostatic signals later in an immune response. As important molecules 
in the prevention of autoimmunity, mice deficient in either of these receptors develop 
severe autoimmune disorders shortly after birth (56). CTLA-4 is thought to antagonize T-
cell activation by multiple mechanisms including competition with CD28 for costimulatory 
B7.1/B7.2 interaction, evidenced by CTLA-4’s higher binding affinity for B7.1/B7.2, as 
well as intrinsic immunoreceptor tyrosine-based inhibitory motif-mediated signaling 
mechanisms that interfere with TCR signaling upon CTLA-4 binding to its ligands (56). 
Additionally, CTLA-4 is constitutively expressed on T-regs and is essential for their 
inhibitory activity (57, 58). PD-1, through engagement with its ligands PD-L1 and PD-L2 
sends inhibitory signals through an immunoreceptor tyrosine-based switch motif to inhibit 
T-cell activation at the immunological synapse (59). PD-L1 is constitutively expressed on 
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T-regs and suppressive myeloid cells such as MDSCs and TAMs. Expression may also 
be increased in response to hypoxia (35). In addition to immune cells, PD-L1 is also 
directly expressed by tumor cells in several cancers as part of their immune-inhibitory 
repertoire and is correlated with a negative prognosis (60).  
 
IMMUNOTHERAPY, CYTOKINES AND CHECKPOINT INHIBITION 
Cytokine therapy 
Cytokines are the primary messengers of the immune system, and the cytokine 
milieu present in the TME largely controls the activation or inhibition of an anti-tumor 
immune response. One strategy used to reverse tumor-mediated immune suppression is 
to manipulate the cytokine environment. To this end, systemic administration of 
immunostimulatory cytokines has been examined for efficacy in several cancer models, 
and cytokines such as IL-2 and IFNα have been used clinically for several years to treat 
malignancies such as metastatic melanoma and renal cell carcinoma (61). As 
immunological knowledge increases, more recently characterized cytokines are being 
tested for potential anti-tumor efficacy. IL-15, for example, elicits many of the beneficial 
effects of IL-2, but also promotes the formation of immunological memory and, unlike IL-
2, does not preferentially induce the proliferation of T-regs (62).  
While cytokine treatments have demonstrated modest clinical benefits, their 
successful usage has been largely limited by extreme toxicities including capillary 
leakage syndrome, fever, malaise, hypotension, renal dysfunction, hepatic dysfunction, 
and death (61, 63). For example, high dose IL-2 infusion is limited to a two-week 
regimen, and lower doses, while less toxic are less efficacious (61). Additionally, IL-12 
has demonstrated dramatic anti-tumor effects in mouse models, but when tested 
clinically, systemic administration of this cytokine was stopped abruptly due to severe 
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toxicities (64). In addition to their toxic effects, direct T-cell-stimulatory methods such as 
cytokine treatment may be naturally limited by inducing the surface expression of 
immunoinhibitory checkpoints such as CTLA-4 and PD-1, which serve as the “brakes” of 
the immune system by priming the TIL for inactivation and limiting the effectiveness of 
immunostimulatory therapy. 
 
Immunoinhibitory checkpoint blockade 
Further insights into the primary regulatory role of inhibitory checkpoints led to 
their suggestion as a target for therapy. This alternative approach would “remove the 
brakes” of the immune system to activate T-cells rather than directly stimulating them 
with cytokines. In the late 1990s and early 2000s, a fully humanized anti-CTLA-4 
antibody (Ipilimumab) entered clinical trials, and for the next decade, anti-CTLA-4 
demonstrated efficacy in several cancer types, including melanoma (65-67), renal cell 
carcinoma (68), prostate cancer (69), urothelial carcinoma (70) and ovarian cancer (71). 
The efficacy observed with anti-CTLA-4 therapy lead to its eventual approval by the food 
and drug administration (FDA) for clinical use in 2011. Similarly and not far behind, PD-
1/PD-L1 antagonism was tested in several clinical trials for the treatment of melanoma, 
renal cell carcinoma, non-small cell lung cancer (72), and bladder cancer (73), which 
lead to FDA approval of two humanized anti-PD-1 antibodies, pembroluzimab and 
nivolumab, at the end of 2014. While immune checkpoint blockade has significantly 
improved the treatment of cancers such as advanced metastatic melanoma, only a 
minority of treated patients actually responds to anti-PDL1 or anti-CTLA-4 antibodies 
alone; however, the durability of the response is often impressive with patients surviving 
years or even decades after treatment (74).  
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Toxicity of checkpoint blockade 
In spite of these successes, inhibitory checkpoint blockade treatments have been 
associated with systemic autoimmune side effects that result from blocking important 
peripheral tolerance mechanisms. These side effects, termed autoimmune related 
adverse events (irAEs), are common and are caused most often by the infiltration of 
highly activated CD4 and CD8-T cells and the production of inflammatory cytokines in 
normal tissues. The side effects are not surprising given preclinical studies 
demonstrating that CTLA-4-deficient mice die early after birth due to lympho-proliferative 
disease and autoimmunity (75, 76), and blockade studies using antibodies have 
demonstrated the development of diabetes, demyelinating lesions, encephalomyelitis 
and colitis (77-79). In humans, the most common irAEs in response to ant-CTLA-4 
therapy affect the GI tract, liver, skin and endocrine system (80) and affect ~60% of 
patients. Severe Grade 3 (requiring hospitalization) to Grade 5 (mortality) toxicities 
appear in 15-20% of patients (81, 82), which makes the likelihood of a patient 
developing a severe irAE in response to the drug at least as common as the patient 
responding favorably to the therapy (83). Blockade of PD-1/PD-L1 seems to result in a 
somewhat more favorable toxicity profile than CTLA-4 blockade. This may be explained 
by PD-1/PD-L1 acting more peripherally at the tumor site, while CTLA-4 acts more 
centrally in lymphoid organs (84). Adverse events in response to anti-PD-1/PD-L1, like 
anti-CTLA-4, are immune related, and include fatigue, decreased appetite, diarrhea, 
nausea, dyspnea, vomiting, rash, pyrexia, and headache (85), and severe adverse 
events occur in about 14% of patients receiving the anti-PD-1 antibody nivolumab (81). 
Unfortunately, the severity of the adverse events associated with checkpoint blockade 
seems to correlate with efficacy, as patients who experience higher-grade irAEs are 
more likely to show a therapeutic response, and higher doses of checkpoint inhibitors 
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have been demonstrated to increase both therapeutic response rates and severe irAE 
incidence (81, 86). This correlation makes intuitive sense, as the same 
immunostimulatory mechanisms of action responsible for the therapeutic benefit are also 
the cause of the adverse events. While irAEs are often successfully managed by 
administration of systemic corticosteroids (81), they have indeed restricted checkpoint 
blockade administration to doses that are therapeutically suboptimal: in a phase II dose-
escalation study including 217 patients (86), ipilimumab was administered at 0.3, 3, or 
10mg/kg doses, and while a significantly greater response rate was observed for the 
10mg/kg dose, the percentage of patients with serious adverse events at this level was 
more than triple the 3mg/kg dose. The current FDA-approved dose of ipilimumab (and 
nivolumab) is 3mg/kg, reflecting the decision to avoid adverse events at the cost of 
potentially greater therapeutic benefit. 
 
Combinatorial immunotherapy 
Recently researchers have begun the clinical investigation of concomitantly 
blocking both CTLA-4 and PD1/PD-L1. This combinatorial approach is attractive 
because these receptors signal through non-redundant pathways, and often the 
activation resulting from CTLA-4 blockade can induce the expression of both PD-1 and 
PD-L1 in the tumor (74). In a recent phase II trial with 142 patients with metastatic 
melanoma (82), the efficacy of ipilimumab alone was compared to the combination of 
ipilimumab and nivolumab. The researchers reported an objective response rate of 61% 
in patients given the combination, which included a 22% complete response rate. These 
results were significantly greater than the objective response rate of 11% in patients 
given ipilimumab plus placebo (and no complete responses). While certainly an exciting 
improvement in efficacy, the combination also more than doubled the occurrence of 
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severe adverse events (grade 3 or higher), including 54% for the combination and 24% 
for ipilimumab plus placebo, illustrating again the correlation between efficacy and 
toxicity. 
Intuitively, the optimal immune-stimulatory approach would include both blocking 
immunoinhibitory mechanisms while simultaneously stimulating directly with stimulatory 
molecules. This could be likened to both stepping on the gas and releasing the brakes at 
the same time. This combinatorial approach of administering a “positive” direct 
stimulatory signal such as IL-15 with a “negative” blocking signal to abrogate the 
resultant immune inhibitory signals has been illustrated preclinically. In metastatic colon 
cancer (87) and prostate (88) tumor models, Yu and colleagues treated mice with either 
IL-15 or antibody blockade of CTLA-4 and PD-L1 versus combinatorial treatment with 
both IL-15 and antibody blockade. IL-15 treatment alone, while slightly reducing tumor 
burden, led to upregulation of PD-1 on CD8+ T-cells and increased secretion of IL-10, 
limiting efficacy; however when administered in combination with the antibodies, IL-10 
secretion was reduced, and CTL-mediated killing and IFNγ secretion were increased 
leading to a greater anti-tumor response and rate of survival. While proof of principle has 
been established, this combinatorial method has received surprisingly little clinical 
investigation. As observed when anti-CTLA-4 was combined with anti-PD-1 (82), the 
synergistic efficacy of cytokine and checkpoint blockade combination therapy may likely 
be accompanied with synergistic immune-related toxic effects, as both are the result of 
an accelerated immune system. Therefore, successful clinical application of this 
combinatorial approach may not be realized until the potential toxicities are addressed. 
One approach that would limit the potential systemic toxicity would be the delivery of 
stimulatory molecules specifically to the diseased tumor microenvironment. This would 
avoid the inflammatory off-target effects that are responsible for the majority of irAEs. 
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This approach would require a suitable vector that is able to target the tumor tissue and 
deliver the therapeutic molecules. In this dissertation the case will be made that bacteria, 
specifically attenuated Gram-negative, facultative anaerobic strains such as Salmonella 
are promising candidates for this task.  
 
BACTERIA AS A CANCER THERAPY  
History 
 Long before the advent of modern immunotherapy, bacteria have been used to 
stimulate an anti-tumor response. The potential of bacteria for cancer therapy may have 
been partly realized as early as 1813, when it was reported that cancer patients who 
developed gangrenous Clostridium infections seemed to have tumor regression (89). 
Subsequently, the German physician W. Busch performed the first intentional bacterial 
cancer treatment in 1868, before bacteria were even known to cause disease. Busch 
cauterized a female patient’s neck tumor and placed the woman in a bed previously 
occupied by a patient suffering from “erysipelas,” a Streptococcus pyogenes infection. 
The patient became infected, and rapid tumor clearance occurred. Unfortunately the 
patient died 9 days later due to the infection (90). In the subsequent decades, many 
physicians tried to improve this therapy using different bacteria or bacterial components. 
The most notable was William Coley, who injected cancer patients with a combination of 
heat-killed Streptococcus pyogenes and Serratia marcescens, termed “Coley’s Toxins.” 
(91). Despite successes, the strong inflammatory side effects of the treatment caused by 
the immune system reacting to the toxins were difficult to control at the time. 
Additionally, the growing popularity of surgery, radiation and chemotherapy in the 20th 
century challenged the continued use of Coley’s Toxins. The proponents of these newer 
therapies refused the use of Coley’s Toxins, and the FDA eventually retracted the use of 
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the toxins in 1962 (92). Interestingly, a study in 2003 performed by Hoption Cann et al 
using data from the Surveillance Epidemiology End Result Cancer Registry examined 
the 10-year survival rates of patients treated with modern conventional external cancer 
therapies and those introduced by Coley (93). The study reported that despite the 
billions of dollars spent developing modern conventional therapies, patients treated with 
these therapies have not fared better than those treated with the therapy started by 
Coley over 100 years ago, which prompted the authors to ask, “Where would cancer 
treatment be today if equivalent effort and funds has been used to develop a better 
understanding of the treatment pioneered by Coley?”  
  
Tumor-targeting propensity of Salmonella 
Interest in bacterial cancer therapy has recently resurged due to a better 
understanding of both bacteria and the mammalian immune system. Preclinical reports 
describing bacterial anticancer therapies have increased exponentially in the last decade 
(94), particularly those reporting the use of Gram-negative facultative anaerobic strains 
such as Salmonella enterica and Escherichia coli (E. coli). Attenuated Salmonella 
enterica Subs. enterica serovar: Typhimurium (S. Typhimurium) has several 
characteristics that make it suitable for cancer therapy. Perhaps the most appealing is 
the propensity of the bacterium to preferentially accumulate in tumor tissue with ratios of 
over 1000/1 compared to tissues high in reticuloendothelial cells such as the liver and 
spleen. This ratio is even higher when compared to other organs (94). This phenomenon 
is likely due to a number of causes including: entrapment of S. Typhimurium in the 
chaotic vasculature of tumors; flooding into tumors following inflammation (95); 
chemotaxis toward compounds produced by tumors (96, 97); preferential growth in the 
hypoxic nutrient rich tumor-microenvironment (96, 98); and protection from surveillance 
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of the immune system (99). It is generally considered that the tumor-targeting is more of 
a passive selection rather than an active trafficking in which the attenuation inhibits the 
bacteria’s ability to avoid immune-mediated clearance unless they are in the immune 
privileged site of the tumor, wherein they thrive in the hypoxic environment with little 
competition for nutrients as they feed on sloughed dead cells and necrotic tissue (90).  
 
Natural cytotoxicity of Salmonella 
 Another beneficial characteristic of bacteria such as S. Typhimurium for cancer 
therapy is the natural cytotoxicity caused by the organisms. This toxicity by itself has 
been sufficient to cause tumor regression in many cancer models, and is described to be 
the result of immune stimulation, competition for nutrients and/or the direct induction of 
apoptosis of tumor cells by bacterial toxins (90, 99). Since many bacterial strains will 
accumulate in tumor tissue, these effects are largely contained within the local tumor 
microenvironment. Therapeutic success due to the natural immune stimulatory effect of 
bacteria has been demonstrated historically with Coley’s Toxins and more recently with 
live, attenuated strains of Clostridium and Salmonella (94). Additionally, the use of an 
attenuated strain of Mycobacterium bovis called Bacille Calmette-Guérin, originally 
developed as a vaccine strain against tuberculosis, is routinely used in clinics to 
successfully treat bladder cancer, although its mechanism of action is unclear (90). 
 
Genetic manipulability of Salmonella, delivery of therapeutic agents 
Finally, increased microbiological understanding and advances in molecular 
biology and recombinant technology have allowed researchers to genetically manipulate 
bacteria to improve its usefulness as a cancer therapy. Researchers have engineered 
several attenuated strains of S. Typhimurium to remove its virulence while maintaining 
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its tumor-targeting propensity. Additionally, S. Typhimurium can be engineered as a 
delivery system to actively express and secrete therapeutic proteins within the TME. 
Tumor vasculature, compared with normal tissue, is chaotic with large intercapillary 
distances; this impedes the delivery of conventional therapeutic molecules deep into 
tumor tissue (100). S. Typhimurium as a delivery vehicle enables intratumoral targeting 
of therapeutic agents. Through flagellar motility, S. Typhimurium can actively swim away 
from tumor vasculature and penetrate more deeply into tumor tissue than passive 
therapeutic molecules (94, 101), and preferential accumulation of the bacteria in tumor 
tissue allows for tumor-targeted delivery and prevention of systemic side effects 
associated with many therapeutic molecules. Using this approach, bacteria have been 
utilized pre-clinically for the tumor-specific delivery of cytotoxic agents such as: cytolysin 
A, Fas ligand, tumor necrosis factor alpha (TNFα) and TRAIL and immunostimulatory 
cytokines and chemokines such as: interleukin 2 (IL-2), interleukin-18 (IL-18), LIGHT, 
and CCL21 (94). Additionally, S. Typhimurium has been engineered to express prodrug-
converting enzymes in tumor tissue and to transfer genetic material for expression in 
mammalian cells such as plasmids containing genes for cytotoxic and anti-angiogenic 
agents, cytokines and growth factors, tumor antigens, and gene-silencing shRNA (94).   
 
Preclinical successes of Salmonella-based cancer therapy 
 The antitumor efficacy and tumor-targeting propensity of S. Typhimurium has 
been demonstrated in several transplantation mouse models of subcutaneous, 
orthotopic and metastatic tumors. These include, but are not limited to: breast cancer, 
colon cancer, hepatocellular carcinoma, melanoma, neuroblastoma, pancreatic cancer, 
prostate cancer, osteosarcoma and spinal cord glioma (for review see (94)). 
Researchers have reported reproducibly high tumor colonization numbers of 1×107 to 
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1×109 colony-forming units (cfu) per gram (g) of tumor tissue when bacteria are injected 
intravenously (IV) and have demonstrated partial or complete regression of transplanted 
tumors along with increases in survival time of treated tumor-bearing mice. In these 
preclinical studies, several different attenuated strains of S. Typhimurium were used 
including: A1-R, auxotrophic for leucine and arginine (102); SL7207 and related strains, 
auxotrophic for aromatic amino acids (95, 103, 104); χ4550, attenuated by knockout of 
cyclic adenosine monophosphate signaling (105), and perhaps the most widely used 
strain VNP20009, which, among many other mutations, lacks lipopolysaccharide (LPS) 
and is auxotrophic for purines (106). 
 
Failure of Salmonella to consistently colonize human tumors 
The promising preclinical efficacy reported has led to three clinical trials in which 
S. Typhimurium was administered IV to cancer patients (107-109). In each trial, the 
attenuated vaccine strain VNP20009 (Δmsb, ΔpurI) was used. The results of these trials 
were largely disappointing and have since been attributed to poor tumor colonization; of 
a combined 32 patients, only six were found to contain the bacterium in the tumors, 
indicating a problem with tumor-targeting in clinical disease. The failure to colonize has 
since been attributed by some to be the result of an over-attenuation of the strain due to 
its (LPS) deficiency (90). The msb knockout strain is unable to synthesize lipid A, the 
base structure of LPS. This attenuating mutation greatly diminishes the TNFα response 
to infection in humans, which reduces the virulence and toxicity of the strain. However, 
this TNFα response may be important for tumor colonization by increasing permeability 
of tumor vasculature, which leads to a Lipid A-dependent blood influx that carries the 
bacteria into the tumor. This hemorrhage then leads to the development of a large 
necrotic core where the bacteria localize and proliferate (95). In support of this 
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hypothesis, Yu and colleagues demonstrated that depleting TNFα caused a reduction in 
hemorrhage and a delay in tumor colonization in mice (95). Therefore, using attenuated 
Salmonella strains that are Lipid A+ may rescue tumor colonization in humans. 
Alternatively, it was recently demonstrated that co-administration of purified Lipid A with 
VNP20009 reduced the variability of colonization and led to more thorough penetration 
throughout the tumor tissue (110). 
 
TRANSPLANT VERSUS AUTOCHTHONOUS TUMOR MODELS 
Clinical relevance of transplant versus autochthonous tumor models 
The failure to consistently target human tumors in the VNP20009 trials was 
somewhat surprising, particularly in light of the extensive preclinical demonstrations of 
successful tumor-targeting by this strain in several mouse models. This discrepancy may 
be due to the artificiality of the tumor models that have been used to demonstrate the 
tumor-targeting propensity of S. Typhimurium strains. Virtually all preclinical reports of 
tumor-targeting Salmonella strains have based conclusions on experiments performed in 
“transplant” cancer models. In these models, a suspension of cells from cancer cell lines 
or actual pieces of human or mouse tumors are transplanted into a particular organ in 
the mouse, or more commonly, into the subcutaneous compartment. These experiments 
are most often performed in immunocompetent mice that develop subcutaneous tumors 
after injection of a syngeneic mouse tumor cell line. While these models offer more 
experimental control and may reduce variability, they do not accurately mimic the 
complexities of the natural tumor development that is encountered in human disease. In 
contrast to transplant tumors, “autochthonous” tumors that have developed from a single 
cell are a more accurate representation of human cancer. In autochthonous models, 
tumor development is typically driven by transgenic oncogene expression in certain 
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organs or by a topical application of a mutagen such as 3-methylcholanthrene, which 
causes mutations that drive tumorigenesis. 
 
Important differences between transplant and autochthonous tumor models 
The differences between transplant and autochthonous tumor models are 
extensive and may help explain the discrepancy between successful targeting of tumors 
in transplant mouse models and unsuccessful targeting of human tumors. First, 
vasculature development and maturity in autochthonous tumors differs significantly from 
that observed in transplanted tumors (111). In autochthonous tumor development, tumor 
angiogenesis occurs in organs over a long period of time while tumor cells are 
transforming and cell populations are evolving (111). During this time tumor cells may 
also be coopting normal vessels for their blood supply (112). In contrast, transplanted 
tumor vasculature develops rapidly and is induced throughout its development by fully 
transformed tumor cells. Tumor vasculature that results from these differences differs 
significantly in morphology and maturity. Autochthonous tumors will often contain more 
mature vasculature that is characterized by a high degree of pericyte coverage, a sign of 
vessel maturity. In contrast, the vasculature of transplant tumors contains less pericyte 
coverage and is primarily neovasculature (111). The differences in vasculature maturity 
between autochthonous and transplanted tumors has led to differences in responses to 
therapeutic agents such as IL-12 (111), anti-angiogenic agents (113, 114) and 
vasculature disrupting agents (115). Similarly, differences in tumor vasculature maturity 
may vitally affect hemorrhage-dependent bacterial tumor colonization described by 
Leschner and colleagues (95), as less mature vasculature of transplant tumors may 
more readily permeabilize and hemorrhage in response to bacterial treatment than the 
more mature vasculature of autochthonous tumors. 
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Second, transplant tumors will often differ from autochthonous tumors in the 
extent of necrosis they contain. When cancer cell lines are inoculated into the 
subcutaneous environment, the majority of the transplanted cells die, leading to an early 
artificial necrosis and an acute inflammatory response surrounded by a thin rim of viable 
tumor cells. This necrotic artifact often remains for about 2 weeks, at which point most 
transplanted tumors are about 1 cm in diameter (116). Autochthonous tumors, having 
developed from a single cell over a longer period of time, do not contain this necrotic 
artifact. Additionally, necrosis in transplanted tumors can be caused by the less mature, 
more chaotic vasculature preventing adequate oxygen diffusion throughout the rapidly 
growing inoculated tumor (117). Human tumors and autochthonous tumor models, 
having developed over longer periods of time with coincident development of 
vasculature may be less consistently necrotic. The presence of necrosis is likely 
important for effective and lasting colonization of tumors, as the majority of colonizing 
bacteria in mouse models are found in necrotic tumor regions (118). However, the 
degree of colonization in tumor tissue may not be determined by pre-existence of 
necrosis alone, as colonization has been observed in less necrotic tumors (118). 
Additionally, the hemorrhage of immature blood vessels in transplant tumors initially 
caused in response to S. Typhimurium may induce the formation of habitable necrotic 
areas, in which case necrosis would be the result of tumor colonization rather than the 
cause; this hemorrhagic necrosis might be prevented in the more mature, less 
hemorrhage-prone vasculature of autochthonous tumors. 
Third, immunological differences may affect bacterial tumor-targeting. Immune-
mediated clearance of bacteria from tumors may be a limiting factor in colonization 
(118). Unlike in autochthonous tumors, the process of immunoediting (discussed in the 
“Tumor Immunology” section) that shapes the immune microenvironment of human 
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tumors is largely absent in transplant tumor models. Rather, the immune response 
against tumors in transplant models is largely shaped by the transplant itself, including 
the initial inflammatory response against the inoculation wound and the death of the 
majority of the transplanted cells. Since transplant recipient mice will typically only live 
for a few weeks post tumor inoculation, it is difficult to separate this acute inflammatory 
response from an anti-tumor immune response that would appear in an established 
tumor microenvironment (119). These differences in tumor immunology have led to 
experimental differences in immunosurveillance and therapeutic immune responses 
between autochthonous and transplanted tumors of identical origin (120), and may 
indeed lead to differences in functional draining lymphatics and populations of 
phagocytic cells that would play a role in the clearance of bacteria from tumor tissue. 
 
CONCLUSION AND HYPOTHESIS 
Immunotherapies have demonstrated exciting potential in the treatment of 
cancer. Theoretically, the immune memory generated during a proper anti-tumor 
immune response would not only remove systemic metastases but would also prevent 
relapse of disease. This is illustrated by the relatively longer disease-free survival of 
many responders to successful immunotherapy compared to conventional therapies, 
particularly when more than one immunotherapeutic agent is used in combination. 
However, immunotherapies such as cytokine administration and/or immune checkpoint 
blockade strategies are limited in their administration by systemic immune-related 
adverse side effects, and these irAEs are compounded when multiple agents are used 
simultaneously. One approach to avoid these toxicities is to deliver the therapeutic 
molecules specifically to the TME in order to avoid their systemic inflammatory effects. In 
this thesis, the applicability of S. Typhimurium for such a role is investigated. Attenuated 
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S. Typhimurium will be assessed initially for its ability to express and secrete functional 
cytokines and antagonistic single chain antibodies against CTLA-4 and PD-L1. Secondly 
the native anti-tumor efficacy and tumor-targeting propensity of S. Typhimurium will be 
investigated in multiple models including both transplanted and autochthonous tumors. 
The overall hypothesis for this thesis is stated as: Recombinant attenuated Salmonella 
enterica Typhimurium is a promising tumor-targeting immunotherapy vector. 
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CHAPTER 2 
 
EXPRESSION AND SECRETION OF FUNCTIONAL IMMUNOMODULATORY 
PROTEINS IN ATTENUATED SALMONELLA ENTERICA TYPHIMURIUM 
 
 
Authorship Note: Jeremy Drees performed all experimental work in this chapter alone 
or with assistance from colleagues with the following exceptions: the surface plasmon 
resonance measurements to measure affinity (Table 2-1) were performed by 
LakePharma (Belmont, CA); the colonization and growth curve experiments (Figure 2-
10A and B) and protein preparation and western blots (Figure 2-11B) were performed by 
Michael Mertensotto (Research Scientist U of MN Dept. Surgery).  
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INTRODUCTION 
 The ability to genetically engineer Salmonella to express recombinant proteins of 
interest make it appealing as a deliver system for therapeutic proteins. Our lab has 
experience using the attenuated S. Typhimurium strain χ4550 (Δcya, Δcrp, Δasd) to 
deliver a truncated human IL-2 protein to stimulate T-cells and mediate tumor regression 
in murine models of neuroblastoma (121), metastatic osteosarcoma (122), and 
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metastatic colon cancer (123-125). This bacterium, named SalpIL-2, was given orally to 
mice, and while efficacious, may have been limited by a truncation in the recombinant 
human IL-2 sequence that may have affected its bioactivity. Additionally, SalpIL-2 was 
not engineered to actively secrete the IL-2 molecule, making its dissemination 
dependent on the lysis of the bacterial cells. Improved efficacy of bacterially delivered 
agents may be realized if they are actively secreted into the extracellular space, where 
they are required for the signaling through receptors on the surface of effector cells.  
As discussed, the immunoinhibitory checkpoints CTLA-4 and PD-1 are 
expressed on activated T-cells and are constitutively expressed by T-regulatory cells. 
Inhibiting the binding of these receptors to their ligands, B7.1/2 and PD-L1 respectively, 
would remove this auto-inhibitory mechanism making simultaneous cytokine stimulation 
presumably much more effective. Conventionally, these signals are blocked using 
antagonistic antibodies, but because antibodies are too complex for efficient expression 
in Salmonella, we propose to express the binding portion of the antibody, including the 
variable light (VL) and heavy (VH) portions of one arm of an antibody combined via a 
flexible peptide linker. This type of construct is termed a single chain variable fragment 
(scFv). scFvs can retain specificity and affinity for their antigens with the reduced 
complexity of a single polypeptide chain without the Fc or other constant region making 
them suitable for bacterial expression (126). There are a few reports that describe 
antagonistic anti-mouse CTLA-4 scFvs (127, 128); however, data about their biological 
activity or binding characteristics is lacking, and since they were cloned from monoclonal 
antibody (mAb) hybridomas, there is no surety of their expression in a bacterial host. 
Additionally, there are no antagonistic anti-mouse PD-L1 scFv sequences to our 
knowledge. 
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Typically, scFvs are cloned from the variable regions of existing high-affinity B-
cell hybridomas, which often results in scFvs that are unstable, of low affinity, or fold 
incorrectly due to the absence of stabilizing constant regions. These limitations have 
restricted their use as blocking agents (129). Selection for scFvs by phage display can 
overcome some of these limitations but is most often performed on suboptimal variable 
region libraries from naïve mammalian hosts, preventing the isolation of high-affinity 
scFvs (130). Alternative hosts, such as chickens, have been shown recently to be more 
effective for scFv development (130). The avian germline sequences encoding Ig 
variable regions are well suited for scFv library development. Consisting of a single set 
of VH and VL regions, the entire Ig repertoire can be easily captured via PCR (131). 
Additionally, scFvs generated from chicken variable-region libraries typically have higher 
affinities due to the greater immune response to mammalian proteins generated in a 
non-mammalian host. Other advantages include greater inherent stability of polypeptides 
generated from chicken variable regions (130) and the reported successes of multi-
antigen immunizations (132-134). For these reasons, we constructed an immunized 
chicken scFv library and used phage display to successfully isolate biologically active 
antagonistic scFvs against mouse PD-L1 and CTLA-4 that are readily expressed and 
secreted as soluble protein from Salmonella. 
In this chapter, the hypothesis that Salmonella can be engineered to successfully 
express and secrete immunotherapeutic proteins is explored by describing the 
development of recombinant Salmonella strains that secrete biologically active 
antagonistic scFvs against CTLA-4 and PD-L1. The aim is to ultimately use these strains 
in combination with strains that secrete immunostimulatory cytokines such as IL-2 and 
IL15 for the delivery of combinatorial immunotherapy to the tumor microenvironment. 
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METHODS 
Development and characterization of scFvs 
Chicken immunizations and IgY purification 
Immunizations were based on a protocol developed by Finlay et al (135), and 
were performed at Aves Labs (Oregon). Three female chickens of egg-laying age were 
immunized intramuscularly with purified recombinant mouse CTLA-4 and PD-L1 (Sino 
Biological). The immunization regime included four intramuscular injections three weeks 
apart: 1) 50 µg of each protein emulsified in complete Freund’s adjuvant; 2) 50 µg of 
each protein in incomplete Freund’s adjuvant; 3 and 4) 25 µg of each protein in 
incomplete Freund’s adjuvant. Eggs were collected for 10 days before immunization and 
after final the immunization. IgY from egg yolk was purified at Aves Labs (Oregon). 
 
IgY ELISA 
High protein-binding 96-well plates (Costar: 3590) were coated with 1.25 µg/ml 
recombinant PD-L1 (Sino biological: 50010-M08H) in 0.1 M sodium carbonate pH 9.5 
overnight at 4ºC. Plates were washed three times in PBS + 0.1% Tween-20. Plates were 
blocked using 5% milk for two hours at room temperature and washed as before. 
Varying dilutions of IgY from each chicken were added to plates and incubated for 90 
minutes at room temperature. Plates were washed, and bound IgY was detected using 
an anti-IgY-HRP conjugate (Aves Labs: H-1004) diluted 1:5000 in 5% milk for 90 
minutes at room temperature followed by washing and detection with OptEIA substrate 
(BD: 555214) for 30 minutes according to manufacturers’ protocol. Absorbance at 450 
nm was corrected for background by subtracting absorbance at 570 nm. 
 
RNA isolation and cDNA generation 
  
29 
Chickens were sacrificed and their spleens were frozen in RNAlater (Qiagen). 
Total RNA was isolated from 200 mg of each spleen using an RNeasy Midi Kit (Qiagen) 
according to manufacturers’ instructions. cDNA was generated from total RNA using 
SuperScriptTM 1st Strand Synthesis System for RT-PCR (Life Technologies) with random 
hexamers according to manufacturers’ instructions. 
 
PCR synthesis of scFv library 
Library synthesis was performed according to methods published by Finlay et al 
(135), including PCR primers and temperature parameters. Briefly, VL and VH libraries 
were amplified from cDNA from each chicken using PCR primers flanking the variable 
regions. PCR reactions were repeated 10 times with new cDNA to in order to retain as 
much library diversity as possible. Resulting DNA fragments were purified from an 
agarose gel using a Qiaquick Gel Extraction Kit (Qiagen) and pooled for each chicken. 
Individual VL and VH region libraries were randomly combined with the addition of a 
flexible peptide linker using splice overlap extension PCR with defined primers (135), 
and 4 µg of gel-purified scFv DNA from each chicken was combined to generate the final 
scFv library.  
 
Ligation and transformation of TG1 cells for phage display 
The scFv library was ligated into pComb3x phagemid vector (from Dr. Barbas, 
Scripps Research Inst.). Before ligation, 40 µg of pComb3x vector and 10 µg of the 
combined scFv library were digested with Sfi1 in a 200 µl final reaction volume (New 
England Biolabs) according to manufacturers’ instructions for 8 hours at 50ºC. Digested 
fragments were separated by gel electrophoresis and extracted from agarose using a 
Gel Extraction Kit (Qiagen). The pComb3x vector was treated with Antarctic 
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phosphatase (New England Biolabs: M0289S) to prevent self-ligation according to 
manufacturers’ instructions. Phosphatase was removed before ligation using a PCR 
cleanup Kit (Qiagen). The pComb3x vector and scFv library were ligated with T4 DNA 
ligase (New England Biolabs) using 1.5 µg of vector and 1 µg scFv library for a 1:3 
vector to insert molar ratio in 200 µl total reaction volume for 16 hours at 16ºC. Following 
ligation, the DNA library was freed of enzyme and ligation buffer using a PCR Cleanup 
Kit and eluted in 40 µl sterile deionized water. The entire ligation was added to 300 µl of 
electrocompetent E. coli TG1 cells (Agilent Technologies), and cells were electroporated 
according to manufacturers’ instructions, rescued in 5 ml of pre-warmed S.O.C. medium, 
and the entire transformation plated on 2x yeast-tryptone agar containing 100 µg/ml 
carbenicillin in a 22x22 cm Qtray (Genetix) and incubated overnight at 37ºC. A 100 µl 
aliquot of the transformation was serially diluted and plated for counting to determine the 
theoretical library diversity. After incubation, colonies were scraped from Qtrays in 20 ml 
2x yeast-tryptone broth + 15% glycerol and stored in aliquots at -80oC for phage display 
and panning.  
 
Phage display and panning for binding sequences 
Phage display and binding screens were performed according to methods 
published by Finlay et al (135). Briefly, the E. coli TG1 cells containing the scFv library 
were infected with M13K07 helper phage (New England Biolabs). Infected cultures were 
grown overnight and phage displaying the scFvs were precipitated and allowed to bind 
immobilized PD-L1 (Sino Biological: 50010-M08H). Unbound phage were removed by 
washing 10 times with PBS-0.1% Tween-20 and 10 times with PBS. Antigen-bound 
phage were eluted with 0.1 M glycine pH 2.2 and used to infect E. coli strain ER2738 
(Agilent Technologies), which were spread onto QTrays containing 50 µg/ml 
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carbenicillin. The selection and re-infection procedure was repeated for four total rounds. 
An aliquot of input and output phage was titered for each panning round to monitor 
enrichment of binding sequences.  
 
ELISA screen for binding sequences 
Several colonies from the output of round 4 of panning were tested for antigen 
binding. Colonies were inoculated into individual wells of a 96-deepwell plate 
(Eppendorf: 951033502) containing 1ml of 2x YT medium containing 100 µg/ml 
carbenicillin and induced with 0.02 mM IPTG at log phase. Induced cultures were grown 
overnight, and the periplasmic protein was extracted via osmotic shock in 100 µl of 
sterile, ice-cold H2O. High protein-binding 96-well plates (Costar: 3590) were coated with 
1.25 µg/ml recombinant PD-L1 or CTLA-4 (Sino Biological) in 0.1 M sodium carbonate 
pH 9.5 overnight at 4ºC. Plates were washed four times in PBS + 0.1% Tween-20 and 
blocked using 200 µl 5% milk for two hours at room temperature. Periplasmic protein 
containing scFvs (50 µl) was mixed with 50 µl of 10% skim milk, added to plate-bound 
antigen, and incubated for two hours at room temperature. Plates were washed and 
bound scFv was detected using 0.5 µg/ml anti-hemagglutinin tag/HRP conjugate 
(GenScript: A00169) in 5% milk, followed by incubation with OptEIA substrate (BD: 
555214) for 30 min according to manufacturers’ protocol. The top five binding scFvs 
were sequenced and Top 10F’ E. coli cells (Life Technologies: C3030-03) were 
transformed for subsequent protein expression and characterization. 
 
Expression, purification and detection of scFv 
E. coli Top10F’ cells harboring phagemid with the selected scFv sequences 
(αPD-L1 scFv) were grown in 250 ml 2x YT medium, induced at log phase with IPTG at 
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a final concentration of 1 mM and incubated at 37o C overnight at 250 RPM. Cultures 
were pelleted at 4000×g for 15 minutes and resuspended in 30 ml of 20% sucrose, 50 
mM Tris-HCl, 1 mM EDTA and incubated with mild shaking for 15 minutes at room 
temperature. Bacteria were at pelleted at 4oC and resuspended in 6 ml ice-cold sterile 
H2O to release the periplasmic fraction via osmotic shock. scFvs were purified from total 
periplasmic protein using 100 µl of His-Tag Isolation & Pulldown beads per 1 ml of 
periplasmic protein (Life Technologies: 10103D) according to manufacturers’ 
instructions. Purified protein was then desalted twice in PBS using Amicon® Ultra 0.5 ml 
10K centrifugal filters (Millipore: UFC501008) and quantified using a BCA protein assay 
(Pierce®) for subsequent experiments. 
Protein was isolated from culture media after 0.22 µm filtration to remove all cells 
and TCA precipitation (10% TCA in acetone) on ice for 2 hours. Precipitated protein was 
pelleted at 10,000 RCF for 30 minutes and dissolved in SDS sample buffer (Boston 
Bioproducts) for gel analysis. 
For detection of scFvs, protein was denatured in SDS sample buffer and 
separated on 10-20% gradient polyacrylamide gels. Proteins were detected using either 
Coomassie stain (GelCode Blue, Thermo Scientific) or transferred to a PVDF membrane 
and detected with anti-hemagglutinin-HRP conjugate (GenScript: A00169). 
 
Affinity mearsurements by surface plasmon resonance (SPR)  
 To measure binding kinetics, SPR was performed at LakePharma using an Octet 
QKe system (ForteBio). Anti-hFc kinetic grade biosensors (ForteBio: 18-5060) were 
hydrated in sample diluent (0.1% BSA in PBS and 0.02% Tween 20) and preconditioned 
in 10mM glycine pH 1.7. Mouse PD-L1 human Fc fusion protein (R&D systems: 1019-
B7) was reconstituted at 100 µg/mL in PBS and was further diluted to 10 µg/mL with 
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sample diluent for loading. The PD-L1-Fc solution was immobilized onto anti-hFc 
biosensors for 120 seconds. After the baseline was established for 120 seconds in 
sample diluent, the biosensors were moved to wells containing either αPD-L1 scFv or 
one of three monoclonal anti-mouse PD-L1 antibodies: 10F9G2 (Biolegend: 12403), 1-
111a (eBioscience: 14-9971) or MIH5 (eBioscience: 14-5982) at a series of 
concentrations to measure the association. Association was observed for 120 seconds 
and dissociation was observed for 300 seconds for each protein of interest in the sample 
diluent. The Kon and Koff rates were measured by fitting of kinetics sensorgrams to a 
monovalent binding model using Octet software on global fitting (1:1 binding). KD was 
calculated for each protein of interest by the Koff/Kon ratio. 
αPD-L1 scFv T-cell stimulation assay 
M450 tosylactivated beads (Life Technologies: 140.13) were coated with 3 µg 
anti-CD3 antibody (BioLegend: clone 17A2) and 2 µg mouse PD-L1-Fc chimera (R&D 
Systems: 1019-B7) according to manufacturers instructions. Control beads were coated 
with 3 µg of anti-CD3 and 2 µg human Fc control protein (Abcam: 90285). Anti-CD3/PD-
L1-coated beads were then blocked with varying concentrations of either αPD-L1 scFv, 
an antagonistic anti-PD-L1 positive control mAb (clone 10F.9G2), or Fc protein as a 
negative control, for 2 hours at 37o C. Primary T-cells were purified from murine 
splenocytes using T-cell purification columns (R&D Systems: MTCC-10) and incubated 
at a 1:1 bead:cell ratio with coated/blocked beads for 4 days in RPMI medium (Gibco) 
containing 10% fetal bovine serum, 2mM l-glutamine and 2µg/mL B7.1-Fc protein (R&D 
Systems: 740-B1) at 37oC in 5% CO2. Following incubation, culture supernatant was 
tested for IL-2 secretion using an ELISA (BD OptEIATM Mouse IL-2 ELISA Set) according 
to manufacturers’ instructions.  
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Anti-CTLA-4 scFv antagonistic binding assay 
96-well plates (Costar® 3590) were coated with recombinant mouse CTLA-4 
(Sino Biological) at 1.25 µg/mL and incubated overnight. Plates were washed 3x in 
PBS+0.1%Tween-20 and blocked for 90 minutes at room temperature with 5% milk. 
Recombinant hB7.1-Fc fusion protein (Sino Biological) was added to plates at a 
concentration of 1.25 µg/mL along with varying concentrations of either anti-CTLA-4 
mAb (clone: 63828, R&D Systems), anti-CTLA-4 scFv or a negative control (anti-PD-L1) 
scFv and incubated at room temperature for 120 minutes. After washing, bound hB7.1-
Fc fusion protein was detected with anti-human Fc-HRP antibody (Millipore) diluted 
1:50,000 in 5% milk followed by incubation with BD OptEIATM TMB substrate according 
to manufacturer’s instructions. 
 
In vivo survivability experiments 
Female BALB/c mice of 10-12 weeks of age were injected IV with the indicated 
S. Typhimurium strain. Mice were euthanized 21 days post-S. Typhimurium 
administration. Indicated tissues were harvested and minced with sterile razor blades to 
about 1 mm diameter pieces. Minced tissues were then homogenized in 3 ml of sterile 
PBS using gentleMACS M Tubes (Miltenyi Biotec) with a gentleMACS Tissue 
Dissociator (program RNA_01). The homogenates were serially diluted in sterile PBS, 
plated on LB agar, and incubated for 16-18 hours at 37°C for CFU enumeration.  
For tumor survivability studies, 4T1 breast cancer cells (ATCC #CRL-2539) were 
grown in RPMI-1640 medium containing 10% fetal bovine serum. Cells were detached 
from flasks using 0.05% trypsin-EDTA, counted with a hemocytometer, washed with 
sterile PBS, and diluted to the appropriate concentration prior to injection. Mice were 
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given a subcutaneous injection of 1×105 4T1 cells in 50 µL of sterile PBS superficial to 
the right inguinal mammary fat pad. 11 days post-tumor inoculation, mice were similarly 
injected with the indicated strain, and tumor tissue was harvested, homogenized, and 
plated as were other tissue samples. 
 
Salmonella strains and expression systems 
Attenuated Salmonella strains 
 Attenuated S. Typhimurium strain χ4550 (Δcya, Δcrp, Δasd) was a gift from Roy 
Curtiss III (Arizona State University). χ4550 is deficient in aspartate semialdehyde 
dehydrogenase (asd), which allows for plasmid maintenance by encoding asd on its 
expression plasmid. Attenuated S. Typhimurium strain SL3261 (ΔaroA, ΔhisG) was 
obtained from the Salmonella Genetic Stock Centre (SGSC #439). The strain “SalpNG” 
was constructed by transforming χ4550 with pNG, a plasmid containing cDNA coding for 
the asd gene to complement the χ4550 requirement for diaminopimelic acid. To 
construct plasmid pNG, plasmid pYA292 (136) was cut with EcoRI and HindIII, the ends 
filled in, and the plasmid recircularized to eliminate the LacZ(alpha) coding sequence. 
SL3262 (ΔaroA, ΔhisG, Δasd) was generated by knocking out the asd gene from 
SL3261 using the phage λ Red recombinase method (137) and two PCR primers: FWD: 
CGGCCTACAGAACCACACGCAGGCCCGATAAGCGCTGCAAATTGTGTAGGCTGGA
GCTG and REV: CACAGGATACTGGCGCGCATACACAGCACATCTCTTTGCAGTCCA 
TATGAATATCCTCCTTAGTTC. Transforming SL3262 with the pNG plasmid generated 
the strain DSpNG. 
 
Plasmid construction, recombinant gene cloning 
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 All bacterial plasmid construction and recombinant cDNA cloning (including scFv 
and cytokine cDNA sequences, secretion accessory proteins, and periplasmic 
chaperone proteins) were accomplished by PCR amplification of the desired sequences, 
insertion into the vector via blunt-end ligations, and electroporation into electrocompetent 
cells using standard techniques. To increase electroporation efficiency, ligations were 
cleaned before electroporation using a Qiagen PCR Cleanup Kit. Correct orientation of 
gene inserts was validated by restriction digests and agarose gel separations of DNA 
fragments. 
 
RESULTS 
Isolation and characterization of single chain antibodies against murine CTLA-4 
and PD-L1 
Immunoglobulin library development 
To develop the immune library, three female chickens of laying age were 
immunized simultaneously with purified PD-L1 and CTLA-4 protein intramuscularly four 
times over a period of nine weeks. Eggs from each chicken were collected before and 
after the immunization, and egg yolk immunoglobulin (IgY) was purified in order to verify 
successful sensitization to PD-L1 and CTLA-4. Pre- and post-immune IgY were 
qualitatively compared for antigen specificity using an ELISA with plate-bound PD-L1 
and CTLA-4. Each chicken demonstrated a robust increase in antigen specificity in 
response to the immunization (Figure 2-1). 
Total RNA was isolated from the spleens of immunized chickens. cDNA was 
generated from RNA using reverse transcriptase and random hexamers. The VH and VL 
sequences were amplified from cDNA using PCR primers flanking the variable regions 
(Figure 2-2A). The resulting variable domain fragments were randomly combined with 
  
37 
the addition of a linker sequence (Figure 2-2B) generating the full-length scFvs. The 
resulting individual scFv libraries were combined with equal representation from each 
chicken and ligated into the pComb3x phagemid vector (138). Electroporation into E. coli 
TG1 cells resulted in 2.5x108 colonies, which represents the theoretical library diversity 
of unselected scFvs. While the size of the library allows for 2.5x108 different scFv 
sequences, the library likely consisted of replicates of high affinity scFv sequences that 
would have been enriched in vivo during clonal expansion and affinity maturation of B-
cells recognizing immunogenic epitopes on PD-L1 and CTLA-4. Next, phage display was 
used to enrich for antigen-specific scFvs from the immunized sequence pool and to 
select the highest binding scFvs for further characterization. 
 
Phage display and panning 
The scFv library is contained within the pComb3x vector (Figure 2-3), which 
expresses scFvs as fusion proteins attached to the p3 coat protein of M13 filamentous 
phage. The library was rescued via infection with helper phage, which provided the 
accessory proteins necessary for replication in and release from infected E. coli. Phage 
precipitated from infected cultures displayed the encoded scFvs on their surface and 
were incubated with immobilized recombinant PD-L1 or CTLA-4 to allow binding. 
Rigorous washing removed unbound phage, and the bound phage were eluted, titered, 
amplified and used to re-infect E. coli. This panning procedure was repeated for a total 
of four rounds for each antigen. The output phage titer after the first round of selection 
was ~1x104 for each antigen, implying that only one in ~25,000 clones of the original 
immune library bound antigen strongly enough to be selected by phage display. These 
binding sequences were enriched in subsequent rounds of panning as output titers 
increased. There was not an increase in output titer from round 3 to 4, which may be 
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explained by reaching a maximum occupancy of available antigen in these rounds 
(Figure 2-4A). However, there may have been further enrichment of strongly binding 
scFvs during round four as they competed for antigenic “space.” The binding capabilities 
of several scFvs from the output of the final round of panning was tested with an ELISA 
against PD-L1 or CTLA-4; the majority of the selected scFvs bound their antigen in 
varying degrees when compared to negative controls (Figure 2-4B). The DNA 
sequences of the top five binding scFvs for both antigens were determined. All five PD-
L1-binding scFvs shared the same sequence, which was labeled “αPD-L1 scFv.” Three 
of the top five CTLA-4 binding scFvs shared the same sequence, which was labeled 
“αCTLA-4 scFv.” These sequences have been submitted to the GenBank database 
under accession numbers KF041825 and KF041824, respectively. 
 
Expression, purification and binding capability of soluble scFvs 
In order to express the scFvs as mature proteins without the fused P3 peptide for 
further characterization, the non-suppressor E. coli strain Top10F’ was transformed with 
phagemid harboring the αPD-L1 scFv or αCTLA-4 sequence and induced for protein 
production. The mature scFv contains the C-terminal hemagglutinin (HA) and 
polyhistidine tags for detection and purification (Figure 2-3). Soluble scFv was detected 
in both the periplasm and culture supernatant of transformed cells using an anti-HA-
tag/HRP conjugate (Figure 2-5A). The OmpA signal peptide directs type II sec-
dependent secretion into the periplasmic space; therefore we suspect the scFv detected 
in the culture supernatant is due to passive leakage of the scFv across the outer 
membrane or cell lysis resulting in the accumulation of periplasmic proteins in the 
supernatant. 
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Soluble scFvs were purified from the periplasmic protein of recombinant Top10F’ 
cells using cobalt-based immobilized metal affinity chromatography. ScFvs were eluted 
in imidazole solution and desalted using 10kD molecular weight cutoff filters. 
Approximately 1 mg of purified αPD-L1 scFv was obtained from the periplasmic protein 
extraction of 250 ml of culture. A high degree of purity was achieved as indicated by 
separation on SDS-PAGE and Coomassie blue staining (Figure 2-5B). By evaluating 
band intensity of protein gels, we estimated that over half of the protein was found in the 
periplasm and culture supernatant of recombinant bacteria (not shown). In addition to 
the supernatant and periplasm, each scFv was found in the cytoplasm and insoluble 
fraction of cell lysates. There was some difficulty in the production and purification of 
αCTLA-4 scFv, which hindered the subsequent purification and binding affinity 
characterization of the protein when produced from E. coli.   
 
Binding affinity of αPD-L1 scFv 
To address the potential of bacterially delivered αPD-L1 scFv for PD-L1 
blockade, we examined the affinity of αPD-L1 scFv to its antigen using surface plasmon 
resonance (SPR), which can directly measure the rate of binding of antibodies to their 
antigens (Kon) and the rate at which the antibody/antigen complex dissociates (Koff). 
Affinity to antigen is often expressed as a dissociation constant (Kd), which is the molar 
concentration of an antibody at which half of the total available antigen is bound by the 
antibody, calculated as the ratio of Koff/Kon. The higher an antibody’s affinity, the lower its 
Kd. We utilized a PD-L1-Fc chimera as the target antigen, which allowed capturing the 
PD-L1 antigen onto a biosensor in the correct orientation. The PD-L1-coated biosensor 
was immersed in an scFv-containing solution, the αPD-L1 scFv was allowed to bind the 
captured antigen, and the bound scFv was measured over time to give a Kon value. 
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Moving the biosensor into a buffer solution containing no scFv allowed the measurement 
of Koff. In addition to αPD-L1 scFv, three commercially available antagonistic blocking 
mAbs against murine PD-L1 were tested for comparison (clones 10F.9G2, MIH5 and 1-
111a). The, Koff, Kon and Kd values of αPD-L1 and the mAbs are shown in Table 2-1. Due 
to difficulties in the expression and purification of αCTLA-4 scFv (see chapter 2 
discussion), the binding affinity of this molecule was not tested. 
 
Biological activity of αCTLA-4 and αPD-L1 scFvs 
 CTLA-4 when binding to its ligand B7.1 inhibits T-cell activation. Therefore a 
functional antagonistic scFv must inhibit CTLA-4/B7.1 binding. In order to assay for 
αCTLA-4 scFv blocking activity an in vitro competitive binding assay was used. Plates 
coated with purified CTLA-4 protein bound B7.1 (Figure 2-6A). However when αCTLA-4 
scFv was added, CTLA-4/B7.1 binding was inhibited in a dose-dependent manner. 
Blocking activity was compared to the conventional αCTLA-4 mAb clone 63828 and to a 
αPD-L1 scFv as a negative control (Figure 2-6A). 
  In order to assay for blocking activity of αPD-L1 scFv, we utilized a T-cell 
activation assay. Activated T-cells will begin to proliferate and secrete effector molecules 
such as interleukin 2 (IL-2). PD-L1 attenuates T-cell activation in response to antigen by 
binding its receptor PD-1, expressed on T-cells during activation. This interaction 
inactivates T-cells, reducing effector function and IL-2 secretion. Therefore, blocking PD-
1/L1 activity increases T-cell activation, indirectly stimulating proliferation and IL-2 
secretion. To determine if αPD-L1 scFv has PD-1/L1 antagonistic activity, T-cells were 
activated in the context of PD-L1 and observed for a rescue of IL-2 secretion by the 
addition of αPD-L1 scFv. In order to mimic an antigen presenting or target cell, 
tosylactivated beads were coated with an anti-CD3 mAb. The anti-CD3 antibody binds to 
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the CD3 subunit of the TCR and acts as a non-specific primary signal for T-cell 
activation. In addition to anti-CD3, tosylactivated beads were coated with either PD-L1-
Fc fusion protein, “PD-L1(+) beads,” or Fc control protein, “PD-L1(-) beads.” Primary T-
cells were purified from the spleens of Balb/C mice and cultured in the presence of either 
PD-L1(-) beads or PD-L1(+) beads. In addition, the culture medium was supplemented 
with B7.1-Fc protein to facilitate co-stimulation of T-cells. In the presence of PD-L1(-) 
beads, T-cells expanded and produced IL-2, measured by an ELISA of the culture 
supernatant on day 4 of incubation (Figure 2-6B). Conversely, when cultured in the 
presence of PD-L1(+) beads, T-cell activation was prevented, as indicated by a 
reduction in IL-2 secretion. However, when PD-L1(+) beads were blocked with αPD-L1 
scFv, T-cell activation was rescued, as indicated by a dose-dependent increase in IL-2 
production. The T-cell stimulatory activity of αPD-L1 scFv was compared to the mAb 
10F.9G2, which had shown the highest affinity to PD-L1-Fc of the antibodies tested 
(Table 2-1). The αPD-L1 scFv was found to be as effective as 10F.9G2 at stimulating T-
cells in the context of PD-L1 (Figure 2-6B). Therefore both scFvs demonstrated 
antagonistic biological function against immune checkpoint receptor-ligand binding and 
were ready for recombinant expression in S. Typhimurium. 
 
Recombinant scFv expression in S. Typhimurium 
Attenuated Salmonella strains and plasmid  
The attenuated strains of S. Typhimurium focused on in this study are χ4550 and 
SL3261. These strains were chosen based on previous experience with χ4550 and 
several reports demonstrating successful tumor colonization with SL3261 (90). χ4550 is 
an asd – strain that lacks aspartate semialdehyde dehydrogenase and therefore cannot 
synthesize diaminopimelic acid (DAP), an essential component of the bacterial cell wall. 
  
42 
Bacterial plasmid maintenance is therefore maintained by complementing asd on our 
basic expression plasmid, pNG (Figure 2-7A). χ4550 cells that do not contain a plasmid 
must be grown in medium supplemented with DAP and will not survive in vivo. The asd 
complement system removes the need for antibiotic selection of transformants and 
allows for continual recombinant plasmid maintenance in an animal host. In addition to 
asd, the basic pNG plasmid contains a p15 origin of replication, leading to 15-20 plasmid 
copies per cell, and the trc promoter (139) upstream from the cloning site (Figure 2-7A). 
The trc promoter (139) is a Lac-based promoter modified from the lac operon found in E. 
coli that is constitutively active in Salmonella due the absence of a functional lac operon 
and LacI repressor protein.  
  
Periplasmic scFv expression in attenuated Salmonella 
 When expressed in bacteria, scFvs are typically fused to an N-terminal type II 
secretion tag. This facilitates secretion into the more oxidative environment of the 
periplasm, where stabilizing disulfide bond formation occurs more readily (140). Since 
the scFvs had been selected by phage display using an OmpA secretion tag, we chose 
this tag for type II secretion in χ4550. Sequences for αCTLA-4 scFv and αPDL1 scFv 
were inserted into the pNG expression vector under the constitutively active trc promoter 
to generate pTrc-OmpA-αCTLA-4 and pTrc-OmpA-αPD-L1, respectively (Figure 2-7B). 
Recombinant plasmids were then used separately to transform electrocompentent χ4550 
to generate SalpαCTLA-4 and SalpαPD-L1. These strains were grown in culture 
overnight and prepped for recombinant scFv expression. Coomassie-stained protein 
gels revealed high quantities of αPDL1 scFv in both the periplasm and culture 
supernatant of SalpαPD-L1 (Figure 2-8A) however, the growth rate of SalpαPD-L1 was 
slower than χ4550 containing a control pNG plasmid (SalpNG), and the culture 
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contained a white precipitate thought to be caused by bacterial cell lysis (not shown). 
SalpαPD-L1 cell lysis during culturing may explain the slower growth rate, the presence 
of the precipitate, and the accumulation of the scFv in the culture supernatant in the 
absence of an extracellular secretion mechanism. In contrast to SalpαPD-L1, very little 
to no αCTLA-4 scFv was observed in the SalpαCTLA-4 culture (Figure 2-8A). 
Subsequent analysis revealed a mutation that occurred during the culturing of 
SalpαCTLA-4 that inserted a premature stop codon. These observations indicated that 
forced periplasmic expression of the scFvs is deleterious to the fitness of χ4550, 
particularly expression of the αCTLA-4 scFv. This was verified by subsequent 
SalpαCTLA-4 cloning attempts resulting in strains with unique mutations to the cDNA or 
promoter sequence that prevented αCTLA-4 scFv expression. Therefore, generation of 
SalpαCTLA-4 was unsuccessful at this point.  
 To determine whether the altered growth kinetics of SalpαPD-L1 affected its in 
vivo survivability, 4T1 tumor-bearing mice were orally gavaged with SalpNG or SalpαPD-
L1 and examined for tumor colonization. Each tumor from mice treated with SalpNG 
contained viable bacteria; however tumors from mice treated with SalpαPD-L1 did not 
contain bacteria (Figure 2-9A). This suggests that constitutive expression of periplasmic 
αPDL1 scFv reduces the fitness of SalpαPD-L1 and its survivability in vivo. The 
attenuating effects of periplasmic protein expression may be caused by the aggregation 
of mis-folded recombinant scFvs affecting the fitness of the bacteria. This issue has 
been partially addressed by Schaefer and Pluckthun (141), who observed greater 
success in recombinant periplasmic scFv expression in E. coli by co-expressing multiple 
periplasmic chaperones (FkpA, SurA, Skp, DsbA, and DsbC) on a separate plasmid. We 
investigated if this approach would lessen the deleterious effects of periplasmic αPDL1 
scFv expression in SalpαPD-L1. The chaperone proteins were cloned into the pTrc-
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OmpA-αPD-L1 plasmid forming pCH-OmpA-αPD-L1 (Figure 2-7C) and the resulting 
construct was used to transform χ4550 to generate “SalpCH-αPD-L1.” The co-
expression of periplasmic chaperone proteins seemed to improve the health of the cells 
in culture, indicated by a lack of precipitate and an improved growth rate (not shown). In 
addition, αPDL1 scFv was no longer found in the culture supernatant, indicating that 
bacterial cells were no longer lysing due to scFv expression (Figure 2-8B). However, 
periplasmic chaperone co-expression did not improve the in vivo survivability defects of 
periplasmic αPD-L1 scFv expression (Figure 2-10A). To determine if chaperone 
expression itself affected in vivo survivability, we tested S. Typhimurium expressing 
periplasmic chaperones alone (SalpCHAP) and found that periplasmic chaperone 
expression actually reduced the in vivo survivability of the bacteria (Figure 2-10A), 
despite having no apparent effect on in vitro growth (Figure 2-10B). Therefore, it was 
apparent that periplasmic secretion was impractical for in vivo bacterial delivery of 
scFvs. 
 
Extracellular secretion of scFvs in attenuated Salmonella 
 We next sought to investigate whether Salmonella could be engineered to 
actively secrete the recombinant scFvs out of the bacterial cell and into the extracellular 
space. Extracellular secretion was desirable for two reasons: it would not require lysis of 
the bacterial cell in order to deliver the anti-tumor agents, leading to a more consistent 
delivery of therapeutic proteins during bacterial tumor colonization, and secreting the 
proteins through the inner and outer membrane to the extracellular space could 
circumvent the attenuating effects we observed with periplasmic secretion.  
 Successful secretion of recombinant proteins from Salmonella has been reported 
using Type I, Type III, and flagellin secretion systems. These mechanisms involve fusing 
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an N or C-terminal tag to the protein of interest, which is recognized by periplasmic 
proteins that mediate the secretion of the tagged protein out of the cell. Several 
secretion tags were fused to the αPDL1 scFv sequence and assayed for secretion; the 
descriptions of these systems and the results obtained are summarized in Table 2-2. 
Ultimately, successful secretion of both scFvs was achieved using the hemolysin (Hly) 
secretion system, based on the type I secretion of the hemolysin protein in Gram-
negative bacteria such as E. coli. In this system, hemolysin (Hly A) is recognized by the 
inner membrane protein HlyB via a 60 amino acid C-terminal signal sequence (HlyA-ss). 
HlyB, in concert with the inner membrane protein HlyD and the outer membrane protein 
TolC, forms a channel through which the target protein unfolds as it is secreted out of 
the cell where it then refolds (142). Secretion using the Hly system was accomplished in 
Salmonella by encoding the HlyB and HlyD accessory proteins on our expression vector 
(TolC is constitutively expressed in Salmonella) and fusing the αPDL1 scFv sequence 
with the C-terminal HlyA-ss sequence to generate pTrc-αPDL1-Hly and pTrc-αCTLA4-
Hly (Figure 2-7D), which when electroporated into χ4550 generated SalpαPDL1-Hly and 
SalpαCTLA4-Hly, respectively. αPDL1 scFv and αCTLA4 scFv were found exclusively in 
the culture medium of SalpαPDL1-Hly and SalpαCTLA4-Hly (Figure 2-11A). To verify 
that this was due to secretion of the molecules and not cell lysis, the expression of DnaK 
was also examined as a cytoplasmic control protein (Figure 2-11A). The Hly system not 
only allowed for secretion of the αPDL1 scFv, but also removed the in vivo survivability 
defects that were observed with periplasmic secretion (Figure 2-9B). Additionally, the Hly 
secretion system improved the cloning and expression issues with the αCTLA-4 scFv 
sequence that were encountered when attempting to initially clone this sequence in 
Salmonella. 
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 The Hly secretion system was also utilized to generate scFv-secreting strains 
based on the SL3261 attenuated Salmonella strain (ΔaroA, ΔhisG). These strains, 
named DSpαPDL1-Hly and DSpαCTLA4-Hly, secreted their recombinant scFvs at levels 
similar to SalpαPDL1-Hly and SalpαCTLA4-Hly (Figure 2-11B). Although unlikely, the 
presence of the Hly-ss on the mature scFvs may prevent them from binding their 
ligands. To test this possibility, an ELISA was performed to determine the binding 
capability αPDL1 scFv against PD-L1-Fc-coated plates. In this assay, the scFv bound its 
ligand in a dose-dependent manner, which indicated that the Hly-ss sequence does not 
interfere with the ligand-binding region of the protein (Figure 2-11C). 
 
DISCUSSION 
Generation of functional immune checkpoint-blocking scFvs 
Immunized avian libraries have been used before to generate high affinity scFvs 
(130). In addition to the benefits described in the introduction of this chapter (page 27), 
selection of functional scFvs using phage display was advantageous by selecting only 
functional scFvs that can be expressed in Gram-negative bacteria, which increased the 
likelihood of successful downstream expression in Salmonella. The scFvs and the 
molecules they block are roughly the same size, and theoretically many ligand-binding 
scFvs selected during panning would bind their antigen in areas that would not block 
signaling. We were fortunate to find that both of the scFvs selected from our phage 
display pool actually blocked the receptor/ligand binding of their target proteins. Indeed, 
when the library was subsequently revisited (for experiments irrelevant to this thesis), 
scFv sequences were characterized that bound their antigen but did not interrupt 
receptor/ligand binding. 
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Typically, antibody affinities in response to immunization will be in the 10-7-10-10 
M range (143). We observed a notably high affinity with a Kd value of 7.11x10-10 M for 
αPD-L1 scFv binding to PD-L1-Fc, especially when compared to the reported Kd of the 
cellular PD-1/PD-L1 interaction of 4.17x10-6 (144). This could be attributed to the higher 
affinity that is typical of chicken derived anti-mammalian variable regions after 
immunization (130) and the use of phage display to select the highest affinity scFv from 
the immunized library. However, when compared to the antagonistic mAbs tested, the 
scFv had a slightly lower affinity than MIH5 and was more than an order of magnitude 
lower than 10F.9G2 and 1-111a. In many cases, scFvs will bind antigen more weakly 
than full-length antibodies, as an scFv has only one antigen-binding Fv region, and a full-
length mAb has two Fv regions. When the antigen is carrying more than one available 
antigenic determinant, such as in the case of PD-L1-Fc (the Fc portion of this protein 
causes dimerization), the bivalent avidity of two binding sites adds a considerable 
advantage by decreasing the Koff of the mAb, as both antigen-antibody bonds must be 
broken simultaneously before dissociation can occur (145). We suspect this difference 
accounts for the lower affinity of αPD-L1 scFv when compared to the mAbs, as the 
calculated differences in KD are largely reflective of Koff rather than Kon (Table 1).  
 While αPD-L1 scFv binds PD-L1 more weakly than 10F.9G2, it demonstrated 
comparable blocking activity to the full-length mAb. This may be because the affinity of 
both αPD-L1 scFv and 10F.9G2 are several orders of magnitude above the affinity of 
PD-L1 to its receptor PD-1, and are both in the upper theoretical limit of antibody affinity 
(145). Their blocking ability may therefore be limited more so by diffusion rates and the 
proximity and availability of antigen rather than by their rate of dissociation. Additionally, 
while more PD-L1 molecules may remain unbound in the case of αPD-L1 scFv when 
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compared to 10F.9G2, these antibodies are comparable in their ability to block PD-
L1/PD-1 inhibitory signals in a cellular context.  
 
Expression and secretion of recombinant proteins in Salmonella 
When producing scFvs, it is not unusual to encounter problems with solubility 
and proper folding (146), and in most cases, scFvs generated in bacteria will accumulate 
as insoluble protein in inclusion bodies and require extra steps to refold before functional 
use (147-151). We did not encounter these issues with the αPD-L1 scFv when 
expressed in E. coli, which eased the production and purification of the protein. However 
there was some difficulty in the production of soluble αCTLA-4 scFv, which hindered the 
subsequent characterization and binding affinity of the protein, but sufficient amounts of 
soluble protein were generated to determine its antagonistic bioactivity. 
Even though both αPD-L1 scFv and αCTLA-4 scFv were expressed and secreted 
to the periplasm in E. coli for selection by phage display, their constitutive expression 
and periplasmic expression in Salmonella proved deleterious for the bacteria as 
evidenced by the slowed growth in culture and lack of in vivo survivability in the case of 
SalpαPDL1. These negative effects were seemingly more pronounced in the initial 
attempts to clone the αCTLA-4 scFv in Salmonella (echoing the expression issues of this 
scFv encountered in E. coli); in this case, the only recoverable transformants had 
recombinant pTrc-OmpA-αCTLA-4 plasmids with altered sequences that prevented 
expression of the scFv. These deleterious effects may have been due to an 
accumulation of potentially poorly folded and/or aggregated scFvs in the periplasmic 
space, which can sometimes accompany recombinant scFv expression in bacteria. 
While the co-expression of recombinant periplasmic chaperone proteins may have 
prevented lysis of scFv-secreting bacterial strains in vitro, the expression of these 
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chaperone proteins in vivo lessened the survivability of the bacteria. Therefore, we 
hypothesized that extracellular secretion would not only allow the accumulation of scFvs 
in the extracellular space without bacterial cell lysis, but also would increase the fitness 
of the bacteria by circumventing the periplasmic accumulation of the scFvs that may 
have been the cause of these attenuating effects. In support of this, we found that type I 
extracellular secretion of αPD-L1 scFv via the Hly system eliminated the burdening 
effects of this expression and increased the in vivo survivability of the recombinant 
bacteria. Therefore utilizing the Hly secretion system allowed for the generation of 
attenuated strains of S. Typhimurium that successfully secreted scFvs that block PD-L1 
or CTLA-4. Additionally, the same expression and secretion system has been applied in 
our lab to generate strains that secrete the biologically active stimulatory cytokines IL-2 
and an IL-15/IL-15 receptor alpha fusion protein. Ultimately, SalpαPD-L1-Hly and 
SalpαCTLA-4-Hly would be used in combination with these cytokine-secreting strains to 
deliver a combinatorial immunostimulatory therapy to the tumor microenvironment.  
The goal of this study was to investigate the ability of S. Typhimurium to express 
and secrete immunostimulatory proteins, with a specific focus on PD-L1 and CTLA-4 
immune checkpoint-blocking scFvs. At a minimum, this work serves as a proof of 
principle demonstrating the expression capabilities of attenuated S. Typhimurium. 
Ultimately, the strains generated would be assayed alone and in combination for their 
ability to deliver therapeutic concentrations of their recombinant proteins to the tumor 
microenvironment. The remaining chapters of this thesis will investigate the tumor-
targeting potential of the more well-characterized αPD-L1 scFv, with the assumption that 
reasonably similar results could be expected for the delivery of other scFvs in parallel or 
future studies. 
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Figure 2-1. Immunized chickens develop strong Ig responses against CTLA-4 
and PD-L1 antigens. 
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Figure 2-1. Immunized chickens develop strong Ig responses against CTLA-4 and 
PD-L1 antigens. IgY purified from host chickens before (open symbols) and after 
immunizations (filled symbols) was tested for antigen specificity. Antibody concentration 
was normalized and compared in triplicate by ELISA against plate-bound mouse CTLA-4 
(A) or PD-L1 (B) as the target antigen. Bound IgY was detected using anti-chicken IgY-
HRP conjugate (Aves Labs) and BD OptEIATM TMB substrate. Absorbance was 
measured at 450nm and corrected for 570nm background absorbance. Chickens 1, 2 
and 3 are represented by ,  and ¢ symbols, respectively. 
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Figure 2-2. Chicken variable regions were amplified and combined to generate 
the scFv library. 
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Figure 2-2. Chicken variable regions were amplified and combined to generate the 
scFv library. (A): VH and VL sequences (~450 and 350 bp, respectively) were amplified 
from chicken cDNA using PCR with primers flanking the variable regions. (B): After gel 
purification, VH and VL sequences were combined with splice-overlap extension PCR to 
generate full length scFvs of about 800-900 bp. Multiple PCR reactions were combined 
to generate >1 µg of purified DNA after gel extraction. 
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Figure 2-3. Schematic representation of the pComb3x phagemid vector 
including the scFv library. 
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Figure 2-3. Schematic representation of the pComb3x phagemid vector including 
the scFv library. The scFv library is expressed as a P3 fusion protein in amber 
suppressor strains of E.coli for phage display and panning. In non-suppressor strains of 
E. coli, the amber stop codon is recognized and soluble scFv protein is expressed 
without the p3 protein. The ompA signal sequence is cleaved in the periplasm, leaving 
mature scFv that consists of the variable regions and the C-terminal HA and His tags.  
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Figure 2-4. Antigen-specific scFvs were enriched from the immunized library 
and demonstrated antigen-binding capability. 
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Figure 2-4.  Antigen-specific scFvs were enriched from the immunized library and 
demonstrated antigen-binding capability. (A): Output phage titers were measured 
with each round of panning. Output phage were enumerated by infecting excess 
ER2738 E. coli cells with an aliquot of phage eluted after selection and plating for colony 
formation on 2xYT agar containing carbenicillin. Each colony formed corresponded to a 
single plaque-forming unit (PFU) of phage. (B): ELISA of selected scFvs from panning 
output round 4. Soluble protein was prepared from the periplasm of E. coli TG1 cells 
containing scFv sequences from round 4 of panning. Protein was tested for binding to 
recombinant plate-bound PD-L1 or CTLA-4. Absorbance was measured at 450nm and 
corrected for absorbance at 570nm. Each dot represents an individual scFv from the 
enriched library. The five top binding scFvs were selected for sequencing and further 
characterization. Negative controls containing no periplasmic protein are indicated by the 
X symbols. 
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Figure 2-5. Soluble αPD-L1 scFv is detected in the periplasm and culture 
supernatant of E. coli and is readily purified. 
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Figure 2-5. Soluble αPD-L1 scFv is detected in the periplasm and culture 
supernatant of E. coli and is readily purified. E. coli T10F’ cells were transformed 
with phagemid harboring the αPD-L1 scFv sequence (for schematic, see Figure 2-3). 
(A): Western blot of soluble αPD-L1 scFv in culture supernatant (lane 1) and periplasm 
(lane 2) of bacterial cultures using an anti-HA tag-HRP conjugate. (B): Total periplasmic 
protein was isolated (lane 1), and αPD-L1 scFv was purified using IMAC beads (lane 2). 
Proteins were visualized using Coomassie Brilliant Blue dye.  
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Table 2-1: Antibody affinity measurements. SPR measurements were 
performed at LakePharma (Belmont, CA). 
Antibodya  Kd (M) Kon (1/Ms) Koff (1/s) 
10F.9G2 (Biolegend) 1.67 × 10-11 7.22 × 105 1.21 × 10-5 
1-111a (eBioscience) 5.66 × 10-11 1.31 × 106 7.43 × 10-5 
MIH5 (eBioscience) 2.05 × 10-10 1.04 × 106 2.13 × 10-4 
αPD-L1 scFv 7.11 × 10-10 4.91 × 105 3.94 × 10-4 
a Vendor sources for monoclonal antibodies are shown in parentheses. 
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Figure 2-6. ScFvs demonstrate antagonistic biological activity. 
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Figure 2-6. ScFvs demonstrate antagonistic biological activity. (A) Anti-CTLA-4 
scFv blocks CTLA-4 binding to B7.1. B7.1-Fc fusion protein was incubated with plate-
bound CTLA-4 in the presence of anti-CTLA-4 scFv (), a positive control anti-CTLA-4 
blocking mAb (¢) or a non-specific anti-PD-L1 scFv (). B7.1-Fc fusion protein binding 
was detected using anti-Fc HRP antibody. Absorbance was measured at 450nm and 
corrected for absorbance at 570nm. (B) Tosylactivated beads were coated with a 
stimulatory anti-CD3 mAb and either PD-L1-Fc fusion protein (anti-CD3/PD-L1-Fc 
fusion; PD-L1+), or Fc control (anti-CD3/Fc; PD-L1-). To test the blocking activity of the 
scFv, PD-L1+ beads were blocked with 10µg (¢), 1µg (¢) or 0.1µg (¢) of purified αPD-
L1 scFv and incubated with T-cells from Balb/c mice for 4 days. To measure T-cell 
activation, IL-2 secretion after incubation was quantified using ELISA. Beads were 
blocked with human Fc protein or 10F.9G2 mAb as negative and positive controls, 
respectively. Experiments were performed in triplicate; results were normalized to the IL-
2 secretion with the PD-L1- beads in each experiment and combined for the data shown. 
Error bars indicate +/- standard deviation. 
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Figure 2-7. Plasmid vector maps along with their size and recombinant protein 
sequences. 
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Figure 2-7. Plasmid vector maps along with their size and recombinant protein 
sequences. Sizes of each vector are shown below the vector name in nucleotide base 
pairs (bp). The asd gene, Trc promoter, and p15A origin of replication are found in each 
plasmid. Blue “scFv sequence” gene denotes the sequence for either αCLTA-4 or αPD-
L1 scFv, depending on the plasmid. Accessory chaperone or secretion protein genetic 
sequences are indicated in green. 
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Figure 2-8. Secretion of scFvs into the periplasm. 
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Figure 2-8. Secretion of scFvs into the periplasm. (A) αPD-L1 scFv but not αCTLA-4 
scFv is found at high quantities in the periplasmic space and culture supernatant of 
overnight bacterial cultures. Purified αPDL1 scFv was used for size comparison. (B) 
Coexpression of periplasmic chaperone proteins (CH) maintains periplasmic expression 
but prevents the accumulation of αPDL1 scFv in the culture supernatant. A SalpNG 
culture was used as a negative control for expression, and purified αPDL1 scFv was 
used for size comparison. In both (A) and (B), polyacrylamide gels were stained with 
Coomassie for protein visualization. Lighter exposure of panel B shows a clearer picture 
for lanes one and two, with no notable scFv bands. Additionally, western blots against 
polyhistadine tags verify no scFv in the medium in these lanes (not shown). 
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Figure 2-9. The location of αPD-L1 scFv affects the in vivo survivability of 
attenuated Salmonella. 
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Figure 2-9. The location of αPD-L1 scFv affects the in vivo survivability of 
attenuated Salmonella. Mice bearing subcutaneous 4T1 tumors were injected 
intravenously with 5×104 CFU of either SalpNG or SalpαPD-L1 in (A) or SalpNG and 
SalpαPDL1-Hly in (B). Tumors were harvested after 3-4 weeks, homogenized, plated 
and incubated overnight for colony formation and enumeration. Periplasmic scFv 
expression of SalpαPD-L1 reduced intratumoral colonization of the bacterium compared 
to the SalpNG control (A). Extracellular scFv-secreting SalpαPDL1-Hly colonized tumors 
at least as well as the SalpNG control (B). Bars indicate the average of 4 mice, and error 
bars = 1 standard deviation. 
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Figure 2-10. Recombinant periplasmic chaperone expression reduces 
Salmonella strain survival in vivo while not affecting in vitro growth rate. 
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Figure 2-10. Recombinant periplasmic chaperone expression reduces Salmonella 
strain survival in vivo while not affecting in vitro growth rate. (A) Mice were injected 
with 5×104 CFU of either SalpNG, SalpCHαPD-L1, or SalpCHAP. Animals were 
sacrificed 3 weeks later and their tissues were homogenized, plated, and incubated 
overnight for CFU enumeration. Experiments were performed twice on 3 mice each (6 
mice total). Bars show the average result of all mice. Error bars indicate 1 standard 
deviation. (B) SalpNG and SalpCHAP were grown at 37°C in LB and plated every 30 
minutes to enumerate CFU/ml over time.  
Experiments in this figure were performed by Michael Mertensotto. 
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Table 2-2: Extracellular secretion systems tested. Multiple systems reported to 
successfully secrete proteins from Salmonella were tested for scFv secretion. Their 
descriptions, references, and findings are summarized. 
 
 
Tag 
ID 
 
 
 
Secretion system 
 
 
 
Reference 
 
 
 
Tag description 
 
Accessory 
proteins 
required? 
Successful 
secretion of 
scFvs from 
Salmonella? 
Yops Yersinia outer proteins 
(Yops) type III secretion 
signal. 
(152, 153) 8 amino acid N-
terminal secretion 
signal: MISSSSIS 
no may improve 
intracellular 
expression, but no 
secretion detected. 
Flag Segment of the flagellin 
protein sequence 
(amino acids 26-47) 
directs secretion of 
protein through bacterial 
flagella. 
(154) 22 amino acid N-
terminal secretion 
signal. 
no, bacterium 
needs active 
flagella 
no protein secretion 
detected. 
YebF sec-dependent 
extracellular secretion 
used to produce 
proteins toxic to host 
bacteria 
(155) 21 amino acid N-
terminal tag. Cleaved 
in the periplasm 
before extracellular 
secretion 
no no protein secretion 
detected. 
Hly Type I secretion signal 
used for native 
hemolysin secretion. 
(156, 157) 60 amino acid C-
terminal HlyA-ss tag. 
HlyB and HlyD yes (see figure 2-11) 
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Figure 2-11. The Hly secretion system mediates successful extracellular 
secretion of both αPD-L1 and αCTLA-4 scFvs. 
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Figure 2-11. The Hly secretion system mediates successful extracellular secretion 
of both αPD-L1 and αCTLA-4 scFvs. (A) SalpαCTLA-4-Hly and SalpαPD-L1-Hly were 
grown in culture overnight. The supernatant (medium), cytoplasm and insoluble fraction 
of cell cultures were isolated and examined by Western blot for the presence of scFv 
using anti-His-tag and and IR800 secondary antibodies. Both scFvs were found 
exclusively in the culture supernatant. DnaK was detected by antibody binding as a 
cytoplasmic control to verify secretion rather than cytoplasmic leakage or cell death. (B) 
The SL3261-based attenuated strains DSpαCTLA-4-Hly and DSpαPD-L1-Hly were 
tested for extracellular secretion as in (A). DnaK is sometimes detected as a doublet 
protein band and did so in these blots, which does not affect the interpretation of results.  
(C) The αPD-L1-scFv tagged with the HlyA-ss was tested in an ELISA to determine 
whether the HlyA-ss prevented antigen-binding. Plates were coated with PD-L1-Fc 
protein, and varying concentrations of purified αPD-L1-Hly scFv were tested for binding. 
Bound scFv was detected using an anti-HisTag-HRP conjugate.  
Protein preparation and Western blotting for the gels in panel (B) were performed by 
Michael Mertensotto. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
74 
CHAPTER 3 
 
ATTENUATED S. TYPHIMURIUM DEMONSTRATES ANTI-TUMOR EFFICACY 
INDEPENDENT OF TUMOR COLONIZATION 
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INTRODUCTION 
 
The characteristics of tumors that affect their susceptibility to S. enterica 
Typhimurium (S. Typhimurium) colonization (outlined in Chapter 1, page 16) are general 
features that would theoretically be relevant to many types of cancer and are not 
dependent on tissue locations or the expression of specific tumor antigens. Therefore, 
successful development of salmonellae-based cancer therapy would likely have 
widespread application in several types of solid cancers. We investigated this potential 
by assessing the anti-tumor efficacy and tumor-targeting propensity of attenuated S. 
Typhimurium in a variety of murine tumor models including osteosarcoma pulmonary 
metastases, subcutaneous and metastatic breast cancer, and transgenic autochthonous 
breast cancer. 
Osteosarcoma is a disease with a peak incidence in early adolescence. Current 
therapies have increased the 3-year survival of patients with local disease to greater 
than 70%. However, in patients with metastatic disease, often presenting as pulmonary 
metastases, disease-free survival is limited to less than 30% (158). In mice, metastatic 
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osteosarcoma can be modeled using K7M2 cells. The K7M2 cell line was derived from a 
metastasis on the lung of a mouse with metastatic osteosarcoma, and when injected into 
the bone of BALB/c mice, this cell line will give rise to tumors that will metastasize to the 
lungs. Alternatively, the cell line can be injected directly into the bloodstream of mice, 
wherein it travels to the lungs and forms tumors that model pulmonary metastases (159).  
Breast cancer is the most common cancer among women, including over 
200,000 new diagnoses every year (U.S. Cancer Statistics Working Group, 2011). The 
most common diagnosis is ductal carcinoma, a cancer of the ductal cells of the 
mammary glands. Invasive ductal carcinoma can spread to other parts of the breast and 
into other parts of the body. There are several mouse models of invasive breast cancer; 
however, the focus of this thesis will be on the metastatic 4T1 tumor model and the 
transgenic BALB-neuT model. The 4T1 cell line is a highly metastatic cell line derived 
from a mouse mammary tumor (160) and is is often used to study breast cancer 
metastases due to its highly metastatic potential. A subcutaneous inoculation of 4T1 
cells into BALB/c mice will develop a primary tumor that metastasizes into the lungs in 
>95% mice (160). The BALB-neuT model is a genetically engineered mouse (GEM) 
model of invasive breast cancer on the BALB/c background that expresses a 
constitutively active rat Her2 receptor (neu) driven by the mouse mammary tumor virus 
promoter. As opposed to transplant models such as such the 4T1 model, BALB-neuT 
mice positive for the transgene develop cancer over several months, which appears on 
the mammary pads of female mice as palpable tumors around 16 weeks of age. The 
tumors closely resemble the aggressive Her2-driven cancer found in human patients 
(161). 
In this chapter, the tumor-targeting propensity, immune effects, and anti-tumor 
efficacy of attenuated S. Typhimurium were investigated in multiple models including 
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subcutaneous and metastatic transplanted tumors as well as transgenic autochthonous 
tumors.  
 
METHODS 
 
 
S. Typhimurium strains and preparation for injection 
 
S. Typhimurium strain χ4550 (Δcya, Δcrp, Δasd) was used as the host strain for 
these experiments (105). Plasmid pNG was used as the cloning vehicle, and bacteria 
carrying pNG are referred to as SalpNG. SalpαPDL1-Hly are S. Typhimurium carrying 
the pNG plasmid with the αPDL1-Hly scFv gene. SalpαCTLA4-Hly are S. Typhimurium 
carrying the pNG plasmid with the αCTLA4-Hly scFv gene. See Figure 2-7 for the 
relevant plasmid maps.  
Overnight cultures of SalpNG or indicated strain were grown in LB (10 g tryptone, 
10 g NaCl, 5 g yeast extract per 1 L dH2O). Cells were chilled in ice water, pelleted and 
resuspended in ice cold 15% glycerol in LB. Aliquots were then flash frozen in liquid 
nitrogen and stored -80°C. One vial from each batch was thawed and plated to 
determine live colony-forming units (CFU)/mL of bacterial stock after thawing. Before 
treatment, frozen bacteria were thawed at 37°C and diluted in phosphate-buffered saline 
(PBS) to the indicated concentrations and injected in a 100µl injection volume. 
 
Animal care 
 BALB-neuT and BALB/c mice were maintained in specific pathogen free 
conditions and fed standard mouse chow (Harlan). Animals were cared for by the 
University of Minnesota’s Research Animal Resources, and all animal use was approved 
by the University’s Institutional Animal Care and Use Facility.  
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K7M2 tumor studies 
For metastatic osteosarcoma experiments, K7M2 osteogenic carcoma cells 
(ATTC: CRL-2836) were grown in RPMI-1640 medium containing 10% fetal bovine 
serum. Cells were detached from flasks using 0.05% trypsin-EDTA, counted with a 
hemocytometer, washed with sterile PBS, and diluted to the appropriate concentration 
prior to injection. Female Balb/c mice were injected via the tail vein with 5x105 K7M2 
osteogenic sarcoma cells. SalpNG was administered intravenously 7 to 14 days post 
tumor inoculation as indicated. Mice were either sacrificed 14-21 days post treatment for 
tumor burden studies or when they were moribund for survival studies. To estimate 
tumor burden in the lungs of mice, lungs were excised, rinsed with PBS and dried with 
sterile guaze. The average lung weight of tumor-free (0.18 g, based on 10 mice) was 
subtracted from the lung weight of tumor-burdened mice (sex and age-matched) to 
calculate “net tumor burden.”  
 
4T1 tumor studies  
4T1 cells (ATCC #CRL-2539) were grown in RPMI-1640 medium containing 10% 
fetal bovine serum. Cells were detached from flasks using 0.05% trypsin-EDTA, counted 
with a hemocytometer, washed with sterile PBS, and diluted to the appropriate 
concentration prior to injection. Female BALB/c mice of approximately 12 weeks of age 
were given a subcutaneous injection of 1×105 4T1 cells in 50 µL of sterile PBS 
superficial to the right inguinal mammary fat pad. Tumor growth was measured over time 
by caliper. Mice were treated with SalpNG or SalpαPD-L1-Hly by IV injection 11 days 
post tumor inoculation. In the indicated experimental groups, mice were injected with 
125µg of αPD-L1 mAb (10F.9G2, BioXCell) twice weekly for the duration of the 
experiment and/or 125µg of αCD137 (3H3, BioXCell) twice weekly for two weeks. At the 
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conclusion of the experiments, tumors were weighed, homogenized, diluted, and plated; 
plates were incubated overnight to determine CFU/gram of tissue. In some cases, lungs 
were removed and weighed to determine net pulmonary metastatic burden as in the 
K7M2-treated mice. 
 
BALB-neuT tumor studies 
 Genotyping for the neu transgene was performed by Transnetyx on male and 
female pups in the BALB-neuT mouse colony. Breeding pairs consisted of heterozygous 
males and homozygous negative females. Female mice that were positive for the neu 
transgene were monitored for tumor development. Upon initial tumor palpation (~16 
weeks), mice were injected IV with 6 × 104 CFU of the indicated S. Typhimurium strain. 
Tumors were measured weekly with a digital caliper, and individual tumor volumes were 
calculated as spheroid (L x W2 x 0.52). Individual tumor volumes were added to give 
total tumor burden for each mouse. For survival studies, mice were monitored for 
survival and euthanized if they became moribund or if a single tumor reached 2 cm3 in 
volume. 
 
Bacterial tissue colonization experiments 
 For bacterial tissue colonization experiments, tumor-bearing mice were sacrificed 
17-21 days post-treatment. Spleens and tumors were harvested from mice and minced 
to ~1 mm3 pieces. Resulting samples were homogenized in 5 ml of sterile PBS in 
gentleMACS M Tubes with Strainers (Miltenyi Biotec) using a gentleMACS Tissue 
Dissociator and running program RNA_01. The homogenate was serially diluted in 
sterile PBS and plated on LB agar containing 100 µg/ml nalidixic acid for selection. 
Plates were incubated overnight at 37°C, and CFU were enumerated the next day. 
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Tissue preparation for flow cytometry 
 Tumors, spleens or tumor-bearing lungs were homogenized using a Mouse 
Tumor Dissociation Kit (Miltenyi Biotec) according to manufacturer’s instructions. Cell 
suspensions were stained or cells were fixed and permeabilized for intracellular staining 
of Foxp3 and IFNγ after extracellular staining using the Foxp3 Transcription Factor 
Staining Buffer Set (eBioscience). Cells were gated and identified as follows: CD8 T-
cells (CD8+), CD4 T-cells (CD4+), Th1 cells (CD4+, IFNγ+), T-regs (CD4+, CD25+, 
Foxp3+) NK cells (CD8-, CD4-, CD49b+), monocytic MDSCs (CD45+, CD11b+, Ly6CHi), 
granulocytic MDSCs (CD45+, CD11b+, Ly6GHi). Cells/sample were enumerated using 
CountBright absolute counting beads (Life Technologies). Cells/gram measurements 
were calculated based on the percent of sample analyzed, tumor weight, and 
homogenate volume. Antibody conjugates were purchased from BioLegend: αCD8/FITC 
(100705), αCD4/PerCP-Cy5.5 (100539), αCD49b/PE/Cy7 (108921), αCD45.2/BV510 
(109837), αCD25/BV650 (102038), αCD11b/BV650 (101239), αPDL1/PE-Cy7 and 
isotype control (400617, 124313); BD Pharmingen: αLy6C/PerCP/Cy5.5 (560525) and 
αLy6G/AF700 (561236), and αFoxp3/AF700 (ebioscience: 56-5773-80). 
 In order to differentiate tumor leukocytes from blood leukocytes in K7M2 mice, 
we performed intravascular staining, adopted from Anderson et al (162), using an 
αCD45.2/PE antibody (Biolegend: 109808). Briefly, mice were injected IV with 4µg of 
CD45.2/PE antibody in 200µl of PBS and euthanized 4 minutes later using IV 
Beuthanasia D. The only cells that stained positively with PE were those in the blood 
stream; these cells were gated out from the analysis. Blood and inguinal lymph nodes 
were collected from mice for positive and negative in vivo staining controls, respectively.  
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 All flow cytometry was performed on an LSR II flow cytometer (BD Biosciences) 
with FACS Diva acquisition software. Subsequent analysis was performed using FlowJo 
(version X). 
 
RESULTS 
S. Typhimurium exhibits anti-tumor efficacy in transplanted metastatic and 
subcutaneous tumor models 
  Before determining the therapeutic efficacy of the recombinant scFv-secreting 
strains (SalpαPDL1-Hly and SalpαCTLA4-Hly), we investigated the anti-tumor efficacy of 
SalpNG. As described in the introduction (page 17), S. Typhimurium has demonstrated 
native tumoricidal effects in multiple murine tumor models. However, these effects have 
not been characterized for the SalpNG bacterium. Additionally, the models that describe 
the anti-tumor effects of S. Typhimurium  treatment used subcutaneous transplant 
models in which a tumor develops from a suspension of cells or a tumor piece that has 
been transplanted into the subcutaneous space. Therefore, we investigated the anti-
tumor capabilities of S. Typhimurium treatment in a more diverse set of mouse models 
including both transplanted primary and metastatic tumors as well as autochthonous 
tumors. 
 
SalpNG reduces tumor burden and increases survival in K7M2 osteogenic sarcoma. 
 To model osteosarcoma pulmonary metastases, BALB/c mice were injected IV 
with the metastatic osteogenic sarcoma cell line K7M2, which caused the development 
of numerous metastasis-like tumors in the lungs of inoculated mice. The total tumor 
weight in the lungs was determined by subtracting the average weight of tumor-free 
lungs from age and sex-matched mice from the weight of lungs from tumor-bearing 
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mice. When left untreated, by 28 days post-tumor cell inoculation, mice contained an 
average of 0.4 g of tumor in their lungs (Figure 3-1A). A single intravenous (IV) treatment 
of 5 × 104 CFU of SalpNG 7 days post-tumor cell inoculation reduced the tumor burden 
by approximately 80% (Figure 3-1A). Similar results were obtained when mice were 
treated 14 days post-tumor cell inoculation (Figure 3-1B). This reduction corresponded 
to an approximate 120% increase in average survival time from 29 days to 64 days post 
treatment (Figure 3-1C).  
 
SalpNG reduces the percentage of infiltrating T-regs and increases CD4 T-cell IFNγ 
expression in K7M2 osteosarcoma. 
 To investigate the immune-modulating effects of SalpNG treatment on tumor-
infiltrating lymphocytes, an intravascular staining method developed by Anderson and 
colleagues (162) was adapted for the K7M2 model. In order to differentiate between the 
blood lymphocytes in the lung vasculature and lung tissue/tumor-infiltrating lymphocytes, 
an αCD45.2/PE antibody was injected IV into tumor-bearing mice. The antibody 
specifically stained all leukocytes in the blood of the mice for four minutes before they 
were rapidly euthanized and their lungs homogenized and diluted to prevent antibody 
percolation into lung tissue. In subsequent flow cytometry analysis of infiltrating cells, 
those positive for PE staining were gated out of the analysis as blood cells (Figure 3-2A). 
Lymphocytes from blood and lymph nodes were harvested from each mouse and 
stained ex vivo with αCD45.2/BV650. These served as positive and negative technical 
controls for blood-specific PE staining (Figure 3-2B and C).  
 The CD4+ T-cell compartment of untreated K7M2 tumor-infiltrating lymphocytes 
was highly enriched for Foxp3+, CD25+ T-regs, which comprised an average of 
approximately 60% of CD4+ cells. However, treatment with SalpNG reduced this 
  
82 
percentage to about 25% (Figure 3-2D-F). Additionally, SalpNG treatment increased 
CD4+ IFNγ expression, indicating an increase in Th1 cells in K7M2 tumors (Figure 3-2G-
I). There was no significant change in CD8+ T-cell IFNγ expression (not shown). These 
changes suggest an immunostimulatory effect of SalpNG treatment. 
 
SalpNG reduces metastatic tumor burden in 4T1 breast cancer. 
 To determine if the antitumor effects of SalpNG observed in K7M2-treated mice 
would also affect tumors generated from the invasive metastatic 4T1 breast cancer cell 
line, mice bearing 4T1 tumors were treated IV with 5x10^4 CFU of SalpNG. The 
resulting primary tumors were reduced approximately 30% compared to saline-treated 
controls (Figure 3-3A). To determine an effect on metastases, lungs were also harvested 
and weighed as with K7M2 mice to estimate metastatic tumor burden in the lungs. The 
difference in lung metastases between SalpNG-treated and PBS-treated groups was 
more dramatic than what was observed for the primary tumor, with an approximate 88% 
reduction in response to SalpNG treatment (Figure 3-3B). 
 
αPDL1 scFv secretion does not improve anti-tumor efficacy of S. Typhimurium in 4T1 
tumors. 
 In order to investigate the functionality of bacterially delivered αPDL1 scFv, a 
model with adequate tumor colonization that would respond to PD-L1 blockade was 
required. Hirano and colleagues recently reported a complete clearance of 4T1 tumors in 
BALB/c mice given a combination of an immune-stimulating agonistic αCD137 mAb and 
an inhibitory αPD-L1 mAb (163). Given our experience with the 4T1 model and the 
tumor-colonization observed in 4T1 tumors (Figures 2-9B and 3-8B), we sought to 
replicate the efficacy observed by Hirano and colleagues and validate a bacterially 
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delivered checkpoint blockade by treating 4T1 tumor-bearing mice with a combination of 
αCD137 and SalpαPDL1-Hly. In this experiment, a combination of αCD137 mAb and 
αPD-L1 mAb was used as a positive control for efficacy as reported (7). Additionally, 
SalpNG was tested as a control for comparison to SalpαPD-L1-Hly alone. Mice were 
treated with the indicated strains when tumors reached approximately 100 mm3 by 
caliper. Indicated mice were given intraperitoneal αCD137 mAb twice weekly for two 
weeks and/or αPD-L1 mAb twice weekly for the duration of the experiment. While a 
modest effect on the primary tumor was observed for both SalpNG and SalpαPDL1-Hly, 
there was no significant difference in efficacy between these strains (Figure 3-4A). 
Additionally no improvement over SalpNG was observed in mice given both SalpαPDL1-
Hly + αCD137 mAb treatment or the combination of αCD137 and αPD-L1 mAbs (Figure 
3-4A). Mice given a combination of SalpNG and αPD-L1 mAb were excluded from the 
analysis due to lethal toxicity that occurred when these treatments were combined. 
Additionally, a similar efficacious effect of SalpNG treatment was observed on lung 
metastases as seen in previous experiments; however, there was no difference between 
SalpNG and SalpαPDL1-Hly (Figure 3-4B). Tumors from mice treated with either 
SalpNG or SalpαPDL1-Hly were homogenized, diluted, and plated as before to verify 
4T1 tumor colonization. SalpNG and SalpαPDL1-Hly colonized tumors with an average 
of approximately 4×107 and 6×107 CFU/g of tumor, respectively, at 22 days post 
bacterial treatment. 
 
S. Typhimurium  exhibits anti-tumor efficacy in a transgenic, autochthonous 
breast cancer model 
SalpNG reduces tumor burden and increases survival of BALB-neuT mice. 
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 There are many differences in tumors generated in transplant models and those 
that model autochthonous (i.e. developed from a single cell in its place of origin) tumor 
development (see introduction pages 21-23). Virtually all preclinical reports of S. 
Typhimurium-based cancer therapy in mice have been performed in transplanted tumor 
models. Therefore in order to investigate the anti-tumor properties of SalpNG in an 
autochthonous tumor model, a GEM model of mammary carcinoma was used. 
Mammary fat pad tumors in female BALB-neuT mice became palpable (~50-60 mm3) 
around 16 weeks of age. At this time (day 0), the mice typically had 1-3 palpable tumors. 
These tumors enlarged over time, and new tumors appeared on the remaining fat pads, 
usually until each mammary pad developed a tumor. Individual tumors were measured 
weekly by caliper, and their volume was calculated and combined to give a total tumor 
burden measurement for each mouse. When left untreated, average total tumor burden 
per mouse reached 5.66 cm3 by day 35 (Figure 3-5A). In contrast, if the mice were given 
a single IV injection of 6x10^4 CFU of SalpNG at day 0, tumor progression was 
significantly delayed, and average total tumor burden at day 35 was only 0.85 cm3, 
corresponding to an 85% tumor reduction (Figure 3-5A). This correlated to a significant 
increase in survival time of SalpNG-treated mice (median = 66 days) when compared to 
untreated mice (median = 35 days) (Figure 3-5B). In order to test if multiple injections of 
SalpNG improved efficacy, the experiments were repeated with mice treated on day 0 
and every 21 days following. No difference in tumor burden or survival was observed 
between single and multiple treatments (data not shown). 
 
Efficacy of S. Typhimurium is correlated with increased infiltration of cytotoxic 
lymphocytes. 
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An important role of NK cells and CD8 T-cells in the anticancer efficacy of χ4550-
based strains has been demonstrated using transplant models (123). In order to 
examine the role of these immune cells in BALB-neuT breast cancer, tumors from mice 
were homogenized 21 days post-treatment, and tumor-infiltrating lymphocytes were 
isolated and characterized using flow cytometry. Tumors from treated mice contained 
greater than 10-fold more infiltrating CD8 T-cells than tumors from untreated mice. 
Similarly, infiltrating NK cell numbers were approximately 6-fold greater in treated mice, 
indicating an immune response in reaction to SalpNG treatment (Figure 3-6A). CD4 T-
cells were also examined, but the difference between the treated and untreated groups 
was insignificant (data not shown). 
 
Treatment with S. Typhimurium increases monocytic myeloid-derived suppressor cells 
both systemically and within tumors. 
In spite of a reduction in tumor burden and an increase in survival time of BALB-
neuT mice, eventually all treated mice succumbed to disease. We examined changes in 
myeloid-derived suppressor cell (MDSC) numbers as a potential contributor to tumor 
progression. MDSCs are a suppressive subset of immature myeloid cells that express 
CD11b and the Gr-1 epitope and are present in several cancer models including BALB-
neuT breast cancer (161). MDSCs are conventionally subdivided into monocytic (Ly6CHi) 
and granulocytic (Ly6GHi) subsets, and while both subsets have been implicated in 
tumor immunosuppression and cancer progression, monocytic MDSCs have been 
shown to be more consistently immunosuppressive on a per-cell basis than granulocytic 
MDSCs (for more detail on MDSCs, see introduction pages 8, 9). We investigated 
whether SalpNG treatment affected MDSC presence in tumor tissue. When examined 21 
days post-treatment, tumors from treated mice displayed a greater than 10-fold increase 
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in monocytic MDSCs, while granulocytic MDSCs were not significantly affected (Figure 
3-6B-C). In addition, the ratio of monocytic to granulocytic MDSCs in the spleen was 
increased in response to treatment, suggesting that the increase in tumor-infiltrating 
monocytic MDSCs was due to a systemic immunological effect of the bacteria rather 
than a tumor-specific effect (Figure 3-6D). 
 
ScFv-secreting strains did not improve anti-tumor efficacy in BALB-neuT mice over 
SalpNG. 
To determine if the recombinant strains that secrete immune checkpoint inhibiting 
scFvs characterized in Chapter 2 would demonstrate greater anti-tumor efficacy than 
SalpNG, tumor-bearing BALB-neuT mice were treated as before but instead with a 
combination of SalpαPDL1-Hly and SalpαCTLA-4-Hly. These strains were used in 
combination due to the reported advantages of combinatorial immune checkpoint 
blockade (see introduction page 86). No significant improvement in efficacy over SalpNG 
was observed with the recombinant scFv strains (Figure 3-7A). This was despite tumor 
specific expression of PD-1 on infiltrating CD8 T-cells and PD-L1 expression in the 
tumor (Figure 3-7B-C).  
 
Tumor-targeting of attenuated S. Typhimurium is inconsistent between tumor 
models  
 The lack of an efficacious improvement against BALB-neuT tumors using the 
scFv-secreting strains may be due to a lack of sufficient tumor-targeting. The propensity 
of S. Typhimurium to preferentially accumulate in tumor tissue over healthy tissues has 
been reported extensively (94). However, these observations have been from 
experiments performed in subcutaneous and orthotopic transplant mouse models. 
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Therefore we investigated the tumor-targeting propensity of SalpNG in autochthonous 
tumors in the BALB-neuT model. Twenty-one days following treatment with SalpNG, 
tumors and spleens were removed, homogenized and plated onto selective nutrient agar 
for colony formation. No CFU were found in any of the tumors processed. In contrast, 
CFU were found in each spleen tested, with an average of 1.5 × 104 CFU/gram tissue 
(Figure 3-8A).  
The lack of tumor-targeting in the BALB-neuT model may explain the insignificant 
difference in efficacy between SalpNG and the scFv-secreting strains. Tumors from the 
K7M2 and 4T1 models were similarly examined for bacterial tumor-targeting. Unlike 
BALB-neuT tumors, 4T1 tumors contained approximately 1×107 CFU/g of tumor tissue at 
17 days post treatment, compared to approximately 1×105 CFU/g of spleen (Figure 3-
8B). CFU numbers in K7M2 tumors were difficult to quantify due to treated mice having 
such small tumor masses in their lungs, but by homogenizing and plating whole lungs 
and estimating tumor mass from total lung mass, CFU/g of tumor values were 
approximated. While bacteria were usually present to some degree in K7M2 tumors, the 
numbers were highly variable and were several orders of magnitude less than values 
commonly reported for tumor colonization (Figure 3-8C). Therefore despite the efficacy 
observed in all of the models tested, only the subcutaneously inoculated 4T1 tumors 
contained substantial bacterial colonization.  
 
DISCUSSION 
 
S. Typhimurium exhibits anti-tumor efficacy and immune effects in transplanted and 
autochthonous tumor models. 
 The native cytotoxicity of Gram-negative bacteria has led to its application as a 
single agent for the preclinical treatment of many tumor types (reviewed in (94)). We 
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observed a reduction in tumor burden in response to IV treatment with an attenuated S. 
Typhimurium strain carrying an empty expression vector (SalpNG) in mouse models of 
K7M2 osteosarcoma, 4T1 primary and metastatic breast cancer, and BALB-neuT 
autochthonous breast cancer.  
 The efficacious effects of S. Typhimurium have been attributed to immune 
stimulation, competition for nutrients and/or the direct induction of apoptosis of tumor 
cells by bacterial toxins (90, 99). Where examined, the efficacy we observed was 
correlated with an increased tumor infiltration of immune cells and a reduction in 
suppressive populations such as T-regs. Therefore, we believe the anti-tumor efficacy 
was mainly the cause of a general immune-stimulation in response to the bacteria that in 
turn stimulated an anti-tumor immune response. Although it is not clear whether the 
changes in tumor-infiltrating lymphocytes observed in K7M2 and BALB-neuT tumors of 
treated mice were tumor-specific or Salmonella specific, we suspect they are tumor 
specific because these changes were observed in tumors that were not colonized by S. 
Typhimurium. 
Along with cytotoxic lymphocytes, we observed an increased number of 
monocytic MDSCs in the tumor tissue of SalpNG-treated BALB-neuT mice. This change 
was likely due to systemic immune-modulatory effects of the bacteria rather than a 
tumor-specific response, as we also observed an enrichment of monocytic MDSCs in the 
spleen. The lipopolysaccharide surface molecules on S. Typhimurium have been shown 
to increase the presence and suppressive activity of MDSCs (164, 165), and a recent 
report demonstrated the recruitment of monocytic MDSCs from the bone marrow to 
tissues during S. Typhimurium infection (166). The potential efficacy of S. Typhimurim-
based cancer immunotherapy may not be fully realized until MDSC recruitment and/or 
inhibitory activity is addressed.  
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S. Typhimurium efficacy was not improved by recombinant αPDL1-scFv secretion. 
We observed greater than 1×107 CFU/g of 4T1 tumor tissue 22 days post- 
treatment. According to Hirano and colleagues (7), if Salmonella-delivered αPD-L1 
scFvs were properly blocking PD-1/L1 signaling, the tumors in mice treated with 
SalpαPDL1-Hly + αCD137 mAb would have been cleared; yet we observed no 
difference in anti-tumor efficacy between SalpNG and SalpαPDL1-Hly + αCD137 mAb. It 
could be that SalpαPDL1-Hly did not colonize 4T1 tumors at levels high enough to 
deliver a therapeutic concentration of αPDL1-scFv. However, we were also unable to 
reproduce the tumor clearance that was reported by treating mice with αCD137 and 
αPD-L1 mAbs (163). Therefore, the 4T1 model may not be a suitable model to test for 
functional PD-L1 blockade.  
Additionally, in K7M2 and BALB-neuT models we observed no difference in 
efficacy between SalpNG and either SalpαPDL1-Hly or the combination of SalpαPDL1-
Hly and SalpαCTLA-4. However, since there was a lack of adequate tumor colonization 
in these models, and thus no delivery of the scFvs to tumor tissue, improved efficacy 
over SalpNG would not be expected.  
 
S. Typhimurium tumor-targeting is inconsistent between tumor models. 
Interestingly, there were little to no bacteria colonizing the tumor tissue of two of 
the three models tested. Therefore, we conclude that the observed efficacy and immune 
cell recruitment were due to a systemic immune stimulation rather than a tumor 
microenvironment-specific stimulation. This may have also been true of the efficacy 
observed in the 4T1 model, as there was a less dramatic anti-tumor effect on the 
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colonized primary tumor than there was on the systemic metastases measured in the 
lungs. 
 The lack of tumor colonization in the K7M2 model could be explained by 
technical limitations and/or the metastatic tumors being insufficiently developed in the 
lungs of inoculated mice by the time bacteria were administered. However, the lack of 
tumor colonization in the BALB-neuT model was unexpected given the empirical 
evidence of attenuated S. Typhimurium strains accumulating to high levels in tumors in 
subcutaneous or orthotopic models. This observation may be attributed to differences in 
tumor development and microenvironment physiology between autochthonous tumors 
and tumors developed in transplantation models (167).  
It is becoming increasingly clear that necrosis in tumors is important for bacterial 
colonization (118). Early necrosis in transplanted tumor models is often caused by the 
death of a majority of the inoculated tumor cells leading to an early inflammatory 
response and a necrotic center (116, 169). Since this necrosis is absent in early stage 
autochthonous tumors, future studies might benefit from the inclusion of radiation 
therapy or other strategies such as the addition of a vascular-disrupting agent to cause 
necrosis of tumor tissue and allow colonization to the degree that is observed in 
transplant models. Also, differences in vasculature development between autochthonous 
and transplant tumor models have lead to varying responses to treatments such as 
interleukin-12 (111). These differences may have similar implications in bacterial tumor 
colonization. The more chaotic and less mature vasculature that characterizes 
transplantation tumors may more readily hemorrhage in response to S. Typhimurium 
than the more mature vasculature of autochthonous tumors. This may allow the bacteria 
to more easily colonize transplant tumors than autochthonous tumors, as hemorrhaging 
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of tumor blood vessels may be required for infiltration of the bacteria into the tumor 
tissue (95).  
The differences in tumor-targeting between preclinical transplant and 
autochthonous models could potentially explain the lack of bacterial colonization in 
tumor biopsies of reported clinical trials (107-109) that used attenuated S. Typhimurium 
for cancer treatment and might illustrate a limitation of S. Typhimurium as a viable 
tumor-targeting cancer therapy. Therefore, it may be prudent to specifically address S. 
Typhimurium’s tumor-targeting capability before further assessment of its potential for 
delivery of cytokines or immune checkpoint blockades. Achieving consistent tumor-
targeting in an autochthonous tumor model will likely be more predictive of successful 
targeting of human tumors. Advances in bacterial tumor-targeting will be addressed in 
the next chapter of this thesis. 
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Figure 3-1: SalpNG demonstrates native anti-tumor efficacy in K7M2 pulmonary 
metastases.  
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Figure 3-1: SalpNG demonstrates native anti-tumor efficacy in K7M2 
pulmonary metastases. (A) and (B): BALB/c mice were inoculated IV with 5×105 
K7M2 osteosarcoma cells on day 0. Mice were treated with 5×104 CFU of SalpNG 
or saline control (PBS) on day 7 (A) or day 14 (B). On day 28, mice were 
harvested and “net tumor mass” was calculated for each mouse as lung weight – 
average lung weight of tumor free age/sex matched mice. Average values for 
treated mice are displayed as a percent of PBS-treated controls in each 
experiment. Bars indicate average of 4 (A) and 5 (B) mice per cohort. Error bars 
indicate 1 stdev. (C) Kaplan-meier curve comparing the survival of 8 mice per 
cohort inoculated and treated as in panel B. P-values were generated using a 
students unpaired T-test for (A) and (B) and a log-rank test for (C). 
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Figure 3-2: SalpNG treatment decreases the percentage of infiltrating T-regs 
and increases IFNγ expression of infiltrating CD4+ T-cells. 
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Figure 3-2: SalpNG treatment decreases the percentage of infiltrating T-regs 
and increases IFNγ expression of infiltrating CD4+ T-cells. (A-C) Intravascular 
staining allows the differentiation of leukocytes in lung/tumor tissue from blood 
leukocytes. An αCD45.2/PE antibody was injected into mice before harvesting and 
allowed to stain leukocytes in the blood. Cells isolated from homogenized lung tissues 
were then stained ex vivo with αCD45.2/BV650. BV650+/PE+ cells were excluded 
from analysis as blood cells and BV650+/PE- cells were further analyzed in panels (D-
I). A representative plot is shown in (A). Cells from blood (B) and lymph nodes (C) 
from each mouse were also stained as positive and negative controls, respectively, 
for CD45.2/PE staining. (D-F) Cells isolated from lungs of mice inoculated with K7M2 
cells and treated two weeks later with PBS or SalpNG were fixed and stained for 
CD25 and Foxp3 expression. T-regs were defined as (CD4+, CD25+, Foxp3+). 
Representative plots for PBS-treated and SalpNG-treated mice are shown in (D) and 
(E), respectively, and values for multiple mice are quantified in (F). (G-I) Cells 
prepped as in panels D-F were stained for intracellular IFNγ. Representative plots for 
PBS-treated and SalpNG-treated mice are shown in (G) and (H), respectively, and 
values for multiple mice are quantified in (I). N=4 mice/group. Bars indicated average 
+ 1 standard deviation. P-values were generated using a student’s unpaired T-test. 
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Figure 3-3: SalpNG treatment slightly reduces primary tumor burden and 
greatly reduces pulmonary metastases of 4T1 breast cancer. 
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Figure 3-3: SalpNG treatment slightly reduces primary tumor burden and 
greatly reduces pulmonary metastases of 4T1 breast cancer. (A) BALB/c mice 
were inoculated subcutaneously with 4T1 breast cancer cells on day 0 and treated IV 
with either PBS or 5×104 CFU SalpNG on day 11. Tumors were harvested on day 28 
and weighed. (B) Mice inoculated and treated as in (A) were sacrificed 22 days post 
treatment, and their lungs were weighed to determine net tumor mass in lungs. N=6 
mice/group in (A) and 3 mice/group in (B). Bars indicated average + 1 standard 
deviation. P-values were generated using a student’s unpaired T-test. 
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Figure 3-4: αPD-L1 scFv secretion does not improve anti-tumor efficacy of 
Salmonella in 4T1 tumors. 
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Figure 3-4: αPD-L1 scFv secretion does not improve anti-tumor efficacy of 
Salmonella in 4T1 tumors. BALB/c mice were inoculated subcutaneously with 
4T1 (day 0) and treated with the indicated S. Typhimurium strains and/or 
antibodies. Bacteria were given as a single IV injection of 1×106 CFU on day 11, 
mAbs were injected IP at 125µg/injection twice weekly starting on day 11 and 
continuing two weeks for αCD137 and for the duration of the experiment for αPD-
L1. Average tumor volume on day 28 (measured by caliper: L×W2×0.52) is 
displayed for 4 mice per cohort in (A) and average net tumor mass of lung 
metastases on day 32 is displayed for 4 mice per cohort in (B). Error bars indicate 
1 standard deviation. NS= no significant difference based on ANOVA in A and a 
Student’s unpaired T-test in B. 
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Figure 3-5: SalpNG reduces tumor burden and increases survival of BALB-neuT 
mice with autochthonous tumors. 
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Figure 3-5: SalpNG reduces tumor burden and increases survival of BALB-
neuT mice with autochthonous tumors. (A) Mice were monitored for tumor 
development. Upon tumor palpation (day 0), mice were either treated with a single 
dose of 6×104 CFU of SalpNG or left untreated. Total tumor size was measured 
over time. Data displayed is an average + 1 standard deviation of 4 mice per 
group. * = p-value < 0.05 (B) Kaplan-Meier survival plot of treated and untreated 
mice shown in panel A. P-value was generated using the log-rank test. 
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Figure 3-6: SalpNG treatment increases tumor infiltration of cytotoxic 
lymphocytes and causes enrichment of monocytic MDSCs. 
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Figure 3-6: SalpNG treatment increases tumor infiltration of cytotoxic 
lymphocytes and causes enrichment of monocytic MDSCs. (A) Infiltrating 
lymphocytes were isolated from the tumors of mice 21 days after SalpNG treatment. 
Cells were labeled with antibodies and analyzed using flow cytometry. CD8 and NK 
cells per gram were calculated based on tumor mass and cells counted. (B-D) 
MDSCs in tumor and spleen homogenates from treated or untreated mice were 
labeled with antibodies and identified using flow cytometry as monocytic (Ly6CHi) or 
granulocytic (Ly6GHi). Representative plots are shown in B1 (untreated) and B2 
(treated), and resulting cells per gram of tumor tissue were quantified for multiple 
mice in (C). In (D) the average ratio of monocytic/granulocytic MDSCs in spleens from 
treated or untreated mice was calculated. Bars represent the average of 3 mice + 1 
standard deviation. p-values were calculated using a Student’s unpaired T-test. 
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Figure 3-7: S. Typhimurium secreting αPD-L1 and αCTLA-4 scFvs does not 
improve efficacy in BALB-neuT mice, despite expression of PD-1 on infiltrating 
CD8 T-cells and PD-L1 on infiltrating MDSCs. 
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Figure 3-7: S. Typhimurium secreting αPD-L1 and αCTLA-4 scFvs does not 
improve efficacy in BALB-neuT mice, despite expression of PD-1 on infiltrating 
CD8 T-cells and PD-L1 on infiltrating MDSCs. (A) BALB/neuT mice were treated 
as in (Figure 3-4) with either 6x10^4 CFU SalpNG or a combination of SalpαPDL1-Hly 
and SalpαCTLA-4-Hly (3x10^4 CFU each). Total tumor burden was measured 
overtime. Data displayed is an average + 1 standard deviation of 4 mice per group. 
(B) Cells isolated from homogenized tumors and spleens were stained for CD8 and 
PD-1 and examined using flow cytometry. The average percent PD-1+ CD8 T-cell 
fraction is displayed for 3 mice + 1stdev. (C) MDSCs isolated from tumors on BALB-
neuT mice were stained for PD-L1 expression (open histogram) or isotype control 
(shaded histogram). 
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Figure 3-8: The tumor-targeting propensity of SalpNG is inconsistent between 
tumor models. 
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Figure 3-8: The tumor-targeting propensity of SalpNG is inconsistent 
between tumor models. BALB-neuT mice bearing palpable tumors (A), BALB/c 
mice bearing subcutaneous 4T1 tumors (B), or BALB/c mice incoculated with IV 
K7M2 cells (C) were treated with IV SalpNG. Depending on mouse health, mice 
were sacrificed 17-21 days post bacterial treatment and their tissues were 
harvested, homogenized, and plated on LB agar overnight for CFU enumeration. 
Bars indicate the averages of 6 mice in (A), 3 mice in (B), and 3 mice in (C). Error 
bars indicate 1 standard deviation. 
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CHAPTER 4 
 
BACTERIAL TARGETING OF AUTOCHTHONOUS TUMORS IS ENHANCED BY 
VASCULAR DISRUPTION AND PD-L1 INHIBITION 
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INTRODUCTION 
Many published reports demonstrate the efficacy of attenuated Salmonella 
enterica Typhimurium (S. Typhimurium) strains in mouse models of cancer, either by 
themselves or as vectors to deliver recombinant therapeutic proteins directly to the 
tumor microenvironment (94). In addition to efficacy, these studies report reproducibly 
high tumor colonization numbers of 108-109 colony-forming units (CFU) of S. 
Typhimurium per gram of tumor tissue with ratios of over 1000:1 when compared to 
healthy tissue (171).  
 When tested clinically, the results were largely disappointing. This was most 
likely due to insufficient tumor colonization. When tumors from 32 patients in clinical 
trials of parenterally administered S. Typhimurium strain VNP20009 were biopsied, less 
than 20% contained any measurable S. Typhimurium colonization (107-109). The results 
of the VNP20009 trials were unexpected given the preclinical demonstrations of bacterial 
colonization of subcutaneous tumors. Since all of the preclinical studies were performed 
in mouse transplant models of cancer, it may be that the tumor-targeting observed in 
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these models is due, at least partially, to characteristics of transplanted tumors that do 
not accurately mimic the autochthonous tumors that develop in human cancer. Necrotic 
tissue and hemorrhage of tumor blood vessels have been demonstrated to be important 
for the colonization of murine tumors (95, 118). Moreover, both necrosis and immature 
vasculature have been shown to be present at artificially high levels in transplant 
models. Indeed, transplantation tumors often contain large necrotic regions due to rapid 
growth of the inoculated tumor cells, inflammation and lack of mature vasculature, 
whereas human tumors develop much more slowly from a single cell and tend to be less 
necrotic due to suppression of an inflammatory immune response and coincident 
development of vasculature (111, 116, 117). These observations may help explain the 
difference between the high bacterial colonization of tumors in transplantation mouse 
models and the low colonization observed in clinical studies.  
The BALB-neuT model is a genetically engineered mouse (GEM) model in which 
mammary tumor development is driven by expression of a constitutively active rat 
homolog of human epidermal growth factor receptor 2 (161). In this model, 
autochthonous tumors develop over several months and are palpable in the mammary 
pads of female mice around 16 weeks of age. In Chapter 3 of this thesis, anti-tumor 
efficacy was observed in the BALB-neuT model with attenuated S. Typhimurium 
treatment. Yet, similar to results reported in human trials, no bacteria were observed in 
tumor tissue of treated mice at the time point tested, and the reduction in tumor burden 
was concluded to be due to a systemic immune response.  
To address bacterial tumor-targeting, we compared colonization of the 
transplantation tumors that develop in BALB/c mice subcutaneously inoculated with the 
syngeneic 4T1 breast cancer cell line to colonization of the autochthonous tumors that 
develop sporadically in the mammary glands of BALB-neuT mice. One approach that 
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has been used to cause necrosis in tumors and enhance the targeting of anaerobic 
Clostridium spores to transplant tumors is the administration of the vascular-disrupting 
agent (VDA) combretastatin A-4 phosphate (CA4P) (172). Therefore, we also 
investigated the use of CA4P to improve S. Typhimurium targeting of autochthonous 
tumors in BALB-neuT mice. 
 
METHODS 
 
S. Typhimurium strain growth and preparation for treatment 
S. Typhimurium strains VNP20009 (Δmsb, ΔpurI) (106) and SL3261 (ΔaroA, 
ΔhisG) (173) were obtained from The American Type Culture Collection (ATCC 
#202165) and The Salmonella Genetic Stock Centre (SGSC #439), respectively. 
Cultures of VNP20009 and SL3261 were grown from single colonies in lysogeny broth 
(LB) and MSB broth (174), respectively, at 37ºC until reaching mid-log phase at 
approximately 108 Colony Forming Units per ml (CFU/ml). Cultures were then chilled by 
swirling the flasks in ice water, and diluted in ice-cold PBS to concentrations required for 
injections. 
 
Mouse maintenance 
 All mice were maintained in specific pathogen free conditions and fed standard 
mouse chow (Harlan). Research Animal Resources at the University of Minnesota 
provided animal care. All protocols were approved by the Institutional Animal Care and 
Use Committee.  
 
4T1 experiments 
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4T1 cells (ATCC #CRL-2539) were grown in RPMI-1640 medium containing 10% 
fetal bovine serum. Cells were detached from flasks using 0.05% trypsin-EDTA, counted 
with a hemocytometer, washed with sterile PBS, and diluted to the appropriate 
concentration prior to injection. Female BALB/c mice of approximately 12 weeks of age 
were given a subcutaneous injection of 1×105 4T1 cells in 50 µL of sterile PBS 
superficial to the right inguinal mammary fat pad. Tumor growth was measured over time 
by caliper. Mice were treated with S. Typhimurium by IV injection when tumors reached 
approximately 400 mm3 volume calculated as an ellipsoid (length × width × depth × 
0.52). 
 
BALB-neuT experiments 
BALB-neuT colony maintenance and husbandry was performed as previously 
described (175). Tumor growth was monitored over time. Mice were treated by IV 
injection with S. Typhimurium when a single tumor reached the indicated sizes. In most 
cases, mice had additional smaller tumors on other mammary pads; these tumors were 
not considered in the analyses. Mice were either euthanized for bacterial CFU 
enumeration or measured over time for tumor response to treatment. Tumors were 
measured with a digital caliper, and tumor volumes were calculated as length × width × 
depth × 0.52.  
 
Treatment of mice 
Mice were injected IV with the indicated CFU of the appropriate S. Typhimurium 
strain in 100 µL of PBS via the tail vein. In some cases as indicated, bacteria were 
injected twice, 3 hours apart. For VDA pre-treatment, mice were given two IV injections 
of 0.4 mg (20 mg/kg) of combretastatin A-4 phosphate (CA4P): one injection 48 hours 
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prior to and one injection immediately before S. Typhimurium treatment. Similarly as 
indicated, some mice were injected with the same CA4P dose twice, 3 hours apart (i.e. 
four VDA injections total). For mice treated with anti-IL-6, 1 mg of anti-mouse IL-6 (αIL-6) 
monoclonal antibody (mAb) (MP5-20F3, BioXCell) was injected IP immediately following 
the first S. Typhimurium injection.  
 
Tissue harvest and CFU enumeration 
Mice were euthanized 48 hours post-S. Typhimurium administration. Tumors and 
spleens were harvested and minced with sterile razor blades to about 1 mm diameter 
pieces. Minced tissues were homogenized in 3 ml of sterile PBS using gentleMACS M 
Tubes (Miltenyi Biotec) with a gentleMACS Tissue Dissociator (program RNA_01). The 
homogenate was serially diluted in sterile PBS, plated on LB agar, and incubated for 16-
18 hours at 37°C for CFU enumeration. For histology, tumors were harvested from 
untreated control mice and from mice 48 hours after administration of 0.4 mg CA4P. 
Tissue was fixed in 10% neutral-buffered formalin solution for two days followed by 70% 
ethanol for two days. Tissues were then paraffin-embedded, sectioned and stained with 
hematoxylin and eosin (H&E) according to standard protocols. 
 
Generation of luminescent (lux) S. Typhimurium strains 
 The luxCDABE operon was inserted into the chromosome of DS3262 (see 
Chapter 2 methods for the generation of DS3262) using a Tn7 transposon method as 
described by McKenzie and Craig (176). Briefly, the luxCDABE operon was PCR-
amplified from the pAKlux2 plasmid (Addgene plasmid #14080) using the primers: Fwd: 
5'ATGACTAAAAAAATTTCATTCATTATTAACGGC and Rev: 5' TTATCAACTATCAAAC 
GCTTCGGTTAAG. The luxCDABE operon was then inserted into a plasmid containing 
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the lacUV5 promoter and re-amplified with the lacUV5 promoter with primers containing 
PacI and Xho1 sites to generate lacUV5-luxCDABE. The pGRG36 plasmid (Addgene 
plasmid #16666; temperature sensitive for replication) and lacUV5-luxCDABE were 
digested with PacI and XhoI restriction endonucleases and ligated with T4 DNA ligase 
(New England Biolabs). The resulting plasmid was amplified in Stbl3 E. coli cells and 
then used to transform electrocompetent DS3262 cells. Transformed cells were then 
cured of the delivery plasmid by growing at 42°C. The resulting DS3262-lux strain was 
transformed with pNG or pTrc-αPDL1-Hly to generate the luminescent S. Typhimurium 
strains DSpNG-lux and DSpαPDL1-Hly-lux, respectively. The pNG and pTrc-αPDL1-Hly 
plasmids were described in Chapter 2 of this thesis. 
 
In vivo imaging of tumor colonization 
 To measure the radiance of tumors in mice treated with luminescent bacteria, 
mice were anesthetized by isoflurane inhalation at 3.5% in oxygen and imaged using an 
IVIS Spectrum In Vivo Imaging System with Living Image software (PerkinElmer). Total 
flux (luminescence) was acquired for 60 seconds and recorded as radiance 
(photons/sec/cm2/sr) for the tumors of interest. 
 
RESULTS  
 
Attenuated S. Typhimurium targets subcutaneous transplant but not 
autochthonous tumors. 
Reports of cancer treatment using the attenuated S. Typhimurium strain 
VNP20009 demonstrated successful targeting of transplanted mouse tumors with IV 
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injections. In a phase I clinical trial, the maximum tolerable dose of IV VNP20009 in 
human cancer patients was 3×108 CFU/m2 (177). This dose translates to 2×106 CFU per 
20 g mouse. In order to avoid toxic effects, we used a dose of 5×105 CFU. IV 
administration of this dose to mice did not result in significant weight loss compared to 
saline-treated controls (data not shown). To verify successful tumor-targeting in a 
transplant model of breast cancer, 4T1 cells were injected subcutaneously superficial to 
the mammary fat pads of female BALB/c mice. When tumors reached 400 mm3 in 
volume, mice were given a single IV injection of VNP20009. Mice were harvested 48 
hours post injection and their tissues were examined for bacterial colonization. In 
agreement with published studies (94), we observed invariably high tumor colonization 
of greater than 1×108 CFU/gram of tumor tissue, which was more than 1000-fold greater 
than colonization of the spleen (Figure 4-1A). To investigate the colonization of 
autochthonous tumors, BALB-neuT mice with size-matched mammary tumors were 
given the same injection of VNP20009 and examined 48 hours later for tumor 
colonization. Compared to 4T1 tumors, the autochthonous BALB-neuT tumors contained 
approximately 10,000-fold fewer CFU/g (Figure 4-1A). While tumor colonization was 
greatly reduced in the autochthonous tumors, splenic colonization was similar when 
compared to mice bearing 4T1 tumors (Figure 4-1A). 
It has been suggested that the failure of VNP20009 to successfully target human 
tumors may be due to its lack of lipopolysaccharide (LPS) endotoxin, which may elicit a 
cytokine-dependent blood influx that is critical for tumor colonization (90, 95). To address 
whether a Lipid A+ strain would result in better BALB-neuT tumor colonization, we 
treated both 4T1 and BALB-neuT tumor-bearing mice as before using the attenuated S. 
Typhimurium strain SL3261. This strain has been studied for tumor colonization 
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extensively (for background on this strain, see Chapter 2 of this thesis). As observed 
with VNP20009, SL3261 readily colonized 4T1 tumors, but not autochthonous BALB-
neuT tumors (Figure 4-1B). In attempts to improve tumor colonization, we tested doses 
of SL3261 and VNP20009 containing up to 5×106 CFU and also included “primer” doses 
of varying sizes, which have been reported to improve tumor-targeting in some instances 
(178). While increasing colonization marginally, these dosing strategies were limited by 
toxicity, as mice that received 2×106-3×106 total CFU of either strain experienced 
significant weight loss, and doses >3×106 CFU were lethal in some cases (data not 
shown). 
 
Vascular disruption improves bacterial targeting of autochthonous mammary 
tumors. 
 As an alternative approach to improve tumor-targeting, we investigated whether 
pre-treatment of mice with a vasculature-disrupting agent (VDA) would make 
autochthonous tumors more susceptible to colonization by affecting vasculature and 
necrosis. VDAs cause the destruction of immature vasculature that is often found in 
tumor tissue, which leads to hemorrhagic necrosis (179). Female BALB-neuT mice with 
autochthonous mammary tumors were given two IV injections of the VDA combretastatin 
A-4 phosphate (CA4P) at 20 mg/kg, 48 hours apart. Immediately following the second 
CA4P injection, mice were injected IV with 5×105 CFU of SL3261 and harvested two 
days later to determine tissue colonization. When SL3261 injection was combined with 
CA4P pre-treatment, there was an approximate 1000-fold CFU/g increase in tumors 
when compared to mice not pre-treated with CA4P, while splenic colonization was not 
affected (Figure 4-1B). The combination of CA4P pre-treatment with SL3261 treatment 
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in this manner did not cause any overt behavioral changes or significant weight loss of 
the mice. 
To verify the necrotic effect of CA4P pre-treatment on tumor tissue, tumors from 
BALB-neuT mice treated with CA4P were excised two days post-treatment and 
histologically compared to tumors from untreated mice. As expected, CA4P treatment 
induced the formation of necrotic regions that were largely absent in the tumors of 
untreated mice (Figure 4-2A-B); however, the extent of necrosis was somewhat less 
than expected. This may have been due to the more mature vasculature of 
autochthonous tumors being less responsive to the disruption caused by CA4P than is 
typically observed for transplanted tumors. Hill and colleagues demonstrated an 
improved effect of CA4P on spontaneous tumors when administered twice in a 3-hour 
period rather than once (115). Similarly, we observed more extensive necrosis of BALB-
neuT tumors when CA4P was administered in two equal doses separated by 3 hours 
(Figure 4-2C). 
 
Split dosing of VDA and S. Typhimurium further improves the targeting of 
autochthonous tumors. 
 BALB-neuT mice bearing 400mm3 tumors typically have greater than a cubic cm 
of systemic tumor burden, which may be physiologically unrealistic for efficacy studies. 
Therefore we investigated the VDA-assisted targeting of smaller tumors. When CA4P 
pretreatment was administered as described previously (Figure 4-3A), and mice were 
treated IV with 5×105 CFU of DSpNG (SL3261-based strain carrying an empty 
expression vector), 150-200mm3 tumors were examined for colonization. A similar 
degree of colonization was observed for some tumors; however, colonization was less 
consistent (Figure 4-4). In light of the increased necrosis observed with the split CA4P 
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dose (Figure 4-2C) and the reported advantage of incorporating a similar primer dosing 
strategy for bacterial tumor-targeting (178), we investigated whether combining these 
approaches would further improve the consistency of autochthonous tumor-targeting. 
When CA4P and bacterial injections were administered as a dose that was split between 
3 hours (illustrated in Figure 4-3B), the resulting tumor colonization was more consistent 
(Figure 4-4); however, this treatment strategy also caused an acute toxicity that led to 
weight loss and, in rare cases, death of the treated mice. This toxic effect was only 
observed when both CA4P and S. Typhimurium were administered together, as neither 
agent alone was notably toxic at these levels (Figure 4-5). We hypothesized that the 
toxicity observed was caused by a systemic cytokine release in response to the bacteria, 
the effects of which were augmented by the vasculature disrupting effects of CA4P. One 
strategy that has been used to prevent the toxic effects of a systemic cytokine release is 
the blockade of IL-6/IL-6-receptor signaling. To investigate whether IL-6 antagonism 
could prevent the toxic effects of the split CA4P and S. Typhimurium dosing strategy, 
treated mice were given a single 1 mg IP dose of an αIL-6 mAb following the first 
bacterial injection (Figure 4-3C). The addition of αIL-6 not only reduced the toxic effects 
of mice given 5×105 total CFU of DSpNG (split into two 2.5×105 doses) but also allowed 
an increased non-toxic administration of 1×106 total CFU (Figure 4-5).  
 
Anti-PD-L1 scFv expression may improve tumor colonization in BALB-neuT 
tumors, leading to improved tumor suppression. 
While VDA treatment improved the colonization of autochthonous BALB-neuT 
tumors, not all tumors were colonized equally, and it was unclear how long S. 
Typhimurium remained in tumor tissue. This made it difficult to correlate tumor 
colonization with anti-tumor efficacy. In order to follow individual tumor colonization 
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overtime, DSpNG and DSpαPD-L1-Hly were engineered to express bacterial luciferase 
(lux) by inserting the luxCDABE operon into the bacterial chromosome. This allowed an 
estimation of tumor colonization of individual tumors over time by measuring the 
radiance (photons/second/cm2/steradian) of live mice (Figure 4-6). Due to the single 
copy chromosomal expression of lux, only tumors that contained an approximate 
minimum colonization of 5×106 CFU/g were detectable; tumors that contained fewer 
bacteria were below the background radiance of the mice (approximately 1.3×104). 
To examine tumor colonization and growth overtime after S. Typhimurium 
treatment, BALB-neuT mice bearing at least one tumor between 150-250 mm3 were 
treated with CA4P, αIL-6 and 1×106 CFU of DSpNG-lux as illustrated in Figure 4-3C. By 
measuring tumor radiance, initial tumor colonization was observed at 2-3 days for most 
mice; however most colonization dissipated to undetectable levels within approximately 
one-week post-bacterial injection (Figure 4-7A,C). When mice were treated similarly with 
DSpαPD-L1-Hly-lux, a higher degree of tumor colonization was observed for many 
tumors, which was often measurable for more than 20 days (Figure 4-7B,C). To 
determine whether this improved tumor colonization affected the anti-tumor efficacy of S. 
Typhimurium, the growth of tumors with “high” colonization (>1×105 radiance) and 
tumors with “low” colonization (<1×105 radiance) was compared for treated mice. The 
growth of individual tumors from untreated mice was also included for comparison. 
Untreated BALB-neuT tumors between 150-250 mm3 grew an average of 463% in 19 
days (Figure 4-7D). Tumors from treated mice with low bacterial colonization showed 
significantly less growth than those from untreated mice, with an average volume 
increase of 207% in the same time frame (Figure 4-7D), corroborating the systemic anti-
tumor effects of S. Typhimurium treatment that was described in Chapter 3. The growth 
of tumors in treated mice that displayed high tumor colonization was further reduced to 
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43% over 19 days, indicating a significantly improved therapeutic effect of S. 
Typhimurium treatment when tumors were adequately colonized. Tumors from mice 
treated with αPD-L1 mAb were also examined for growth and did not differ significantly 
from tumors on untreated control mice (Figure 4-7D) 
 
DISCUSSION 
Vasculature disruption enhances bacterial targeting of autochthonous tumors. 
The use of bacteria as nontoxic cancer therapy is based on the ability of 
virulence-attenuated bacterial strains to specifically target tumor tissue. This 
characteristic is highly reproducible in murine tumors developed from transplanted cells 
or tissues (94). In the current study, however, we observed that the more clinically 
relevant autochthonous BALB-neuT tumors are much less readily colonized by IV-
administered bacteria than are transplanted subcutaneous 4T1 tumors. These results 
are consistent with S. Typhimurium failing to colonize tumors when tested in a clinical 
setting and may explain the lack of significant efficacy observed in the clinical trials (107-
109). Therefore, it is important for future preclinical studies of bacterial tumor 
colonization to consider the utilization of autochthonous models that more closely mimic 
the development of human tumors. 
Recently reported studies suggest that S. Typhimurium colonization of tumors is 
constrained by both the amount of necrotic space and the capacity of tumor vasculature 
to facilitate bacterial extravasation (95, 110, 118). Because CA4P causes hemorrhagic 
necrosis by breaking down the epithelial wall of immature vasculature in tumors (179), 
we tested its ability to enhance colonization of autochthonous tumors by IV administered 
S. Typhimurium. The observed 1000-fold average increase in colonization with CA4P 
pre-treatment confirmed the ability of this VDA to enhance tumor colonization. While 
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CA4P increased necrotic regions in the tumors of BALB-neuT mice, it is not clear if 
extravasation of bacteria from vasculature, establishment of necrotic regions, or both 
contributed to the colonization of BALB-neuT tumors. However, in preliminary 
optimization experiments (not shown), we found that the timing of the two CA4P doses 
was important, and a single dose of CA4P was ineffective at improving tumor 
colonization. The dosing strategy described in this report that included two 
administrations 48 hours apart followed immediately by bacterial injection was optimal. 
We suspect that the first dose causes the development of necrotic regions important for 
the colonization (Figure 4-2) and the second injection disrupts the nascent vasculature 
that begins to form after the first injection causing hemorrhage of the tumor blood 
vessels and facilitating entry of bacteria into the tumor. Experimentation to optimize the 
timing and concentration of CA4P dosing may clarify the relative contribution of each 
mechanism to improved bacterial colonization. 
Much of the literature describing the effects of VDAs on tumor vasculature and 
necrosis includes studies performed in transplanted subcutaneous models. Conclusions 
drawn from these models may overestimate the effects of VDA treatment due to the 
unnaturally immature vasculature that characterizes the rapidly growing inoculated 
tumors. One of the few studies published that characterized the effects of VDA treatment 
in autochthonous tumors reported a reduced effect of CA4P on autochthonous tumors 
compared to transplanted tumors. The study reported a single CA4P dose induced a 
40% reduction of the functional vasculature of subcutaneous transplanted CaNT 
adenocarcinoma tumors, whereas significant vasculature disruption was not observed in 
autochthonous T138 mammary tumors. However, when mice bearing autochthonous 
T138 tumors were given the same CA4P dose administered as two half-doses three 
hours apart, functional vasculature in the tumor was reduced approximately 50% (115). 
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Similarly, we observed a greater extent of necrosis in the tumors of mice treated with two 
CA4P injections three hours apart than those from mice that were injected once, and the 
combination of CA4P and S. Typhimurium, when similarly injected twice 2 days following 
the CA4P pretreatment, improved the consistency and the degree of bacterial tumor-
targeting. However, this treatment strategy also caused an adverse toxic effect that we 
suspect is due to a systemic cytokine release in response to the combination of 
intravenous bacteria and CA4P. In support of this hypothesis, the IP administration of an 
anti-mouse IL-6 antibody immediately after the first bacterial injection abrogated the toxic 
effect and allowed an increase bacterial dose without increased toxicity. Continued 
investigation of how autochthonous tumors can be conditioned in this manner to 
increase bacterial colonization will increase the likelihood of successful clinical 
translation of bacterial cancer therapy. 
 
Anti-PD-L1 scFv expression may improve tumor colonization in BALB-neuT tumors, 
leading to improved tumor suppression. 
 When DSpαPDL1-Hly was examined for tumor-targeting propensity, we observed 
a higher degree and duration of colonization than the same bacterium carrying an empty 
expression vector (DSpNG-lux). All tumors that displayed lasting radiance of greater 
than 1×105 (p/s/cm2/st), corresponding to approximately 2.5×107 CFU/g, were in mice 
treated with DSpαPDL1-Hly. It has recently been shown that functional PD-L1 is 
important for the clearance of Salmonella infections in mice (180). Additionally, PD-L1 
can  act as a positive co-stimulatory molecule in Listeria infections (181) and may be 
important for the survival of activated CD8 T-cells (182). In light of these counterintuitive 
reports, it may be that expression and secretion of αPDL1 scFv from S. Typhimurium 
gives it a degree of protection that allows more robust and lasting tumor colonization. 
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 When highly colonized (radiance > 1×105) tumors were compared to those with 
low colonization, a significant improvement in tumor growth reduction was observed. 
However, because the only tumors with high colonization over longer time periods were 
observed in mice treated with DSpαPDL1-Hly, it is unclear whether the increased anti-
tumor efficacy was due to the T-cell stimulatory activity of the αPD-L1 scFv in the tumor 
microenvironment or due to the higher concentration of bacterial cells augmenting the 
native cytotoxic effects of tumor colonization in mice treated with this strain. We suspect 
the latter to be the primary cause, as mice treated with αPD-L1 mAb did not show 
significant growth reduction compared to those from untreated controls. Further 
experiments that investigate DSpαPDL1-Hly tumor-targeting may elucidate the 
mechanisms involved and their relative contributions to the efficacy observed. 
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Figure 4-1 Figure 1: VDA improves tumor-targeting of attenuated S. 
Typhimurium in autochthonous breast cancer.  
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Figure 4-1 Figure 1: VDA improves tumor-targeting of attenuated S. 
Typhimurium in autochthonous breast cancer. A: BALB/c mice bearing 
subcutaneous 4T1 breast tumors or BALB-neuT mice bearing size-matched sporadic 
tumors were administered 5×105 CFU of log phase VNP20009 by tail vein injection. 
Tumors and spleens were harvested from mice two days post bacterial injection and 
were homogenized and plated for CFU determination. B: Mice bearing 4T1 or BALB-
neuT tumors were treated as in (A) with log phase SL3261 and similarly plated for 
CFU determination. The VDA pre-treatment group was administered 0.4 mg CA4P 48 
hours prior to, and once again immediately before, injection of SL3261 (as illustrated 
in Figure 4-3A).  For panels A and B, the log10 of individual CFU/g values were used 
to calculate average and standard deviation of each group. Displayed is the average 
+/- one standard deviation of two separate experiments. Total mice for either the 
VNP20009 or SL3261 experiments: 4T1 N = 4; BALB-neuT N = 6. p-value was 
calculated using a Student’s unpaired T-test.  
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Figure 4-2: VDA treatment leads to development of necrotic areas in 
autochthonous BALB-neuT tumors. 
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Figure 4-2: VDA treatment leads to development of necrotic areas in 
autochthonous BALB-neuT tumors. BALB-neuT mice with autochthonous 
mammary tumors were administered a single tail vein injection of 0.4 mg of CA4P or 
two injections separated by 3 hours. Tumors were excised two days later for slide 
preparation and H&E staining. (A) Necrotic regions were largely absent from CA4P (-) 
control tumors. (B) CA4P treatment caused the development of necrotic regions, 
indicated by black arrows. (C) The extent of necrosis was further increased with two 
CA4P injections 3 hours apart. 
Histology and H&E staining were performed by David Urso (Dept. of Surgery, 
University of Minnesota) 
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Figure 4-3: Schematics illustrating the injection strategies used for tumor-
targeting in the BALB-neuT model.  
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Figure 4-3: Schematics illustrating the injection strategies used for tumor-
targeting in the BALB-neuT model. All CAP4 injections were given 2 days before 
and again on the day of bacterial injections. For “split” injections in (B) and (C), 
CA4P and bacterial injections were administered twice, separated by 3 hours. All 
CA4P and bacterial injections were administered IV via the tail vein. The αIL-6 mAb 
in (C) was administered IP immediately following the first bacterial injection. Blue, 
red, green, and black bars indicate CA4P, S. Typhimurium, αIL-6 mAb, and tissue 
harvest, respectively (bars are also labeled within the figure). 
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Figure 4-4: Split dosing of VDA and CA4P improves the consistency of 
BALB-neuT tumor colonization. 
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Figure 4-4: Split dosing of VDA and CA4P improves the consistency of BALB-
neuT tumor colonization. BALB-neuT mice bearing tumors ranging in size from 150-
250 mm were treated with 0.4 mg CA4P and 5×105 CFU of DSpNG in single 
injections as before (illustrated in Figure 4-3A) or with both CA4P and DSpNG split 
into two doses separated by 3 hours (illustrated in Figure 4-3B). For the split 
injections, both CA4P and DSpNG were administered on the bacterial treatment day 
as two half doses of 0.2 mg and 2.5×105 CFU, respectively. Tumors were harvested, 
homogenized and plated two days after the bacterial injection(s). The colonization of 
individual tumors is displayed (symbol: −) along with the average colonization 
(symbol: u) of each group. The combined results of two experiments are displayed. 
N=10 total tumors for the single injection group and 6 tumors for the split injection 
group. p-value was calculated using a Student’s’ unpaired T-test. 
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Figure 4-5: IL-6 treatment reduces the toxic effects of CA4P and S. Typhimurium 
treatment.  
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Figure 4-5: IL-6 treatment reduces the toxic effects of CA4P and S. Typhimurium 
treatment. Mice were treated with DSpNG, CA4P, and/or αIL-6 as indicated. Bacteria 
and CAP4 were administered as split injections as illustrated in Figure 4-3B and C. All 
CA4P doses were 0.4 mg per injection (e.g. CA4P+ mice were given four 0.4 mg 
injections of CA4P as illustrated in Figure 3C for a total of 1.6 mg over 2 days). 
Bacterial CFU numbers indicate the total number for each injection; i.e. “1×106” 
represents two 5×105 CFU injections 3 hours apart, or 1×106 total CFU. Mice were 
monitored for weight loss and survival after treatment. The surviving mice/total mice 
treated in each group is depicted as a fraction below each column. The y-value 
represents the average percent weight loss of the surviving mice in each group.  
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Figure 4-6: Tumor radiance of mice treated with luminescent S. Typhimurium 
allows quantification of tumor colonization in live mice. (A) Representative image 
depicting the luminescence quantification of individual tumors (radiance) in a mouse 
treated with luminescent S. Typhimurium. (B) Tumors of varying luminescence from 
treated mice were homogenized and plated for CFU enumeration. CFU/gram of 
tissue correlated with tumor radiance. 
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Figure 4-7: Anti-PD-L1 scFv expression may improve tumor colonization and 
decrease growth of BALB-neuT tumors.  
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Figure 4-7: Anti-PD-L1 scFv expression may improve tumor colonization and 
decrease growth of BALB-neuT tumors. BALB-neuT mice bearing 150-250 mm3 
tumors were treated with CA4P, αIL-6, and 5×105 CFU of either DSpNG-lux or 
DSpαPDL1-Hly-lux with the injection strategy illustrated in Figure 4-3A. 
Luminescence and tumor growth were measured over time. Images demonstrating 
the luminescence of representative mice are shown in (A) and (B).  (C): The radiance 
of multiple individual tumors from treated mice was measured over time. Only tumors 
that were between 150-250mm3 upon treatment were graphed (N=9 for DSpαPDL1-
Hly-lux treated and N=8 for DSpNG-lux treated).  (D): The average percent growth 19 
days post-treatment of all tumors shown in (C) that reached radiance greater than 
1×105 (N=6) were compared to those consistently below 1×105 (N=11). For 
comparison, the average growth of tumors between 150-250mm3 from untreated mice 
(N=8) as well as mice treated twice weekly with 125µg of IP αPD-L1 mAb (N=4) were 
also included. p-values were calculated using Student’s unpaired T-test. 
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CHAPTER 5 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Discussion 
Immunotherapy is an exciting advancement in the treatment of cancer. The 
specificity and memory of the immune system give it potential advantages over 
conventional therapies for lasting therapeutic responses. However, the adverse effects 
of sustained or off-target immune responses can cause serious autoimmune disorders, 
graft or organ transplant rejection, and general symptoms associated with the 
inflammatory response. The immune-related adverse events of systemic checkpoint 
blockade and cytokine therapy limit their therapeutic potential (for review, see 
introduction section “Toxicity of checkpoint blockade”). One method to remove the 
limitation of systemic toxicity is to target the therapeutic agent(s) specifically to the tumor 
microenvironment. The ideal targeting vector would specifically accumulate in tumor 
tissue where it would generate and secrete the immunotherapeutic agent. In this thesis, 
the potential of Salmonella enterica serovar Typhimurium (S. Typhimurium) as a tumor 
targeting immunotherapy vector was investigated. 
 
The native cytotoxicity of S. Typhimurium 
One advantage of S. Typhimurium as an immunotherapy vector is its native 
tumoricidal activity in the absence of any recombinant protein expression. In Chapter 3, 
we demonstrated the anti-tumor efficacy of S. Typhimurium in metastatic and primary 
tumor models of osteogenic sarcoma and transplanted and autochthonous breast cancer 
models. Interestingly, this efficacy was observed in the absence of bacterial tumor 
targeting in both metastatic osteosarcoma and BALB-neuT autochthonous breast 
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cancer. Therefore, we suspect that the efficacy was due to the systemic 
immunostimulatory effects of Salmonella treatment. The immunosuppressive tumor 
microenvironment is characterized by a Th2/M2 immune polarization. S. Typhimurium, a 
potent driver of a Th1 immune response (183), may have induced a Th1 shift that 
prevented tumor growth and/or caused the destruction of tumor cells. The increased 
infiltration of IFNγ+ CD4+ Th1 cells in K7M2 tumors in response to S. Typhimurium 
treatment supports this hypothesis. Additionally, we observed a reduction in the T-reg 
population in K7M2 tumors, indicating a less immunosuppressive tumor environment in 
response to S. Typhimurium treatment in the absence of bacterial tumor colonization. 
In addition to the systemic efficacious effect of S. Typhimurium, we observed an 
apparent tumor colonization-specific anti-tumor effect in highly colonized BALB-neuT 
tumors that was significantly greater than what was observed for tumors with low 
colonization in treated mice. This interesting observation differentiated the systemic 
efficacious effects of S. Typhimurium treatment from a tumor colonization-specific effect. 
Additional work in the BALB-neuT model may further elucidate these two effects (see 
“Future Directions” section below). 
 
S. Typhimurium is able to secrete immune checkpoint-blocking scFvs 
 Another beneficial characteristic of bacterial cancer therapy is the ability to 
engineer strains like S. Typhimurium to express therapeutic proteins. In Chapter 2, we 
demonstrated this capability with the expression and secretion of antagonistic single 
chain variable fragments (scFvs) against the immunoinhibitory checkpoints CTLA-4 and 
PD-L1. Full-length antibodies are difficult to produce in prokaryotic hosts. Whereas 
scFvs, being single chain peptides that include the variable heavy and variable light 
regions of one arm of a full-length antibody, should maintain antigen-binding affinity in a 
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structure simple enough for relatively easy prokaryotic expression (184). However due to 
the lack of a stabilizing framework region, scFvs will occasionally encounter problems 
with proper folding and stability (129). This is particularly common when scFvs are 
generated from B-cell hybridomas or other monoclonal cell lines, as there is no 
guarantee that scFvs will retain stability or even binding affinity when the majority of the 
remaining antibody structure is absent. In order to sidestep these issues, we used a 
phage display and panning approach to select for functional scFvs. Using this method, 
only scFv sequences that expressed and folded correctly in bacteria and retained high 
binding affinity in the absence of the rest of the antibody structure were selected during 
panning. Using an immunized chicken library for our selection pool, we successfully 
isolated antagonistic scFvs against CTLA-4 and PD-L1. αPD-L1 scFv was readily 
expressed and purified from bacterial cultures and displayed an antigen-binding affinity 
in the picomolar range, similar to antagonistic anti-mouse PD-L1 mAbs that are regularly 
used in research. When tested for antagonistic biological activity, both αPD-L1 and 
αCTLA-4 scFvs demonstrated biological activity similar to antagonistic mAbs. Therefore 
apart from their use in bacterial cancer therapy, the scFvs may be alternative immune 
checkpoint-binding reagents for other experimental or therapeutic applications. Using the 
hemolysin type I secretion system from E. coli, we generated S. Typhimurium strains 
that actively secrete the scFvs from their cytoplasm into the extracellular space. We 
encountered some difficulty with the larger scale production and characterization of 
αCTLA-4 scFv, which prevented the more detailed characterization of this scFv, such as 
the determination of its binding affinity. While these issues were largely resolved with 
hemolysin secretion, we decided to focus the subsequent investigation of S. 
Typhimurium as a vector for checkpoint blockade on the delivery of the better 
characterized αPD-L1 scFv.  
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Tumor-targeting propensity of S. Typhimurium in transplant versus autochthonous tumor 
models 
 Central to its applicability as a tumor-targeting vector is S. Typhimurium’s 
propensity to preferentially colonize tumor tissue over healthy tissue. This property has 
been described in numerous preclinical studies using transplanted mouse tumor models. 
However, when tested clinically, less than 20% of biopsied tumors contained any 
measurable S. Typhimurium colonization. These results were unexpected in light of the 
numerous preclinical demonstrations of tumor targeting. When we examined the 
colonization of transplanted subcutaneous 4T1 tumors, we observed invariably high 
colony-forming units/gram of tumor, similar to other published studies in this field. 
However, when the colonization of sized matched autochthonous tumors was examined 
in BALB-neuT mice, little to no tumor colonization was observed, similar to what was 
observed for human tumors in clinical trials. It may be that the reproducibly high bacterial 
tumor colonization in much of the published literature is due in part to the artificiality of 
transplanted tumor models used, which often contain exaggerated levels of necrosis 
and/or immature vasculature than what is encountered in human disease (111, 116, 
117). Conversely tumors in autochthonous cancer models, having developed from a 
single cell in their place of origin, have vasculature and necrosis patterns that more 
closely resemble human tumors (111, 117). Hemorrhage of tumor vasculature and the 
presence of necrotic regions have been demonstrated to be important for bacterial 
colonization (95, 118). Therefore, the differences between transplanted and 
autochthonous tumors in this regard may account for the differences in colonization that 
we observed. In addressing this idea with the hope of improving the bacterial targeting of 
autochthonous tumors (and ultimately human tumors), we sought to condition the 
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autochthonous tumors of the BALB-neuT model to “act” like transplant tumors by 
administering the vasculature disrupting agent (VDA) Combretastatin A-4 phosphate 
(CA4P). CA4P disrupts vasculature by binding to tubulin causing depolymerization and 
disruption of the cytoskeleton of vascular endothelial cells (179). The chaotic vasculature 
of tumor tissue is more susceptible to the effects of CA4P than the vasculature of 
healthy tissue, and CA4P treatment can cause a decreased tumor blood flow in as little 
as five minutes and complete shutdown of tumor blood flow in as little as 20 minutes in 
animal models while leaving healthy vasculature largely unaffected (179). This causes 
the development of necrotic regions in tumors within two days post treatment in animal 
models, which may subsequently be re-vascularized with neovasculature (185). These 
changes may cause autochthonous (and ultimately human) tumors to appear more 
“transplant-like,” making them more susceptible to bacterial colonization. 
 When BALB-neuT mice bearing autochthonous tumors were treated with CA4P 
two days prior to S. Typhimurium treatment (pre-treatment) and again with CA4P co-
administered with S. Typhimurium, we observed an approximate 1000-fold increase in 
tumor colonization. Dosing regimens that excluded either of these two CA4P doses did 
not improve tumor targeting (not shown). Wang and colleagues showed that nascent 
vasculature forms in the necrotic regions that form after CA4P administration (185). We 
suspect that our first CA4P dose induced the formation of necrosis, while the second 
dose caused hemorrhage of the nascent tumor vasculature that facilitated entry of the 
bacteria into the tumor. Additionally, we found that splitting each CAP4 dose into two 
half-doses or two full doses three hours apart (for a total of four doses) improved the 
consistency of tumor colonization. Further experimentation may help to optimize and 
illuminate the mechanisms behind VDA-assisted bacterial tumor targeting. 
  
142 
 At least two conclusions can be drawn from these results. First, bacterial tumor 
targeting studies should be performed in autochthonous models if possible. The difficulty 
encountered in the colonization of human tumors is not modeled well in transplanted 
orthotopic or subcutaneous mouse tumors, which are readily colonized by S. 
Typhimurium. In contrast, we did not see adequate tumor colonization when S. 
Typhimurium was injected as a single agent in BALB-neuT mice bearing autochthonous 
tumors, which is consistent with the poor colonization of human tumors. Second, since 
treatment with a VDA improved the colonization of autochthonous tumors, which more 
closely mimic human tumors, this strategy may also improve the targeting of human 
tumors. At a minimum, these studies illustrate the potential of conditioning tumors to 
improve bacterial targeting by treatment with VDAs or other agents. 
 
Tumor targeting and efficacious effects of bacterial αPD-L1 scFv expression 
 When attenuated S. Typhimurium secreting αPD-L1 scFv (DSpαPDL1-Hly-lux) 
was compared to the same strain carrying an empty expression vector (DSpNG-lux) for 
tumor colonization in the BALB-neuT autochthonous breast cancer model (Chapter 4), 
the majority of tumors examined in DSpαPDL1-Hly-lux treated mice were colonized at a 
higher level and for a longer period of time than those in mice treated with DSpNG-lux. 
As mentioned in the Chapter 4 discussion, it has recently been demonstrated that 
functional PD-L1 is important in the clearance of both Salmonella (180) and Listeria 
(181) infections in mice, and this may be due to a role that PD-L1 plays in CD8 T-cell 
survival (182). Therefore, the secreted αPD-L1 scFv may gave a degree of protection to 
the S. Typhimurium that prevented its immune-mediated clearance and allowed longer 
lasting and more robust tumor colonization. Two additional observations further support 
this hypothesis. First, in Chapter 3 (page 83) we described a lethal toxicity that occurred 
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when αPD-L1 mAb was combined with SalpNG, which prevented the inclusion of this 
control group in 4T1 tumor studies. This toxicity corroborated the published effects of 
PD-L1 blockade on Salmonella infections. Second, when testing for in vivo survivability 
of our recombinant strains in Chapter 2, we saw that the χ4550-based S. Typhimurium 
strain that secreted αPD-L1 scFv (SalpαPD-L1-Hly) not only survived as well as SalpNG, 
but also appeared to have colonized tumors at one to two orders of magnitude higher 
than SalpNG (Figure 2-9B). Therefore we suggest that blocking PD-L1 systemically with 
αPD-L1 mAbs prevents the clearance of S. Typhimurium and is lethal. However, when 
the blocking agents are secreted by DSpαPDL1-Hly-lux or SalpαPD-L1, the PD-L1 block 
is localized to areas of higher bacterial concentrations in the tumor microenvironment 
where the secreted αPD-L1 scFvs can accumulate to functional concentrations to 
prevent the clearance of the bacteria.  
 When tumors that contained high levels of bacterial colonization were measured 
over time for growth, a significantly greater anti-tumor effect was observed than for those 
with low colonization. It is unclear whether this efficacy is the effect of the higher degree 
of bacterial colonization augmenting the native anti-tumor effects of the colonizing 
bacteria, or if it is due to an anti-tumor immunostimulatory activity of the secreted αPD-
L1 scFv. Differentiating between the relative contributions of these mechanisms is 
difficult, as the only strain that achieved robust lasting colonization was DSpαPDL1-Hly-
lux; therefore we were unable to compare highly colonized DSpαPDL1-Hly-lux tumors to 
highly colonized DSpNG tumors. We suspect the former explanation to play a more 
significant role, as tumors in BALB-neuT mice treated with a PD-L1 mAb blockade did 
not show a significant growth difference compared to tumors in untreated mice (Figure 4-
7D), which suggests that PD-L1 may play a secondary role in the immunosuppressive 
microenvironment of BALB-neuT tumors. However, it is possible that the immunological 
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changes of S. Typhimurium colonization may have caused BALB-neuT tumors to 
respond more readily to PD-L1 blockade, resulting in improved efficacy. A proper control 
for this mechanism would involve administering a combination of S. Typhimurium 
treatment and αPD-L1 blockade with mAb; however as mentioned, this treatment 
regimen was lethal in mice, making the comparison difficult. Further experimentation is 
needed to elucidate the mechanisms behind the targeting and efficacious properties of 
DSpαPDL1-Hly-lux (see “Future Directions” section).  
 
Future Directions 
Elucidate the tumor-targeting effects of αPD-L1 scFv secretion 
The observation that αPD-L1 scFv improves the robustness and duration of S. 
Typhimurium tumor colonization was surprising but may prove useful for the 
advancement of Salmonella-based cancer therapy. In order to validate this result, the 
strains should be re-constructed and examined again for their tumor-colonization 
effectiveness; this would rule out the unlikely possibility that a simple cloning variation or 
mutation produced a strain that colonized tumors more effectively, independent of αPD-
L1 scFv secretion.  
The DSpαPDL1-Hly strain may be useful in downstream applications as a 
“colonization driver” strain to improve the tumor colonization of other recombinant 
strains. For example if an IL-2-secreting strain requires a threshold colonization 
concentration for effectiveness, the co-administration of DSpαPDL1-Hly may improve the 
colonization to meet that threshold. This property could be tested by performing an 
experiment in two groups of BALB-neuT mice. Group A would be treated with non-
luminescent DSpαPDL1-Hly and luminescent DSpNG-lux, and Group B would be treated 
with an equal dose of non-luminescent DSpNG and the same DSpNG-lux dose. 
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According to the colonization driver hypothesis, the tumors in mice treated in Group A 
would have greater DSpNG-lux colonization, measured by increased tumor radiance.  
Due to the apparent toxic effects of systemic PD-L1 blockade and S. 
Typhimurium infection that we observed, and in light of the published reports 
demonstrating the importance of PD-L1 in Salmonella clearance, there may be a danger 
of the DSpαPD-L1-Hly strain avoiding systemic clearance and causing an 
unmanageable infection during its initial dissemination. Therefore, the expression of 
αPD-L1 scFv may increase the virulence of the attenuated S. Typhimurium strains. In 
support of this, we have preliminary data that suggests DSpαPDL1-Hly may be slightly 
more toxic than DSpNG (not shown). One approach to prevent this adverse effect of 
αPD-L1 scFv secretion is to limit its expression to the tumor microenvironment. We are 
currently investigating the use of tumor-specific promoters, including the 212b (186) and 
NirB (187) promoters, which are activated in tumor tissue and in hypoxic conditions, 
respectively. This strategy would localize the effects of αPD-L1 scFv expression on 
survivability exclusively to the tumor microenvironment. 
Apart from its effect on bacterial survivability, the anti-tumor function of bacterially 
delivered anti-immune checkpoint scFvs was not specifically addressed. This would be 
most clearly tested in a tumor model known to respond to immune checkpoint blockade. 
In Chapter 3, our attempts to demonstrate this functionality in the 4T1 tumor model are 
described. The combination of αPD-L1 mAb blockade and a stimulatory agonistic CD137 
mAb was reported by Hirano and colleagues to cause the complete regression of 
established 4T1 tumors (163). Therefore, in light of the high bacterial tumor colonization 
that we observed in this model, we sought to replicate this efficacy with αPD-L1 scFv-
secreting S. Typhimurium instead of αPD-L1 mAb. As a positive control for efficacy, one 
group was treated with the same αPD-L1 and αCD137 mAb treatment regimen used by 
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Hirano and colleagues. In these experiments, we were unable to reproduce the efficacy 
that was reported for 4T1 tumor-bearing mice given the mAb treatment, as tumors in 
these mice continued to grow similarly to those in other treatment groups. Therefore, it 
was difficult to draw conclusions about the comparable in vivo function of the bacterially 
delivered αPD-L1 scFv. Future experiments in a tumor model that is known to respond to 
checkpoint blockade in which bacterial colonization would be expected, such as MB49 
bladder cancer for αCTLA-4 (188) and B16 melanoma treated in combination with 
adoptive transfer of IFNα-stimulated T-cells for αPD-L1 (189), would provide a proof of 
principle for bacterially delivered checkpoint-blocking scFvs functioning comparably to 
systemic mAb administration. 
 
Combination of immune checkpoint-blocking scFvs with direct immunostimulatory agents 
 As outlined in the Introduction chapter, multiple immunotherapeutic agents used 
in combination have demonstrated greater anti-tumor efficacy than the agents used 
individually, but this strategy is also associated with greater toxicities. One of the 
benefits of tumor-specific bacterial delivery is the theoretical potential to deliver a 
cocktail of stimulatory agents specifically to the tumor microenvironment, thereby 
avoiding the adverse effects that may result from the combinatorial systemic 
administration. Ultimately, our goal is to combine multiple immune checkpoint-blocking 
scFvs with direct immunostimulatory molecules such as cytokines. Our lab has 
experience treating mice with S. Typhimurium expressing recombinant IL-2 (121-125). 
Since then, subsequent cytokines of even greater anti-tumor interest have been 
characterized, such as IL-15. Both IL-2 and IL-15 require three receptor molecules 
working in concert for optimal signaling. Both molecules share two receptors, the 
common γ chain and IL-2Rβ. The third receptor, IL-2Rα (aka CD25) for IL-2 and IL-15Rα 
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for IL-15, is largely responsible for the cytokines’ unique functions. The α receptors are 
expressed on the surface of different cellular subsets at different stages of an immune 
response. IL-2Rα and IL15rα are both expressed on activated effector T-cells, but IL-
2Rβ is also constitutively expressed at relatively high levels on T-regs, while IL15rα is 
constitutively found on memory T-cells. While both cytokines assist in effector T-cell 
function, this α receptor expression pattern makes IL-2 important for the development 
and maintenance of T-regs and IL-15 important for the maintenance of immunological 
memory. The T-reg-promoting effect of IL-2 lessens its potential as a cancer 
immunotherapy, whereas the memory-promoting effects of IL-15 make it a more 
attractive alternative to IL-2 (190). It has also been demonstrated that IL-15 administered 
in a complex covalently bound to its IL-15rα (IL-15/IL15Rα) greatly improves its CD8 T-
cell stimulatory effects compared to purified IL-15 alone, by removing the requirement of 
IL15rα expression for its activity (191, 192). We have generated recombinant strains that 
express and secrete functional murine cytokines such as IL-2 (DSpIL2-Hly) and an IL-
15/IL-15Rα fusion protein (DSpIL15-Hly) via the hemolysin system. Both molecules are 
functional when secreted from attenuated S. Typhimurium, and the IL-15/IL-15Rα fusion 
protein isolated from bacterial cultures is actually greater than 100-fold more biologically 
active than purified recombinant mouse IL-15 (Figure 5-1). Future experiments 
investigating the efficacy of these strains alone and in combination with checkpoint-
blocking strains are currently planned or underway. 
 
Systemic versus tumor-specific effects of S. Typhimurium treatment 
 An interesting observation that may warrant further investigation is the efficacious 
effect of S. Typhimurium treatment in K7M2 ostosarcoma and BALB-neuT breast cancer 
in the absence of tumor targeting. We suspect this efficacy is due to a systemic 
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immunostimulation in response to the initial bacterial dissemination, probably not unlike 
that which William Coley observed with his toxins several years ago (See Introduction 
pages 15-16). When examining the recent existing bacterial cancer therapy literature 
(reviewed in (94)), the efficacy observed is most often associated with bacterial tumor 
targeting; however as discussed, most of these reports utilize subcutaneous transplant 
tumor models, in which tumor colonization is almost always present. Therefore the 
observations in these experiments cannot be differentiated into systemic effects and 
tumor-targeted effects. The BALB-neuT model and luminescent S. Typhimurium strains 
may be useful tools to elucidate these differences. Using the BALB-neuT model, 
immunological changes and growth or reduction of four different “types” of tumors could 
be investigated: 1) colonized tumors in treated mice, 2) uncolonized tumors in treated 
mice in which other tumors are colonized, 3) uncolonized tumors in treated mice in which 
no tumors are colonized, and 4) tumors in untreated mice. These groups could 
potentially address questions regarding: 1) the tumor colonization-specific effects of S. 
Typhimurium treatment, 2) the off-target or immunological memory effects on 
uncolonized tumors when other tumors are targeted (differentiated based on tumor 
radiance) and 3) the systemic effects of S. Typhimurium treatment on tumor growth 
independent of tumor targeting. Chapter 4 of this thesis begins to compare these groups 
(Figure 4-7), but a more exhaustive investigation may help interpret the results of 
existing literature in this field and thereby increase our understanding of bacterial cancer 
therapy.  
 
Investigate the tumor-targeting and efficacious effects of S. Typhimurium in other 
autochthonous models 
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 We observed differences in bacterial tumor targeting between autochthonous 
tumors and transplanted tumors, and we suspect this was due to differences in 
vasculature and necrosis patterns in these tumors. However, it may be premature to 
generalize these results to autochthonous and transplant tumor models. The 
requirement of VDA treatment for tumor colonization in the BALB-neuT model may be 
unique to that model and not representative of other autochthonous models or human 
tumors. Therefore further validation of these results in other preclinical autochthonous 
cancer models is needed. The Department of Surgery at the University of Minnesota has 
available genetically engineered KPC mice that spontaneously develop p53-, kras-driven 
pancreatic cancer. A non-oncogene driven autochthonous model, such as 3-
methylcholanthrene-induced sarcoma, could be used as well. Testing our strains in 
these autochthonous models and comparing colonization and efficacy to the 
corresponding transplant models would substantiate the targeting differences between 
autochthonous and transplanted tumors and the colonization-enhancing effects of VDA 
treatment.  
 
Additional considerations  
Immune response generated against recombinant scFvs 
We may find that mice develop immunity and antibody titers against the chicken-
derived scFvs, which would lower their half-life in vivo. This possibility may be significant 
since they are being delivered by a highly immunostimulatory bacterium that may act as 
an adjuvant. The immunogenicity of the scFvs could be reduced by removing the 
purification tags (hemagglutinin and poly-histidine) from their sequences. Additionally, 
the scFvs could be “mouseized” by substituting the framework regions of the scFv 
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variable regions with those from mouse immunoglobulin. This strategy also may be 
necessary for the eventual humanization of the proteins before any clinical applications.  
 
The functional concentration of immunostimulatory agents delivered by S. Typhimurium 
 The potential of S. Typhimurium to deliver therapeutic proteins specifically to the 
tumor environment assumes that the delivered proteins will accumulate within tumor 
tissues to therapeutic concentrations. We may find that bacterially delivered cytokines or 
antagonistic scFvs do not reach high enough concentrations in the tumor immune 
microenvironment to have a significant effect. One way to overcome this pitfall would be 
to continue to improve bacterial tumor targeting, as there is a correlation between CFU/g 
of tumor tissue and recombinant protein/g of tumor tissue in colonized tumors (Figure 5-
2). Chapter 4 of this thesis reported methods to increase the levels of tumor colonization, 
and continuing investigations to further improve colonization are underway, which in turn 
should increase the concentrations of therapeutic proteins in the tumors. We have 
noticed additional enhancement in the degree of tumor colonization when bacterial 
doses are pushed to higher levels (Figure 5-3); however this also increases the acute 
toxicity of the treatment (data not shown). Recent experiments to address toxicity 
included supplementing mouse food with the anti-inflammatory drug celecoxib in addition 
to treating the mice with anti-IL-6 mAb; these treatments seemed to reduce toxicity (data 
not shown), illustrating a balancing act between increased bacterial dosing and toxicity. 
Further dosing and toxicity studies will continue to optimize the targeting of 
autochthonous tumors in order to deliver higher concentrations of therapeutic proteins. 
Additionally, other strategies, such as radiation therapy, may condition tumors for 
improved bacterial colonization. 
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 The effective concentration of anti-immune checkpoint scFvs will likely depend 
on how much of their antigen is expressed in different tumor tissues. If tumor 
colonization and recombinant protein expression limit is reached, and this is still 
inadequate for a functional therapeutic response, an alternative approach would be to 
concentrate on the development of strains that secrete stimulatory agents that require 
lower functional concentrations. One candidate is the immunostimulatory cytokine IL-12, 
which is biologically active at low picomolar concentrations (193), which would be 
relatively easy to achieve using S. Typhimurium. This cytokine is also a great candidate 
for bacterial expression because, despite its beneficial effects for cancer immunity, its 
systemic administration was found to be to be prohibitively toxic in humans (64). 
 
Summary and conclusions 
 In this thesis, the potential of S. Typhimurium as a tumor-targeting 
immunotherapy vector was investigated. To this end, functional antagonistic single chain 
antibodies against CTLA-4 (αCTLA-4 scFv) and PD-L1 (αPD-L1 scFv) were isolated 
from an immunized chicken library and engineered for secretion from S. Typhimurium. 
The inherent anti-tumor properties and tumor-targeting capability of S. Typhimurium 
were then investigated in transplanted primary and metastatic tumor models as well as 
in a genetically engineered autochthonous BALB-neuT breast cancer model. In each 
model tested, S. Typhimurium demonstrated native anti-tumor efficacy; however it did 
not adequately colonize autochthonous tumors, reflecting the lack of human tumor 
colonization reported in clinical studies. Disruption of tumor vasculature by treating 
BALB-neuT mice with the VDA CA4P improved the bacterial targeting of autochthonous 
tumors to levels similar to those observed for transplanted tumors. Subsequent 
comparison of the tumor targeting capability and efficacy of S. Typhimurium engineered 
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to secrete αPD-L1 scFv versus a control strain showed that αPD-L1 scFv secretion may 
further improve the colonization of autochthonous tumors, leading to a greater reduction 
in tumor burden of treated mice. 
 Several conclusions can be drawn from this work. First, the genetic manipulability 
of S. Typhimurium makes it capable of expressing and secreting single chain antibody 
fragments that block CTLA-4 and PD-L1 signaling. This provides a proof of principle that 
would likely be true of scFvs sequences specific to any target of interest and illustrates 
S. Typhimurium’s potential as an immunotherapy vector. Second, S. Typhimurium 
displays native tumoricidal activity independent of any recombinant protein expression. 
This activity is likely due to systemic immunostimulatory effects of the bacterium and is 
observable in many different cancer models. Third, while readily targeting transplanted 
tumors, S. Typhimurium did not by itself target more clinically representative 
autochthonous tumors, suggesting that subsequent bacterial tumor colonization studies 
should be performed in autochthonous models or other models that more accurately 
mimic the results reported in human trials. Fourth, disruption of tumor vasculature with 
CA4P improved the bacterial targeting of autochthonous tumors, illustrating the potential 
of this VDA-assisted approach for targeting human tumors. And finally, expression and 
secretion of recombinant proteins such as αPD-L1 scFv, may affect S. Typhimurium’s 
tumor colonization and in vivo viability, which may improve its effectiveness for cancer 
therapy. Taken together, these conclusions support the hypothesis that S. Typhimurium 
is a promising tumor targeting immunotherapy vector. 
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Figure 5-1: IL-15/IL-15ra fusion protein expressed in S. Typhimurium 
demonstrates improved bioactivity over IL-15. 
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Figure 5-1: IL-15/IL-15ra fusion protein expressed in S. Typhimurium 
demonstrates improved bioactivity over IL-15. IL-15/IL-15Ra expressed in S. 
Typhimurium was compared to purified recombinant mouse IL-15 for its ability to 
induce the proliferation of the IL-2/IL-15 growth dependent CTLL-2 cells. CTLL-2 cells 
maintained in RPMI supplemented with 10% FBS and T-STIMTM T-cell supplement 
were harvested at log-phase growth at >90% viability, washed 2x with PBS and 1x 
with RPMI (with no T-STIM). Cells were counted and suspended in RPMI at 4×105 
cells/ml. The cell suspension was added to individual wells of a 96-well plate at 50µL 
per well followed by 50µl of a SalpIL-15/Rα protein preparation. Recombinant mouse 
IL-15 standard was added to protein similarly prepared from S. Typhimurium control 
culture for comparison. Cells were incubated at 37°C, 5% CO2 for 44 hours. Alamar 
blue dye (Life Technologies) was diluted to 30% in RPMI medium, and 50ul of this 
solution was added to experimental wells for a 10% final concentration. Plates were 
incubated for an additional 4 hours at 37°C, 5% CO2. Following incubation, plates 
were measured for “specific absorbance,” calculated by: Absorbance570nm – 
Absorbance600nm. A separate IL-15 ELISA was performed on bacterial cultures to 
determine the concentration of IL15/IL-15Ra added to each well.  
Cloning of the IL-15/IL-15Rα strain and biological activity experiments were 
performed by Michael Mertensotto (Research Scientist, Dept. of Surgery, University 
of Minnesota). 
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Figure 5-2: S. Typhimurium tissue colonization correlates with secreted scFv 
concentration. 
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Figure 5-2: S. Typhimurium tissue colonization correlates with secreted scFv 
concentration. BALB-neuT tumors (open diamonds), 4T1 tumors (filled diamonds), 
and spleens (filled circles) were harvested from mice 5-7 days after treatment with 
DSpαPDL1-Hly. Tissues were homogenized and plated for CFU determination as 
previously described (Chapter 4). In addition, supernatants from tissue homogenates 
were diluted and added to plates coated with recombinant PD-L1-Fc protein, and 
incubated for 120 minutes at room temperature. Bound αPD-L1 scFv was detected 
using an anti-6xHisTag/HRP conjugate and visualized with OptEIATM HRP substrate 
(BD). Absorbance at 450 nm was corrected for background by subtracting the 
absorbance at 570 nm. Values were then fitted to a standard curve of purified αPD-
L1-scFv and used to calculate scFv tissue concentration in ng of scFv/g of tissue. 
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Figure 5-3: Increased bacterial dosing increases tumor colonization. 
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Figure 5-3: Increased bacterial dosing increases tumor colonization. BALB-
neuT mice bearing multiple tumors ranging from 30-200mm3 were treated with 
CA4P and anti-IL-6 mAb as illustrated in Figure 4-3C and a combination of four 
recombinant luminescent S. Typhimurium strains (DSpαPDL1-Hly-lux, 
DSpαCTLA-4-Hly-lux, DSpIL-2-Hly, and DSpIL-15/Rα-Hly). The indicated CFU is 
the total number of bacteria, split evenly between the four strains and 
administered as two doses 3 hours apart as in Figure 4-3C. Tumor radiance was 
measured four or five days post-treatment.  
Experiments shown in panel (B) were performed by Michael Mertensotto 
(Research Scientist, Dept. of Surgery, University of Minnesota). 
 
  
159 
REFERENCES 
 
1. Hanahan D (2014) Rethinking the war on cancer. Lancet 383(9916):558-563. 
2. Dunn GP, Old LJ, & Schreiber RD (2004) The three Es of cancer immunoediting. 
Annu. Rev. Immunol. 22:329-360. 
3. Ehrlich P (1909) Beiträge zur experimentellen Pathologie und Chemotherapie 
(Akademische Verlagsgesellschaft, Leipzig,) pp vii p., 2 l., 3 -247 p. 
4. Lawrence HS (1959) Cellular and humoral aspects of the hypersensitive states; a 
symposium held at the New York Academy of Medicine (P.B. Hoeber, New 
York,) pp xii, 667 p. 
5. Burnet FM (1970) The concept of immunological surveillance. Prog. Exp. Tumor 
Res. 13:1-27. 
6. Grulich AE, van Leeuwen MT, Falster MO, & Vajdic CM (2007) Incidence of 
cancers in people with HIV/AIDS compared with immunosuppressed transplant 
recipients: a meta-analysis. Lancet 370(9581):59-67. 
7. Sternlicht MD & Werb Z (2001) How matrix metalloproteinases regulate cell 
behavior. Annu. Rev. Cell Dev. Biol. 17:463-516. 
8. Vicari AP & Caux C (2002) Chemokines in cancer. Cytokine Growth Factor Rev. 
13(2):143-154. 
9. Benlagha K & Bendelac A (2000) CD1d-restricted mouse V alpha 14 and human 
V alpha 24 T cells: lymphocytes of innate immunity. Semin. Immunol. 12(6):537-
542. 
10. Bancroft GJ, Schreiber RD, & Unanue ER (1991) Natural immunity: a T-cell-
independent pathway of macrophage activation, defined in the scid mouse. 
Immunol. Rev. 124:5-24. 
11. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, & Darnell JE, Jr. (1996) 
Transcriptionally active Stat1 is required for the antiproliferative effects of both 
interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. U. S. A. 
93(15):7673-7678. 
12. Kumar A, Commane M, Flickinger TW, Horvath CM, & Stark GR (1997) Defective 
TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of 
caspases. Science 278(5343):1630-1632. 
13. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, 
Wysocka M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G, & Lee WM 
(1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to 
IL-12 therapy and antiangiogenesis. Immunity 9(1):25-34. 
14. Qin Z & Blankenstein T (2000) CD4+ T cell--mediated tumor rejection involves 
inhibition of angiogenesis that is dependent on IFN gamma receptor expression 
by nonhematopoietic cells. Immunity 12(6):677-686. 
15. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, 
Iwakura Y, Yagita H, & Okumura K (2001) Involvement of tumor necrosis factor-
related apoptosis-inducing ligand in surveillance of tumor metastasis by liver 
natural killer cells. Nat. Med. 7(1):94-100. 
16. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, 
& Okumura K (2001) Tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) contributes to interferon gamma-dependent natural killer cell protection 
from tumor metastasis. J. Exp. Med. 193(6):661-670. 
  
160 
17. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, & Trinchieri G 
(2002) Reciprocal activating interaction between natural killer cells and dendritic 
cells. J. Exp. Med. 195(3):327-333. 
18. Srivastava P (2002) Interaction of heat shock proteins with peptides and antigen 
presenting cells: chaperoning of the innate and adaptive immune responses. 
Annu. Rev. Immunol. 20:395-425. 
19. Murshid A, Gong J, & Calderwood SK (2012) The role of heat shock proteins in 
antigen cross presentation. Frontiers in immunology 3:63. 
20. MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, 
Lanzavecchia A, & Sallusto F (2003) Regulation of dendritic cell migration to the 
draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 
198(4):615-621. 
21. Sallusto F, Mackay CR, & Lanzavecchia A (2000) The role of chemokine 
receptors in primary, effector, and memory immune responses. Annu. Rev. 
Immunol. 18:593-620. 
22. Albert ML, Sauter B, & Bhardwaj N (1998) Dendritic cells acquire antigen from 
apoptotic cells and induce class I-restricted CTLs. Nature 392(6671):86-89. 
23. Yu P, Spiotto MT, Lee Y, Schreiber H, & Fu YX (2003) Complementary role of 
CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor 
antigen to CD8+ T cells. J. Exp. Med. 197(8):985-995. 
24. Cavallo F, De Giovanni C, Nanni P, Forni G, & Lollini PL (2011) 2011: the 
immune hallmarks of cancer. Cancer Immunol. Immunother. 60(3):319-326. 
25. Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 
144(5):646-674. 
26. Garcia-Lora A, Algarra I, & Garrido F (2003) MHC class I antigens, immune 
surveillance, and tumor immune escape. J. Cell. Physiol. 195(3):346-355. 
27. Seliger B (2008) Molecular mechanisms of MHC class I abnormalities and APM 
components in human tumors. Cancer Immunol. Immunother. 57(11):1719-1726. 
28. Colombo MP & Piconese S (2007) Regulatory-T-cell inhibition versus depletion: 
the right choice in cancer immunotherapy. Nat. Rev. Cancer 7(11):880-887. 
29. Facciabene A, Motz GT, & Coukos G (2012) T-regulatory cells: key players in 
tumor immune escape and angiogenesis. Cancer Res. 72(9):2162-2171. 
30. Noy R & Pollard JW (2014) Tumor-associated macrophages: from mechanisms 
to therapy. Immunity 41(1):49-61. 
31. Nucera S, Biziato D, & De Palma M (2011) The interplay between macrophages 
and angiogenesis in development, tissue injury and regeneration. Int. J. Dev. 
Biol. 55(4-5):495-503. 
32. Quail DF & Joyce JA (2013) Microenvironmental regulation of tumor progression 
and metastasis. Nat. Med. 19(11):1423-1437. 
33. Bonde AK, Tischler V, Kumar S, Soltermann A, & Schwendener RA (2012) 
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid 
tumors. BMC Cancer 12:35. 
34. Brown D, Trowsdale J, & Allen R (2004) The LILR family: modulators of innate 
and adaptive immune pathways in health and disease. Tissue Antigens 
64(3):215-225. 
35. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, & 
Chouaib S (2014) PD-L1 is a novel direct target of HIF-1alpha, and its blockade 
under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 
211(5):781-790. 
  
161 
36. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan 
M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, 
Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, & Zou W (2004) 
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune 
privilege and predicts reduced survival. Nat. Med. 10(9):942-949. 
37. Savage ND, de Boer T, Walburg KV, Joosten SA, van Meijgaarden K, Geluk A, & 
Ottenhoff TH (2008) Human anti-inflammatory macrophages induce Foxp3+ 
GITR+ CD25+ regulatory T cells, which suppress via membrane-bound 
TGFbeta-1. J. Immunol. 181(3):2220-2226. 
38. Daurkin I, Eruslanov E, Stoffs T, Perrin GQ, Algood C, Gilbert SM, Rosser CJ, Su 
LM, Vieweg J, & Kusmartsev S (2011) Tumor-associated macrophages mediate 
immunosuppression in the renal cancer microenvironment by activating the 15-
lipoxygenase-2 pathway. Cancer Res. 71(20):6400-6409. 
39. Oh SA & Li MO (2013) TGF-beta: guardian of T cell function. J. Immunol. 
191(8):3973-3979. 
40. Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, & Wraith DC (2013) 
Regulation of adaptive immunity; the role of interleukin-10. Frontiers in 
immunology 4:129. 
41. Sica A & Mantovani A (2012) Macrophage plasticity and polarization: in vivo 
veritas. J. Clin. Invest. 122(3):787-795. 
42. Gabrilovich DI, Ostrand-Rosenberg S, & Bronte V (2012) Coordinated regulation 
of myeloid cells by tumours. Nat. Rev. Immunol. 12(4):253-268. 
43. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich 
M, Winkels G, Traggiai E, Casati A, Grassi F, & Bronte V (2010) Hierarchy of 
immunosuppressive strength among myeloid-derived suppressor cell subsets is 
determined by GM-CSF. Eur. J. Immunol. 40(1):22-35. 
44. Youn JI, Nagaraj S, Collazo M, & Gabrilovich DI (2008) Subsets of myeloid-
derived suppressor cells in tumor-bearing mice. J. Immunol. 181(8):5791-5802. 
45. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, 
Beschin A, De Baetselier P, & Van Ginderachter JA (2008) Identification of 
discrete tumor-induced myeloid-derived suppressor cell subpopulations with 
distinct T cell-suppressive activity. Blood 111(8):4233-4244. 
46. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado 
A, Correa P, Brayer J, Sotomayor EM, Antonia S, Ochoa JB, & Ochoa AC (2004) 
Arginase I production in the tumor microenvironment by mature myeloid cells 
inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer 
Res. 64(16):5839-5849. 
47. Srivastava MK, Sinha P, Clements VK, Rodriguez P, & Ostrand-Rosenberg S 
(2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting 
cystine and cysteine. Cancer Res. 70(1):68-77. 
48. Schmielau J & Finn OJ (2001) Activated granulocytes and granulocyte-derived 
hydrogen peroxide are the underlying mechanism of suppression of t-cell 
function in advanced cancer patients. Cancer Res. 61(12):4756-4760. 
49. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, 
& Segal DM (2002) Myeloid suppressor lines inhibit T cell responses by an NO-
dependent mechanism. J. Immunol. 168(2):689-695. 
50. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, 
Schneck J, & Gabrilovich DI (2007) Altered recognition of antigen is a 
mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13(7):828-835. 
  
162 
51. Hanson EM, Clements VK, Sinha P, Ilkovitch D, & Ostrand-Rosenberg S (2009) 
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ 
and CD8+ T cells. J. Immunol. 183(2):937-944. 
52. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, Divino CM, & Chen SH 
(2010) Immune stimulatory receptor CD40 is required for T-cell suppression and 
T regulatory cell activation mediated by myeloid-derived suppressor cells in 
cancer. Cancer Res. 70(1):99-108. 
53. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, & Chen SH 
(2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the 
development of tumor-induced T regulatory cells and T-cell anergy in tumor-
bearing host. Cancer Res. 66(2):1123-1131. 
54. Serafini P, Mgebroff S, Noonan K, & Borrello I (2008) Myeloid-derived 
suppressor cells promote cross-tolerance in B-cell lymphoma by expanding 
regulatory T cells. Cancer Res. 68(13):5439-5449. 
55. Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, & Korangy F (2011) 
Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of 
myeloid cells. Blood 117(24):6532-6541. 
56. Fife BT & Bluestone JA (2008) Control of peripheral T-cell tolerance and 
autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224:166-182. 
57. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura 
T, & Sakaguchi S (2008) CTLA-4 control over Foxp3+ regulatory T cell function. 
Science 322(5899):271-275. 
58. Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, Appleby M, Der 
SD, Kang J, & Chambers CA (2009) CD4+ regulatory T cells require CTLA-4 for 
the maintenance of systemic tolerance. J. Exp. Med. 206(2):421-434. 
59. Chemnitz JM, Parry RV, Nichols KE, June CH, & Riley JL (2004) SHP-1 and 
SHP-2 associate with immunoreceptor tyrosine-based switch motif of 
programmed death 1 upon primary human T cell stimulation, but only receptor 
ligation prevents T cell activation. J. Immunol. 173(2):945-954. 
60. Zitvogel L & Kroemer G (2012) Targeting PD-1/PD-L1 interactions for cancer 
immunotherapy. Oncoimmunology 1(8):1223-1225. 
61. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat. 
Rev. Cancer 4(1):11-22. 
62. Steel JC, Waldmann TA, & Morris JC (2012) Interleukin-15 biology and its 
therapeutic implications in cancer. Trends Pharmacol. Sci. 33(1):35-41. 
63. Schwartz RN, Stover L, & Dutcher J (2002) Managing toxicities of high-dose 
interleukin-2. Oncology (Williston Park) 16(11 Suppl 13):11-20. 
64. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, 
Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, 
Tahara H, & Sherman ML (1997) Phase I evaluation of intravenous recombinant 
human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 
3(3):409-417. 
65. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, & Hersh 
E (2008) Phase I/II study of ipilimumab for patients with metastatic melanoma. J. 
Clin. Oncol. 26(36):5950-5956. 
66. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, 
Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh 
AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe 
C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol 
  
163 
GM, Hoos A, & Urba WJ (2010) Improved survival with ipilimumab in patients 
with metastatic melanoma. N. Engl. J. Med. 363(8):711-723. 
67. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, 
Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, 
Miller WH, Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen 
TT, Humphrey R, Hoos A, & Wolchok JD (2011) Ipilimumab plus dacarbazine for 
previously untreated metastatic melanoma. N. Engl. J. Med. 364(26):2517-2526. 
68. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, 
Levy C, Allen T, Mavroukakis S, Lowy I, White DE, & Rosenberg SA (2007) 
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell 
cancer associated with enteritis and hypophysitis. J. Immunother. 30(8):825-830. 
69. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van 
Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo 
HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, & 
Gerritsen WR (2012) Combined immunotherapy with granulocyte-macrophage 
colony-stimulating factor-transduced allogeneic prostate cancer cells and 
ipilimumab in patients with metastatic castration-resistant prostate cancer: a 
phase 1 dose-escalation trial. Lancet Oncol. 13(5):509-517. 
70. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso 
P, Logothetis CJ, Allison JP, & Sharma P (2010) Preoperative CTLA-4 blockade: 
tolerability and immune monitoring in the setting of a presurgical clinical trial. 
Clin. Cancer Res. 16(10):2861-2871. 
71. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, 
Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, 
Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, & Dranoff G (2008) 
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-
associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. 
Sci. U. S. A. 105(8):3005-3010. 
72. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, 
Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton 
K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal 
S, Goldberg SM, Pardoll DM, Gupta A, & Wigginton JM (2012) Safety and activity 
of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 
366(26):2455-2465. 
73. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, 
Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, & Vogelzang NJ 
(2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic 
bladder cancer. Nature 515(7528):558-562. 
74. Sharma P & Allison JP (2015) The future of immune checkpoint therapy. Science 
348(6230):56-61. 
75. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, & Sharpe AH 
(1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan 
tissue destruction, revealing a critical negative regulatory role of CTLA-4. 
Immunity 3(5):541-547. 
76. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, 
Thompson CB, Griesser H, & Mak TW (1995) Lymphoproliferative disorders with 
early lethality in mice deficient in Ctla-4. Science 270(5238):985-988. 
77. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, & Allison JP (1997) Specific 
blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic 
  
164 
disease in an actively-induced model of experimental allergic encephalomyelitis. 
J. Neuroimmunol. 73(1-2):57-62. 
78. Perrin PJ, Maldonado JH, Davis TA, June CH, & Racke MK (1996) CTLA-4 
blockade enhances clinical disease and cytokine production during experimental 
allergic encephalomyelitis. J. Immunol. 157(4):1333-1336. 
79. Luhder F, Hoglund P, Allison JP, Benoist C, & Mathis D (1998) Cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of 
autoimmune diabetes. J. Exp. Med. 187(3):427-432. 
80. Weber JS, Kahler KC, & Hauschild A (2012) Management of immune-related 
adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 
30(21):2691-2697. 
81. Gelao L, Criscitiello C, Esposito A, Goldhirsch A, & Curigliano G (2014) Immune 
checkpoint blockade in cancer treatment: a double-edged sword cross-targeting 
the host as an "innocent bystander". Toxins 6(3):914-933. 
82. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, 
Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor 
D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, & 
Hodi FS (2015) Nivolumab and Ipilimumab versus Ipilimumab in Untreated 
Melanoma. N. Engl. J. Med. 
83. Callahan MK & Wolchok JD (2013) At the bedside: CTLA-4- and PD-1-blocking 
antibodies in cancer immunotherapy. J. Leukoc. Biol. 94(1):41-53. 
84. Robert C, Soria JC, & Eggermont AM (2013) Drug of the year: programmed 
death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. 
Eur. J. Cancer 49(14):2968-2971. 
85. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, 
Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, 
Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, 
Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald 
D, Kollia GD, Gupta A, Wigginton JM, & Sznol M (2012) Safety, activity, and 
immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 
366(26):2443-2454. 
86. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, 
Schadendorf D, Smylie M, Guthrie T, Jr., Grob JJ, Chesney J, Chin K, Chen K, 
Hoos A, O'Day SJ, & Lebbe C (2010) Ipilimumab monotherapy in patients with 
pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 
2, dose-ranging study. Lancet Oncol. 11(2):155-164. 
87. Yu P, Steel JC, Zhang M, Morris JC, & Waldmann TA (2010) Simultaneous 
blockade of multiple immune system inhibitory checkpoints enhances antitumor 
activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. 
Clin. Cancer Res. 16(24):6019-6028. 
88. Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, & Waldmann 
TA (2012) Simultaneous inhibition of two regulatory T-cell subsets enhanced 
Interleukin-15 efficacy in a prostate tumor model. Proc. Natl. Acad. Sci. U. S. A. 
109(16):6187-6192. 
89. Barbe S, Van Mellaert L, & Anne J (2006) The use of clostridial spores for cancer 
treatment. J. Appl. Microbiol. 101(3):571-578. 
90. Leschner S & Weiss S (2010) Salmonella-allies in the fight against cancer. J Mol 
Med (Berl) 88(8):763-773. 
  
165 
91. Coley WB (1991) The treatment of malignant tumors by repeated inoculations of 
erysipelas. With a report of ten original cases. 1893. Clin. Orthop. Relat. Res. 
(262):3-11. 
92. Bickels J, Kollender Y, Merinsky O, & Meller I (2002) Coley's toxin: historical 
perspective. Isr. Med. Assoc. J. 4(6):471-472. 
93. Hoption Cann SA, van Netten JP, & van Netten C (2003) Dr William Coley and 
tumour regression: a place in history or in the future. Postgrad. Med. J. 
79(938):672-680. 
94. Forbes NS (2010) Engineering the perfect (bacterial) cancer therapy. Nat. Rev. 
Cancer 10(11):785-794. 
95. Leschner S, Westphal K, Dietrich N, Viegas N, Jablonska J, Lyszkiewicz M, 
Lienenklaus S, Falk W, Gekara N, Loessner H, & Weiss S (2009) Tumor invasion 
of Salmonella enterica serovar Typhimurium is accompanied by strong 
hemorrhage promoted by TNF-alpha. PLoS ONE 4(8):e6692. 
96. Kasinskas RW & Forbes NS (2006) Salmonella typhimurium specifically 
chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol. 
Bioeng. 94(4):710-721. 
97. Kasinskas RW & Forbes NS (2007) Salmonella typhimurium lacking ribose 
chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res. 
67(7):3201-3209. 
98. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, Penman S, & Hoffman 
RM (2005) Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-
expressing Salmonella typhimurium. Proc. Natl. Acad. Sci. U. S. A. 102(3):755-
760. 
99. Sznol M, Lin SL, Bermudes D, Zheng LM, & King I (2000) Use of preferentially 
replicating bacteria for the treatment of cancer. J. Clin. Invest. 105(8):1027-1030. 
100. Jain RK (1998) The next frontier of molecular medicine: delivery of therapeutics. 
Nat. Med. 4(6):655-657. 
101. Dang LH, Bettegowda C, Huso DL, Kinzler KW, & Vogelstein B (2001) 
Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. 
Natl. Acad. Sci. U. S. A. 98(26):15155-15160. 
102. Hoffman RM & Zhao M (2014) Methods for the development of tumor-targeting 
bacteria. Expert opinion on drug discovery 9(7):741-750. 
103. Westphal K, Leschner S, Jablonska J, Loessner H, & Weiss S (2008) 
Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res. 
68(8):2952-2960. 
104. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, Goebel 
W, & Szalay AA (2004) Visualization of tumors and metastases in live animals 
with bacteria and vaccinia virus encoding light-emitting proteins. Nat. Biotechnol. 
22(3):313-320. 
105. Curtiss R, 3rd & Kelly SM (1987) Salmonella typhimurium deletion mutants 
lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and 
immunogenic. Infect. Immun. 55(12):3035-3043. 
106. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, 
Chakraborty A, Fischer J, Lin SL, Luo X, Miller SI, Zheng L, King I, Pawelek JM, 
& Bermudes D (1999) Lipid A mutant Salmonella with suppressed virulence and 
TNFalpha induction retain tumor-targeting in vivo. Nat. Biotechnol. 17(1):37-41. 
107. Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, 
Cahill A, Clairmont C, & Sznol M (2003) Pilot trial of genetically modified, 
  
166 
attenuated Salmonella expressing the E. coli cytosine deaminase gene in 
refractory cancer patients. Cancer Gene Ther. 10(10):737-744. 
108. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry 
RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, 
Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, & Rosenberg SA (2002) 
Phase I study of the intravenous administration of attenuated Salmonella 
typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20(1):142-152. 
109. Heimann DM & Rosenberg SA (2003) Continuous intravenous administration of 
live genetically modified Salmonella typhimurium in patients with metastatic 
melanoma. J. Immunother. 26(2):179-180. 
110. Zhang M, Swofford CA, & Forbes NS (2014) Lipid A controls the robustness of 
intratumoral accumulation of attenuated Salmonella in mice. Int. J. Cancer 
135(3):647-657. 
111. Lee JC, Kim DC, Gee MS, Saunders HM, Sehgal CM, Feldman MD, Ross SR, & 
Lee WM (2002) Interleukin-12 inhibits angiogenesis and growth of transplanted 
but not in situ mouse mammary tumor virus-induced mammary carcinomas. 
Cancer Res. 62(3):747-755. 
112. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, 
Yancopoulos GD, & Wiegand SJ (1999) Vessel cooption, regression, and growth 
in tumors mediated by angiopoietins and VEGF. Science 284(5422):1994-1998. 
113. Benjamin LE, Hemo I, & Keshet E (1998) A plasticity window for blood vessel 
remodelling is defined by pericyte coverage of the preformed endothelial network 
and is regulated by PDGF-B and VEGF. Development 125(9):1591-1598. 
114. Benjamin LE, Golijanin D, Itin A, Pode D, & Keshet E (1999) Selective ablation of 
immature blood vessels in established human tumors follows vascular 
endothelial growth factor withdrawal. J. Clin. Invest. 103(2):159-165. 
115. Hill SA, Chaplin DJ, Lewis G, & Tozer GM (2002) Schedule dependence of 
combretastatin A4 phosphate in transplanted and spontaneous tumour models. 
Int. J. Cancer 102(1):70-74. 
116. Schreiber K, Rowley DA, Riethmuller G, & Schreiber H (2006) Cancer 
immunotherapy and preclinical studies: Why we are not wasting our time with 
animal experiments. Hematology-Oncology Clinics of North America 20(3):567-
584. 
117. Falk P (1982) Differences in vascular pattern between the spontaneous and the 
transplanted C3H mouse mammary carcinoma. Eur. J. Cancer Clin. Oncol. 
18(2):155-165. 
118. Yu YA, Zhang Q, & Szalay AA (2008) Establishment and characterization of 
conditions required for tumor colonization by intravenously delivered bacteria. 
Biotechnol. Bioeng. 100(3):567-578. 
119. DuPage M & Jacks T (2013) Genetically engineered mouse models of cancer 
reveal new insights about the antitumor immune response. Curr. Opin. Immunol. 
25(2):192-199. 
120. Garbe AI, Vermeer B, Gamrekelashvili J, von Wasielewski R, Greten FR, 
Westendorf AM, Buer J, Schmid RM, Manns MP, Korangy F, & Greten TF (2006) 
Genetically induced pancreatic adenocarcinoma is highly immunogenic and 
causes spontaneous tumor-specific immune responses. Cancer Res. 66(1):508-
516. 
  
167 
121. Barnett SJ, Soto LJ, 3rd, Sorenson BS, Nelson BW, Leonard AS, & Saltzman DA 
(2005) Attenuated Salmonella typhimurium invades and decreases tumor burden 
in neuroblastoma. J. Pediatr. Surg. 40(6):993-997; discussion 997-998. 
122. Sorenson BS, Banton KL, Frykman NL, Leonard AS, & Saltzman DA (2008) 
Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary 
metastases in murine osteosarcoma. Clin. Orthop. Relat. Res. 466(6):1285-1291. 
123. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Vigdorovich V, Kelly SM, Curtiss 
R, 3rd, Leonard AS, & Anderson PM (1997) Antitumor mechanisms of attenuated 
Salmonella typhimurium containing the gene for human interleukin-2: a novel 
antitumor agent? J. Pediatr. Surg. 32(2):301-306. 
124. Feltis BA, Miller JS, Sahar DA, Kim AS, Saltzman DA, Leonard AS, Wells CL, & 
Sielaff TD (2002) Liver and circulating NK1.1(+)CD3(-) cells are increased in 
infection with attenuated Salmonella typhimurium and are associated with 
reduced tumor in murine liver cancer. J. Surg. Res. 107(1):101-107. 
125. Soto LJ, 3rd, Sorenson BS, Kim AS, Feltis BA, Leonard AS, & Saltzman DA 
(2003) Attenuated Salmonella typhimurium prevents the establishment of 
unresectable hepatic metastases and improves survival in a murine model. J. 
Pediatr. Surg. 38(7):1075-1079. 
126. Peterson E, Owens SM, & Henry RL (2006) Monoclonal antibody form and 
function: manufacturing the right antibodies for treating drug abuse. AAPS J. 
8(2):E383-390. 
127. Persson J, Beyer I, Yumul R, Li Z, Kiem HP, Roffler S, & Lieber A (2011) 
Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse 
tumor models. PLoS ONE 6(7):e22303. 
128. Tuve S, Chen BM, Liu Y, Cheng TL, Toure P, Sow PS, Feng Q, Kiviat N, Strauss 
R, Ni S, Li ZY, Roffler SR, & Lieber A (2007) Combination of tumor site-located 
CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion 
induces tumor-destructive immune responses. Cancer Res. 67(12):5929-5939. 
129. Rothlisberger D, Honegger A, & Pluckthun A (2005) Domain interactions in the 
Fab fragment: a comparative evaluation of the single-chain Fv and Fab format 
engineered with variable domains of different stability. J. Mol. Biol. 347(4):773-
789. 
130. Finlay WJ, Bloom L, & Cunningham O (2011) Phage display: a powerful 
technology for the generation of high specificity affinity reagents from alternative 
immune sources. Methods Mol. Biol. 681:87-101. 
131. McCormack WT, Tjoelker LW, & Thompson CB (1993) Immunoglobulin gene 
diversification by gene conversion. Prog. Nucleic Acid Res. Mol. Biol. 45:27-45. 
132. Finlay WJ, deVore NC, Dobrovolskaia EN, Gam A, Goodyear CS, & Slater JE 
(2005) Exploiting the avian immunoglobulin system to simplify the generation of 
recombinant antibodies to allergenic proteins. Clin. Exp. Allergy 35(8):1040-1048. 
133. Chiliza TE, Van Wyngaardt W, & Du Plessis DH (2008) Single-chain antibody 
fragments from a display library derived from chickens immunized with a mixture 
of parasite and viral antigens. Hybridoma (Larchmt) 27(6):413-421. 
134. Hof D, Hoeke MO, & Raats JM (2008) Multiple-antigen immunization of chickens 
facilitates the generation of recombinant antibodies to autoantigens. Clin. Exp. 
Immunol. 151(2):367-377. 
135. Finlay WJ, Bloom L, & Cunningham O (2011) Optimized generation of high-
affinity, high-specificity single-chain Fv antibodies from multiantigen immunized 
chickens. Methods Mol. Biol. 681:383-401. 
  
168 
136. Galan JE, Nakayama K, & Curtiss R, 3rd (1990) Cloning and characterization of 
the asd gene of Salmonella typhimurium: use in stable maintenance of 
recombinant plasmids in Salmonella vaccine strains. Gene 94(1):29-35. 
137. Datsenko KA & Wanner BL (2000) One-step inactivation of chromosomal genes 
in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 
97(12):6640-6645. 
138. Andris-Widhopf J, Rader C, Steinberger P, Fuller R, & Barbas CF, 3rd (2000) 
Methods for the generation of chicken monoclonal antibody fragments by phage 
display. J. Immunol. Methods 242(1-2):159-181. 
139. Brosius J, Erfle M, & Storella J (1985) Spacing of the -10 and -35 regions in the 
tac promoter. Effect on its in vivo activity. J. Biol. Chem. 260(6):3539-3541. 
140. de Marco A (2009) Strategies for successful recombinant expression of disulfide 
bond-dependent proteins in Escherichia coli. Microb Cell Fact 8:26. 
141. Schaefer JV & Pluckthun A (2010) Improving Expression of scFv Fragments by 
Co-expression of Periplasmic Chaperones. Antibody Engineering, Vol 2, Second 
Edition:345-361. 
142. Gentschev I, Dietrich G, & Goebel W (2002) The E. coli alpha-hemolysin 
secretion system and its use in vaccine development. Trends Microbiol. 10(1):39-
45. 
143. Foote J & Eisen HN (1995) Kinetic and affinity limits on antibodies produced 
during immune responses. Proc. Natl. Acad. Sci. U. S. A. 92(5):1254-1256. 
144. Zhang X, Schwartz JC, Guo X, Bhatia S, Cao E, Lorenz M, Cammer M, Chen L, 
Zhang ZY, Edidin MA, Nathenson SG, & Almo SC (2004) Structural and 
functional analysis of the costimulatory receptor programmed death-1. Immunity 
20(3):337-347. 
145. Kumagai, Izumi, and Tsumoto, Kouhei (2010) Antigen–Antibody Binding. In: eLS. 
John Wiley & Sons Ltd, Chichester. http://www.els.net 
146. Worn A & Pluckthun A (2001) Stability engineering of antibody single-chain Fv 
fragments. J. Mol. Biol. 305(5):989-1010. 
147. Choi GH, Lee DH, Min WK, Cho YJ, Kweon DH, Son DH, Park K, & Seo JH 
(2004) Cloning, expression, and characterization of single-chain variable 
fragment antibody against mycotoxin deoxynivalenol in recombinant Escherichia 
coli. Protein Expr. Purif. 35(1):84-92. 
148. Lombardi A, Sperandei M, Cantale C, Giacomini P, & Galeffi P (2005) Functional 
expression of a single-chain antibody specific for the HER2 human oncogene in 
a bacterial reducing environment. Protein Expr. Purif. 44(1):10-15. 
149. Wang H, Liu X, He Y, Dong J, Sun Y, Liang Y, Yang J, Lei H, Shen Y, & Xu X 
(2010) Expression and purification of an anti-clenbuterol single chain Fv antibody 
in Escherichia coli. Protein Expr. Purif. 72(1):26-31. 
150. Lamberski JA, Thompson NE, & Burgess RR (2006) Expression and purification 
of a single-chain variable fragment antibody derived from a polyol-responsive 
monoclonal antibody. Protein Expr. Purif. 47(1):82-92. 
151. Chen LH, Huang Q, Wan L, Zeng LY, Li SF, Li YP, Lu XF, & Cheng JQ (2006) 
Expression, purification, and in vitro refolding of a humanized single-chain Fv 
antibody against human CTLA4 (CD152). Protein Expr. Purif. 46(2):495-502. 
152. Loeffler M, Le'Negrate G, Krajewska M, & Reed JC (2007) Attenuated 
Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. 
Proc. Natl. Acad. Sci. U. S. A. 104(31):12879-12883. 
  
169 
153. Lloyd SA, Sjostrom M, Andersson S, & Wolf-Watz H (2002) Molecular 
characterization of type III secretion signals via analysis of synthetic N-terminal 
amino acid sequences. Mol. Microbiol. 43(1):51-59. 
154. Dobo J, Varga J, Sajo R, Vegh BM, Gal P, Zavodszky P, & Vonderviszt F (2010) 
Application of a short, disordered N-terminal flagellin segment, a fully functional 
flagellar type III export signal, to expression of secreted proteins. Appl. Environ. 
Microbiol. 76(3):891-899. 
155. Zhang G, Brokx S, & Weiner JH (2006) Extracellular accumulation of 
recombinant proteins fused to the carrier protein YebF in Escherichia coli. Nat. 
Biotechnol. 24(1):100-104. 
156. Fernandez LA, Sola I, Enjuanes L, & de Lorenzo V (2000) Specific secretion of 
active single-chain Fv antibodies into the supernatants of Escherichia coli 
cultures by use of the hemolysin system. Appl. Environ. Microbiol. 66(11):5024-
5029. 
157. Hotz C, Fensterle J, Goebel W, Meyer SR, Kirchgraber G, Heisig M, Furer A, 
Dietrich G, Rapp UR, & Gentschev I (2009) Improvement of the live vaccine 
strain Salmonella enterica serovar Typhi Ty21a for antigen delivery via the 
hemolysin secretion system of Escherichia coli. Int. J. Med. Microbiol. 
299(2):109-119. 
158. Ferguson WS & Goorin AM (2001) Current treatment of osteosarcoma. Cancer 
Invest. 19(3):292-315. 
159. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, & Helman L (2000) An 
orthotopic model of murine osteosarcoma with clonally related variants differing 
in pulmonary metastatic potential. Clin. Exp. Metastasis 18(3):261-271. 
160. Pulaski BA & Ostrand-Rosenberg S (2001) Mouse 4T1 breast tumor model. Curr 
Protoc Immunol Chapter 20:Unit 20 22. 
161. Conti L, Ruiu R, Barutello G, Macagno M, Bandini S, Cavallo F, & Lanzardo S 
(2014) Microenvironment, oncoantigens, and antitumor vaccination: lessons 
learned from BALB-neuT mice. BioMed research international 2014:534969. 
162. Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, Qunaj L, 
Griffith TS, Vezys V, Barber DL, & Masopust D (2014) Intravascular staining for 
discrimination of vascular and tissue leukocytes. Nat. Protoc. 9(1):209-222. 
163. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, 
Lau JS, Zhu G, Tamada K, & Chen L (2005) Blockade of B7-H1 and PD-1 by 
monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 
65(3):1089-1096. 
164. Greifenberg V, Ribechini E, Rossner S, & Lutz MB (2009) Myeloid-derived 
suppressor cell activation by combined LPS and IFN-gamma treatment impairs 
DC development. Eur. J. Immunol. 39(10):2865-2876. 
165. Ray P, Arora M, Poe SL, & Ray A (2011) Lung myeloid-derived suppressor cells 
and regulation of inflammation. Immunol. Res. 50(2-3):153-158. 
166. Tam JW, Kullas AL, Mena P, Bliska JB, & van der Velden AW (2014) CD11b+ 
Ly6Chi Ly6G- immature myeloid cells recruited in response to Salmonella 
enterica serovar Typhimurium infection exhibit protective and 
immunosuppressive properties. Infect. Immun. 82(6):2606-2614. 
167. Langdon SP (2012) Animal modeling of cancer pathology and studying tumor 
response to therapy. Curr. Drug Targets 13(12):1535-1547. 
  
170 
168. Schreiber K, Rowley DA, Riethmuller G, & Schreiber H (2006) Cancer 
immunotherapy and preclinical studies: why we are not wasting our time with 
animal experiments. Hematol. Oncol. Clin. North Am. 20(3):567-584. 
169. Peters LJ & Hewitt HB (1974) The influence of fibrin formation on the 
transplantability of murine tumour cells: implications for the mechanism of the 
Revesz effect. Br. J. Cancer 29(4):279-291. 
170. Forbes NS (2010) Engineering the perfect (bacterial) cancer therapy. Nat. Rev. 
Cancer 10(11):785-794. 
171. Pawelek JM, Low KB, & Bermudes D (1997) Tumor-targeted Salmonella as a 
novel anticancer vector. Cancer Res. 57(20):4537-4544. 
172. Theys J, Landuyt W, Nuyts S, Van Mellaert L, Bosmans E, Rijnders A, Van Den 
Bogaert W, van Oosterom A, Anne J, & Lambin P (2001) Improvement of 
Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. 
FEMS Immunol. Med. Microbiol. 30(1):37-41. 
173. Hoiseth SK & Stocker BA (1981) Aromatic-dependent Salmonella typhimurium 
are non-virulent and effective as live vaccines. Nature 291(5812):238-239. 
174. Murray SR, Bermudes D, de Felipe KS, & Low KB (2001) Extragenic 
suppressors of growth defects in msbB Salmonella. J. Bacteriol. 183(19):5554-
5561. 
175. Drees J, Mertensotto M, Liu G, Panyam J, Leonard A, Augustin L, Schottel J, & 
Saltzman D (2015) Attenuated Salmonella enterica Typhimurium Reduces Tumor 
Burden in an Autochthonous Breast Cancer Model. Anticancer Res 35(2):843-
849. 
176. McKenzie GJ & Craig NL (2006) Fast, easy and efficient: site-specific insertion of 
transgenes into enterobacterial chromosomes using Tn7 without need for 
selection of the insertion event. BMC Microbiol. 6:39. 
177. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry 
RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, 
Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, & Rosenberg SA (2002) 
Phase I study of the intravenous administration of attenuated Salmonella 
typhimurium to patients with metastatic melanoma. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 20(1):142-152. 
178. Tome Y, Zhang Y, Momiyama M, Maehara H, Kanaya F, Tomita K, Tsuchiya H, 
Bouvet M, Hoffman RM, & Zhao M (2013) Primer dosing of S. typhimurium A1-R 
potentiates tumor-targeting and efficacy in immunocompetent mice. Anticancer 
Res. 33(1):97-102. 
179. Tozer GM, Kanthou C, & Baguley BC (2005) Disrupting tumour blood vessels. 
Nat. Rev. Cancer 5(6):423-435. 
180. Lee SJ, O'Donnell H, & McSorley SJ (2010) B7-H1 (programmed cell death 
ligand 1) is required for the development of multifunctional Th1 cells and 
immunity to primary, but not secondary, Salmonella infection. J. Immunol. 
185(4):2442-2449. 
181. Xu D, Fu HH, Obar JJ, Park JJ, Tamada K, Yagita H, & Lefrancois L (2013) A 
potential new pathway for PD-L1 costimulation of the CD8-T cell response to 
Listeria monocytogenes infection. PLoS ONE 8(2):e56539. 
182. Pulko V, Harris KJ, Liu X, Gibbons RM, Harrington SM, Krco CJ, Kwon ED, & 
Dong H (2011) B7-h1 expressed by activated CD8 T cells is essential for their 
survival. J. Immunol. 187(11):5606-5614. 
  
171 
183. O'Donnell H & McSorley SJ (2014) Salmonella as a model for non-cognate Th1 
cell stimulation. Frontiers in immunology 5:621. 
184. Terpe K (2006) Overview of bacterial expression systems for heterologous 
protein production: from molecular and biochemical fundamentals to commercial 
systems. Appl. Microbiol. Biotechnol. 72(2):211-222. 
185. Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, Vandecaveye V, 
Peeters R, Bosmans H, Hermans R, Marchal G, & Ni Y (2009) Treatment of 
rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic 
evaluation using multiparametric magnetic resonance imaging in correlation with 
microangiography and histology. Invest. Radiol. 44(1):44-53. 
186. Leschner S, Deyneko IV, Lienenklaus S, Wolf K, Bloecker H, Bumann D, 
Loessner H, & Weiss S (2012) Identification of tumor-specific Salmonella 
Typhimurium promoters and their regulatory logic. Nucleic Acids Res. 
40(7):2984-2994. 
187. Chatfield SN, Charles IG, Makoff AJ, Oxer MD, Dougan G, Pickard D, Slater D, & 
Fairweather NF (1992) Use of the nirB promoter to direct the stable expression of 
heterologous antigens in Salmonella oral vaccine strains: development of a 
single-dose oral tetanus vaccine. Biotechnology. (N. Y.) 10(8):888-892. 
188. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, & Totterman TH 
(2010) Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with 
CpG therapy. J. Immunother. 33(3):225-235. 
189. Gerner MY, Heltemes-Harris LM, Fife BT, & Mescher MF (2013) Cutting edge: 
IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 
re-expression levels and tumor control. J. Immunol. 191(3):1011-1015. 
190. Rochman Y, Spolski R, & Leonard WJ (2009) New insights into the regulation of 
T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 9(7):480-490. 
191. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, & Sprent J 
(2006) Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. 
Proc. Natl. Acad. Sci. U. S. A. 103(24):9166-9171. 
192. Stoklasek TA, Schluns KS, & Lefrancois L (2006) Combined IL-15/IL-15Ralpha 
immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177(9):6072-6080. 
193. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, 
Sherman F, Perussia B, & Trinchieri G (1989) Identification and purification of 
natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic 
effects on human lymphocytes. J. Exp. Med. 170(3):827-845. 
 
